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Résumé 
     Les nanoparticules polymériques biodégradable (NPs) sont apparues ces dernières 
années comme des systèmes prometteurs pour le ciblage et la libération contrôlée de 
médicaments. La première partie de cette étude visait à développer des NPs biodégradables 
préparées à partir de copolymères fonctionnalisés de l’acide lactique (poly (D,L)lactide ou PLA). 
Les polymères ont été étudiés comme systèmes de libération de médicaments dans le but 
d'améliorer les performances des NPs de PLA conventionnelles. L'effet de la fonctionnalisation 
du PLA par insertion de groupements chimiques dans la chaîne du polymère sur les propriétés 
physico-chimiques des NPs a été étudié. En outre, l'effet de l'architecture du polymère (mode 
d'organisation des chaînes de polymère dans le copolymère obtenu) sur divers aspects de 
l’administration de médicament a également été étudié. Pour atteindre ces objectifs, divers 
copolymères à base de PLA ont été synthétisés. Plus précisément il s’agit de 1) copolymères du 
poly (éthylène glycol) (PEG) greffées sur la chaîne de PLA à 2.5% et 7% mol. / mol. de 
monomères d'acide lactique (PEG2.5%-g-PLA et PEG7%-g-PLA, respectivement), 2) des 
groupements d’acide palmitique greffés sur le squelette de PLA à une densité de greffage de 
2,5% (palmitique acid2.5%-g-PLA), 3) de copolymère « multibloc » de PLA et de PEG, (PLA-
PEG-PLA)n. Dans la deuxième partie, l'effet des différentes densités de greffage sur les 
propriétés des NPs de PEG-g-PLA (propriétés physico-chimiques et biologiques) a été étudié 
pour déterminer la densité optimale de greffage PEG nécessaire pour développer la furtivité 
(« long circulating NPs »). Enfin, les copolymères de PLA fonctionnalisé avec du PEG ayant 
montré les résultats les plus satisfaisants en regard des divers aspects d’administration de 
médicaments, (tels que taille et de distribution de taille, charge de surface, chargement de 
drogue, libération contrôlée de médicaments) ont été sélectionnés pour l'encapsulation de 
l'itraconazole (ITZ). Le but est dans ce cas d’améliorer sa solubilité dans l'eau, sa 
biodisponibilité et donc son activité antifongique. Les NPs ont d'abord été préparées à partir de 
copolymères fonctionnalisés de PLA, puis ensuite analysés pour leurs paramètres physico-
chimiques majeurs tels que l'efficacité d'encapsulation, la taille et distribution de taille, la charge 
de surface, les propriétés thermiques, la chimie de surface, le pourcentage de poly (alcool 
vinylique) (PVA) adsorbé à la surface, et le profil de libération de médicament. L'analyse de la 
chimie de surface par la spectroscopie de photoélectrons rayon X (XPS) et la microscopie à force 
  
II
atomique (AFM) ont été utilisés pour étudier l'organisation des chaînes de copolymère dans la 
formulation des NPs. De manière générale, les copolymères de PLA fonctionnalisés avec le PEG 
ont montré une amélioration du comportement de libération de médicaments en termes de taille 
et distribution de taille étroite, d’amélioration de l'efficacité de chargement, de diminution de 
l'adsorption des protéines plasmatiques sur leurs surfaces, de diminution de l’internalisation par 
les cellules de type macrophages, et enfin une meilleure activité antifongique des NPs chargées 
avec ITZ. En ce qui concerne l'analyse de la chimie de surface, l'imagerie de phase en AFM et 
les résultats de l’XPS ont montré la possibilité de la présence de davantage de chaînes de PEG à 
la surface des NPs faites de PEG-g-PLA que de NPS faites à partie de (PLA-PEG-PLA)n. Nos 
résultats démontrent que les propriétés des NPs peuvent être modifiées à la fois par le choix 
approprié de la composition en polymère mais aussi par l'architecture de ceux-ci. Les résultats 
suggèrent également que les copolymères de PEG-g-PLA pourraient être utilisés efficacement 
pour préparer des transporteurs nanométriques améliorant les propriétés de certains 
médicaments, notamment la solubilité, la stabilité et la biodisponibilité.  
 
Mots-clés: Acide poly(lactique), Architecture, PEG-PLA, Multi-bloc, Organisation de la chaîne, 
Spectroscopie de photoélectrons Rayon X (XPS), Microscopie à force atomique (AFM), 
Imagerie de phase, Faible solubilité. 
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Abstract 
     Biodegradable polymeric nanoparticles (NPs) have emerged as promising drug delivery 
carriers for the controlled drug release and targeting. The first part of this study aimed to develop 
biodegradable NPs from functionalized copolymers of poly (D,L-Lactide) (PLA). Those 
copolymers were explored as drug delivery systems in attempt to improve the drug delivery 
performance of conventional PLA NPs. The effect of PLA functionalization (insertion of 
chemical substituents onto PLA backbone) on the physicochemical properties of the obtained 
NPs was investigated. Moreover, the effect of polymer architecture (mode of organization of 
polymer chains in the resultant copolymer) on various drug delivery aspects was also studied. To 
reach those goals, various PLA based copolymers namely poly(ethylene glycol) (PEG) grafted 
on PLA backbone at 2.5% & 7% mol/mol of lactic acid monomers (PEG2.5%-g-PLA and 
PEG7%-g-PLA, respectively),  palmitic acid grafted on PLA backbone at 2.5% grafting density 
(palmitic acid2.5%-g-PLA), and multiblock copolymer of PLA and PEG, (PLA-PEG-PLA)n 
were synthesized. In the second part, the effect of different PEG grafting densities over PLA 
backbone on the properties of PEG-g-PLA NPs either physicochemical or biological properties 
was investigated to reveal the optimal PEG grafting density required to develop stealth particles 
(long circulating NPs). Finally, functionalized PEG/PLA copolymers that showed the most 
satisfactory results in terms of various drug delivery aspects, such as size and size distribution, 
surface charge, drug loading, and controlled drug release were selected for encapsulation of 
itraconazole (ITZ) to improve its aqueous solubility, bioavailability and hence its antifungal 
activity. NPs were first prepared from functionalized PLA copolymers then analyzed for their 
major physicochemical parameters such as encapsulation efficiency, size and size distribution, 
surface charge, thermal properties, surface chemistry, % poly(vinyl alcohol) (PVA) adsorbed at 
the surface of NPs, and drug release pattern. Surface chemistry analysis using x-ray 
photoelectron spectroscopy (XPS), and atomic force microscopy (AFM) phase imaging were 
used to study the chain organization behavior of each functionalized copolymer during NPs 
formulation. Generally speaking, functionalized PEG/PLA copolymers showed improved drug 
delivery behavior in terms of narrow size and size distribution, enhanced loading efficiency, less 
plasma protein adsorption onto their surfaces and less macrophage uptake, and finally better 
antifungal activity for ITZ loaded NPs. For the surface chemistry analysis, AFM phase imaging 
and XPS studies revealed the possibility of existence of more PEG chains at the surface of PEG-
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g-PLA NPs than (PLA-PEG-PLA)n during NPs formation. Our results demonstrate that 
properties of PLA-based NPs can be tuned by proper selection of both polymer composition and 
polymer architecture. Results also suggest that PEG-g-PLA copolymers could be used efficiently 
as a nanocarrier to improve various drug properties e.g. solubility, stability, and bioavailability. 
 
Keywords: Poly (D,L lactide), Architecture, PEG-PLA, Multiblock, Chain organization, X-ray 
photon electroscopy (XPS), Atomic force microscopy (AFM) phase imaging, Poor solubility. 
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INTRODUCTION 
Polymeric Nanoparticles (NPs) as Drug 
Delivery Systems 
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1.1. A Brief Overview of Nanotechnology 
            In recent years, significant effort has been devoted to research and applications in the area 
of nanotechnology. Nanotechnology is the design, characterization, synthesis and application of 
materials, structures, devices and systems by controlling shape and size at nanometer scale [1]. 
Nanotechnology is widely applied nowadays to many areas of life as; fiber and textiles [2], 
agriculture [3], electronics [4], forensic science [5], space [6] and many other industrial 
applications. Medicine is one of the areas likely benefited from advances in nanotechnology [7-
10]. Many applications of nanotechnology in medicine have been investigated so far including 
drug delivery, both in vitro and in vivo diagnostics, and production of high quality biocompatible 
materials [11, 12]. It is reported that the global market of nanotechnology is expanding very fast 
with many expectations that it will reach $1.5 trillion by year 2012 [13].  
  
1.2. Nanotechnology and Drug Delivery  
          Development of nanotechnology for drug delivery has attracted a great deal of attention in 
recent years. Nanotechnology for drug delivery aims at formulating medicinal agents in 
biocompatible nanocarries (nanoparticles) for improving their clinical outcomes. The 
development of nanotechnology products for currently existing drugs may optimize their 
therapeutic performance, and minimize the need for developing new drugs with better properties. 
Formulating drugs into nanocarriers has proven successful to achieve all the following tasks [14]. 
To enhance the solubility and hence; absorption of poorly water-soluble drugs; efficiently target 
drugs into distant areas in the body; enhance cellular uptake of drugs across tight epithelial and 
endothelial barriers; efficiently deliver large macromolecular drugs (e.g. proteins, peptides and 
nucleic acids) to intracellular sites; deliver two or more drugs using the same carrier [15, 16]; 
and follow drug delivery journey in the body using imaging tools combined with the drug in the 
same carrier [17].  
        Nowadays, nanotechnology is widely used for encapsulating many drugs/bioactive moieties 
onto nanocarriers to improve either their pharmaceutical performance (e.g. bioavailability, 
stability, and controlled release) or their pharmacological performance (e.g. therapeutic activity, 
reducing side effects, and effective targeting) [18-20]. Several drugs used for treating incurable 
diseases like cancer [21], AIDS [22], diabetes [23], malaria [24], prion disease [25] and 
tuberculosis [26] are in the clinical testing phase and some of them are available in the market 
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[27, 28]. As a result of the last mentioned applications, nanotechnology holds enormous promise 
for drug delivery and it is widely expected that nanotechnology will be able to change the 
landscape of pharmaceutical and biotechnology industries for the foreseeable future [14]. 
 
1.3. Design of Nanotechnology–Polymeric based Drug Delivery Systems 
         There are a number of parameters that need to be considered for the development and 
manufacturing of successful drug delivery vehicles [29]. These include (a) the use of well- 
characterized, biodegradable, biocompatible materials; (b) the ability to tune the 
biophysicochemical properties of the used materials (e.g. hydrophilicity/ hydrophobicity balance, 
charge, molecular weight) to develop nanocarriers with adjustable properties (e.g. size, surface 
charge, release behavior); and (c) developing small unit operations amenable to scaling-up 
(manufacturing large quantities of drug delivery systems) for clinical applications.  Numerous 
classes of drug delivery nanocarriers composed of different materials including lipids, polymers 
and inorganic materials have been developed, resulting in different delivery systems that vary in 
their physicochemical properties and thus their pharmaceutical uses.  
         Growing interest in formulating polymeric nanoparticles is rapidly expanding for the 
following reasons. Advances in the scientific fields of polymer chemistry and polymer colloid 
physicochemistry have resulted in the availability of many tailor-made polymers for drug 
delivery. Polymeric drug delivery systems are often biodegradable, and biocompatible with 
potential of controlled drug release. They often have a superior drug delivery performance (e.g. 
size, surface charge, drug release, and cellular uptake properties) relative to other non-polymeric 
carriers. Moreover, they can be designed with hydrophilic coats, such as poly(ethylene glycol) 
(PEG), which creates a steric barrier decreasing the adsorption of opsonin proteins onto particle 
surface. This helps nanoparticles avoid recognition by the mononuclear phagocytic system 
(MPS) and circulate for prolonged period of time in the blood [30, 31]. Nanoparticles assembled 
from water soluble polymers usually have a molecular weight above glomerular filtration 
threshold (42-50 kDa), which is another cofactor for their prolonged circulation in the body [32].    
         An interesting feature of polymeric carriers is their ability to control the release of a 
therapeutic agent to achieve desired therapeutic level in certain pathological areas in the body. 
This could be achieved by the use of stimuli responsive polymers which release their payload 
under the effect of external stimuli (i.e. change in pH, temperature or ionic strength) [33, 34]. 
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This allows maximum drug release at the target site, achieving optimum therapeutic efficacy 
[35]. Polymeric nanoparticles can be delivered to distant target sites either by localized delivery 
using a catheter-based approach [36] or they can be attached to a recognition marker or/ ligand 
which could direct them to the target area [37]. They usually achieve high drug loading, which 
maximizes drug/excipients ratio. This results into reducing the frequency of administration and 
hence, patient expenses, and risks of toxicity could also be reduced.  
       One of the most distinct advantages of polymeric carriers for drug delivery is their 
adjustable nanometer size range. Due to their sub-cellular and sub-micron size, polymeric 
nanoparticles can homogenously penetrate into tissues, cross the fenestration of the epithelial 
lining (e.g., liver), and efficiently taken up by the cells [38]. In addition, their nanometer size 
range allows them to be efficiently captured by some tumor cells particularly solid tumors, 
infarcts and inflamed tissues. This phenomenon is called enhanced permeability and retention 
effect (EPR) or passive accumulation of nanocarriers into the tumor tissues [39]. EPR mainly 
occurs because of the pathophysiological features of tumors vessels that are mainly distinct from 
normal vessels. Tumor cells are characterized by hypervascularity, incomplete vascular 
architecture, poorly aligned endothelial cells and wide fenestrations (20 nm-1.2 µm) [40, 41]. 
These features make the vasculature of pathological tissues more “leaky” or more “permeable” 
than that of normal tissue. This increased permeability or leaky vasculature together with 
compromised lymphatic drainage facilitates accumulation of macromolecules and nanoparticles 
in pathological tissues. Based on the EPR effect, drug concentration in the tumor tissues was 
found to be 10-30 times higher than that in the blood and other normal tissues [42]. To sum up, 
nanoencapsulation of medicinal drugs using polymeric carriers (nanomedicines) was shown to 
enhance drug efficacy, specificity, tolerability and therapeutic index of many drugs [43-45].  
 
1.4. Review of Polymeric Nanoparticles as Delivery Systems 
         Polymeric nanoparticles are solid or semisolid colloidal particles that vary in size from 10 
nm to 1000 nm [46]. They are mainly consisting of macromolecular substances and can be used 
as drug carrier. The drug is adsorbed, dissolved, entrapped, or encapsulated into the 
nanoparticles matrix. Either nanospheres or nanocapsules can be obtained from the same 
polymer depending on the used method of preparation [47, 48]. Nanospheres are matrix systems 
in which the drug is uniformly dispersed whereas; nanocapsules are vesicular systems in which 
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the drug is confined to a cavity surrounded by a polymer shell (Fig. 1.1).  After preparation, 
nanoparticles are usually dispersed in aqueous solution. The resultant drug nanoparticle 
dispersion can be administered to humans by many routes as injection, oral route, or applied 
topically either to the skin or the eye. Nanoparticles can be also used for pulmonary delivery 
after being dried to a powder, or can be compressed into tablets or capsules.  
 
 
A                                           B                                       C 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.1. Schematics of polymeric nanoprticles. A. Matrix type nanosphere, drug molecules are 
uniformly dispersed in the polymer matrix. B. Core shell nanocapsules, drug molecules are 
presented in an oily or aqueous core covered with polymeric shell. C. matrix type nanosphere 
where drug crystals are embedded in a polymer matrix. 
 
1.5.  Factors affecting Performance of Polymeric Nanoparticles as Delivery Vehicles 
             Formulation of nanoparticles as delivery vehicles depends on the choice of suitable 
polymeric substance having acceptable biocompatibility and biodegradability, higher 
incorporation efficiency, and an extraordinary ability to enhance the drug retention time in vivo. 
Nanoparticles are superior to conventional drug carriers (e.g. tablets, capsules….etc.) with 
respect to control release, targeted delivery and therapeutic potential.  
         Polymer chains 
Oily or aqueous core 
Drug crystals 
Drug molecules 
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          Many factors affect the drug delivery performance of polymeric nanoparticles as particle 
size, surface charge, surface modification, and hydrophobicity (Fig.1.2). Size and size 
distributions of nanoparticles play an important role in determining their release kinetics as well 
as their interaction with the cell membrane and their penetration across the biological barriers. 
The ability of nanoparticles to penetrate different biological barriers is mainly dependent on the 
particle size, the target tissue biophysiological characteristics e.g. tissue size, tissue thickness, 
and blood circulation [49]. It has been shown before that large size particles are rapidly cleared 
by mononuclear phagocytic system (MPS) than smaller size particles [50]. The size of the carrier 
might have a role in complement activation [51]. For long circulating colloidal nanoparticles, 
optimum size is favored to be 150-200 nm [52, 53].  
        Surface charge is also important in determining the in vivo stability as well as cellular 
interaction of nanoparticles. Surface charge measurement (zeta potential) evaluates whether 
nanoparticles would aggregate in blood flow or would adhere to, or interact with oppositely 
charged cells membrane [54]. As a biological rule, to enhance the rate and extent of cellular 
uptake, positively charged surfaces or cationic surface charges are required as it promotes the 
interaction of nanoparticles with the negative charges (phospholipids) of the cell membrane [10]. 
However, cationic charges could enhance the non-specific cell sticking or uptake of the particles. 
As a result, it is recommended that colloidal carriers should have neutral or near neutral surface 
charge to avoid both the non specific cell uptake and uncontrolled plasma protein adsorption 
onto their surfaces [50, 55].  
       Intravenously (IV) administered nanoparticles are easily recognized by the body immune 
system, and then massively cleared by the macrophages (MPS) rich organs such as liver, spleen, 
lungs and bone marrow [56]. The NPs surface hydrophobicity determines the amount of 
adsorbed blood components, mainly proteins (opsonins) which initiate the phagocytosis process 
[57]. Hence, to prolong the circulation time of NPs in the blood, it is necessary to minimize the 
opsonization process (plasma protein adsorption onto NPs surface). This can be achieved by 
surface modification of hydrophobic particles by coating their surfaces with different hydrophilic 
molecules such as polyethylene glycol (PEG), polyethylene oxide, polyoxamer, poloxamine and 
polysorbate 80 (Tween 80) [46, 58]. 
          Finally, the in vivo performance of nanoparticles is affected by morphological 
characteristics, surface chemistry, and molecular weight. Molecular weight of the carrier can 
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play a role in modulating the release behavior. For a slow drug release from the particles, high 
molecular weight of the starting polymer should be used [59]. Careful formulation of polymeric 
nanoparticles with respect to target and route of administration may solve many pharmaceutical 
problems of either marketed drugs or newly discovered drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.2. Factors affecting the drug delivery performance of polymeric nanoparticles 
 
1.6. Applications of Polymeric Nanoparticles 
        Nanoparticles in pharmaceutical applications have gained plenty of research attention 
during recent decades taking advantage of their small size, and their biodegradable nature [13]. 
Nanoparticles can be administered orally as a reconstituted aqueous dispersion. NPs dispersion is 
easily uptaken and absorbed into the systemic circulation across the mucosal epithelium by 
enterocytes [60]. They could protect the encapsulated active ingredient against the gastro-
Different factors 
affecting 
polymeric 
Nanoparticles 
Surface charge Size and size 
distribution 
Surface 
modifications 
Hydrophobicity 
Molecular weight 
(Mwt) 
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intestinal (GI) tract harsh conditions and/or prolong the contact time of its payload on the 
mucous membrane by efficiently adhering to mucosal surfaces (bioadhesion). Many examples of 
the oral applications of NPs are reported in the literature particularly for delicate macromolecules 
e.g. oral delivery of peptides such as salmon calcitonin [61] and elcatonin [62]. NPs were also 
used as an oral carrier for the delivery of hormones as  mifepristone [63] and estradiol [64]. Oral 
delivery of vaccines by NPs has achieved considerable success through the targeted uptake of the 
particles in the M cells of peyer’s patches. Many examples for the oral immunization using 
PLGA nanoparticles are also reported such as tetanus toxoid [65], ovalbumin [66] and bovine 
serum albumin (BSA) [67]. 
           Several applications of stealth (long circulating) nanoparticles can be found in the area of 
tumor/cancer therapy. The mean residence time, effective concentration, half life of some 
anticancer drugs loaded into polymeric nanoparticles have been enhanced compared to pure drug 
e.g. camptothecin [68], and  paclitaxel [69].  
          PLA and PLGA NPs have also been applied for the sustained delivery of many drugs into 
an intracellular target [70-72]. NPs could enhance the cytoplasmic delivery of many drugs 
through their marked ability to rapidly escape the endo-lysosomal compartment to the 
cytoplasmic compartment e.g. PCL nanoparticles [73]. Dexamethasone-loaded nanoparticles  has 
achieved higher antiproliferative activity in vascular smooth muscle cells compared to free 
dexamethasone due to the enhance uptake of NPs by the glucocorticoid receptors which are 
cytoplasmic [74].  
         Another interesting application of nanoparticles is their ability to deliver drugs across the 
Blood–Brain Barrier (BBB) [75]. Nanoparticles has been shown to sustain the delivery of 
therapeutic agents to brain tumours following the opening of tight junctions of the BBB by 
hyperosmotic mannitol [76]. Poly(alkylcyanoacrylate) nanoparticles have been widely 
investigated as a drug carrier to the brain [77]. Many types of polymeric nanoparticles have also 
been used for the brain delivery e.g. PLA-PEG nanoparticles functionalized by lectin [78], PLA-
PEG nanoparticles bearing cationic BSA coating [79], PLA-polysorbate 80 nanoparticles [80], 
and PLGA peptide nanoparticles [81]. Loperamide has been loaded into peptide derivatized 
PLGA NPs then delivered successfully to the central nervous system of rats [82]. Till now, the 
mechanisms of particle uptake across the BBB are not clearly identified; other processes may be 
also involved [83]. 
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       Nanoparticles with mucoadhesive properties have also been investigated as an ocular drug 
delivery carrier. They mainly act as an ocular carrier based on their ability to prolong the mean 
residence time of the drug in the cornea, control its release and reduce irritation after topical 
application. Flurbiprofen loaded into PLGA nanoparticles exhibited higher anti-inflammatory 
action upon instillation into the eye than free drug [84]. Similar enhancement of the ocular 
absorption of acyclovir-loaded PEG-PLA nanoparticles has been observed [85].  
        In gene delivery studies, non-viral vectors are assembled through the interaction between 
the negative charge of nucleic acids and the positive charge of the particles. Non viral vectors 
have been demonstrated a marked ability to encapsulate the entrapped gene, protect it against 
stressful body conditions, sustain its release, and facilitate its delivery and interaction with the 
cell membrane. For example, PLA-PEG nanoparticles administered orally have achieved higher 
transfection efficiency for the encapsulated DNA [86]. PLGA nanoparticles have been used as 
non viral vector for the sustained release of DNA [87]. Many challenges in nanoparticulate gene 
delivery applications are faced particularly the key challenge of enhancing the coupling potential 
between nucleic acid and the polymer while maintain the size of the carrier in the nanometer 
scale. 
      Despite the extensive research in the area of nanotechnology and drug delivery, few 
polymeric nanoparticulate products have marketed so far. A commercialized product, 
Abraxane™, obtained from the protein albumin bound with paclitaxel, is administerd 
intravenously [88]. Another product, Doxorubicin Transdrug®, consisting of doxorubicin-loaded 
poly(isohexylcyanoacrylate) nanoparticles is currently investigated clinically [89].  
      As a general summary of the investigated applications of nanoparticles in the pharmaceutical 
field, nanoparticles could protect the encapsulated active ingredient, enhance its action, reduce 
its toxicity and side effects, sustain its release and target it into the desired area. For clinical 
translation, most of the research is now focused on developing  processes for the  scaling up of 
nanoparticles [90]. A range of different types of nanoparticles and their applications are outlined 
in Table 1.1. 
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Therapeutic 
application 
Carried therapeutic 
agent/fluorescent  
marker 
Ref. Advantages 
Oral and nasal 
therapy 
Salmon calcitonin 
Elcatonin 
Mifepristone 
Estradiol 
Tetanus toxoid 
Oral vaccination, Ova-
albumin 
Bovine serum albumin 
[61] 
[62]  
[63] 
[64] 
[65] 
[66]  
 
[67] 
 
(1)  Sustained release of the encapsulated drug.  
(2) Efficient uptake and transport across the 
mucosal epithelium. 
(3) Protect the encapsulated drug against the 
gastro-intestinal (GI) tract harsh conditions.  
(4) Prolong the residence time of drug on the 
mucous membrane (mucoadhesive properties). 
Cancer therapy Campothecin 
Paclitaxel 
Tamoxifen 
Curcumin 
Doxorubicin 
Neocarzinostatin 
Atinsense oligonucleotides 
(AONs) 
[68] 
[21, 27] [69] 
[10]  
[91] 
[12] 
[39] 
[57] 
 
(1) Enhanced antitumor efficacy. 
(2) Reduced systemic side effects and toxicity 
levels. 
(3) Enhanced tumor specific uptake.  
(4) Enhanced accumulation into tumor tissues. 
Brain therapy Cisplatin 
Dalargin hexapeptide 
6-Coumarin 
FITC-Dextran 
Fluorescein 
Loperamide/ Rhodamine B 
 
[76] 
[77] 
[78, 79]  
[80] 
[81] 
[82] 
 
(1) Efficient passage across the blood brain barrier 
(BBB). 
(2) Effective targeting of the brain endothelium. 
(3) Sustained drug release into the brain cells. 
 
Gene Therapy DNA 
DNA vaccine 
DNA, siRNA, and  AONs 
[86] 
[87]  
[92] 
(1)  Increased transfection efficiency. 
(2) Protection of the encapsulated gene against in           
vivo degradation. 
Intraocular 
delivery 
Flurbiprofen 
Acyclovir 
[84] 
[85] 
 
(1) Prolonging the corneal contact time. 
(2) Controlled drug release. 
(3) Reduced ocular irritation. 
Table 1.1. Different applications of polymeric nanoparticles in pharmaceutical field.   
 (FITC-dextran): Fluorescein isothiocyanate-dextran 
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1.7. Preparation of Polymeric Nanoparticles 
 
            Polymeric nanoparticles for pharmaceutical applications are prepared from a class of 
synthetic and natural polymers. Natural polymers are considered safer and more biocompatible 
than synthetic ones. Synthetic polymers became more acceptable than before in the preparation 
of NPs due to the greater control over their biophysicochemical properties. Natural polymers 
include e.g. albumin [93], casein [91], alginate [94], gelatin [95, 96], and chitosan which is 
considered the most widely used natural polymer for nanoparticle preparation [97, 98]. Synthetic 
polymers include aliphatic polyesters, polyanhydrides, polyorthoesters, and polycyanoacrylates 
[46]. Other investigated synthetic polymers include polystyrene [99] and poyl(vinyl pyridine) 
[100].  
            Two techniques are widely used for nanoparticles preparation; (i) polymerization of 
monomers and (ii) deposition of an already synthesized or preformed polymer [58, 101]. 
Nanoparticle preparation from preformed polymers is more common because of the ease of the 
preparation, more control of the manufacturing process, and reproducibility of the used method. 
Polymer deposition method mainly depends on dissolving a preformed polymer in a convenient 
solvent followed by precipitation in a liquid medium leading to nanoparticle formation. The drug 
intended to be encapsulated in the particles is usually incorporated in the process during the 
polymer solvation process. Nanoprecipitation, salting-out, emulsification/solvent diffusion, and 
emulsification/solvent evaporation methods are widely applied techniques used for nanoparticles 
preparation by polymer deposition method [46, 102-104].   
        Nanoprecipitation method was introduced and patented by Fessi and co-workers [105]. In 
this method, particles are formed spontaneously by precipitation and subsequent solidification of 
the polymer upon rapid solvent diffusion. The polymer is dissolved in a water miscible organic 
solvent (or solvent mixture) and poured under magnetic stirring into a non solvent (usually water 
containing surfactant), in which the organic solvent diffuses. The mechanism of formation of 
NPs by this technique has been explained by the interfacial turbulence generated at the interface 
of the solvent and non-solvent. Thus, the process is often called solvent displacement or 
interfacial deposition. In the salting-out method, nanoparticle formation is based on the 
separation of a water-miscible solvent containing the polymer from aqueous solutions via a 
salting-out effect. Acetone is commonly used as the water-miscible solvent because of its 
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solubilizing efficiency and rapid separation from aqueous solutions by salting-out effect with 
electrolytes. In emulsification/solvent diffusion method, nanoparticle formation starts when the 
saturation limit of a partially water-miscible solvent (e.g. benzyl alcohol) is exceeded by addition 
of water. In both techniques, vigorous stirring is a prerequisite for inducing the phase separation. 
The emulsification solvent evaporation method is presented in section 1.7.5. Another widely 
used technique nowadays for nanoparticles preparation is supercritical fluid technology [106, 
107]. Nanoparticles can also be prepared directly from monomers using different polymerization 
techniques as described in those reviews [46, 102]. A list of some used polymers and the 
commonly used methods to prepare nanoparticles are summarized in Table 1.2.  
         Nanoparticles are usually prepared as an aqueous dispersion. If nanoparticles are stored in 
an aqueous medium, polymer degradation, drug leakage, and/ or drug degradation may occur 
[108]. In addition, handling (storage, transportation) of a liquid particle system is inconvenient. 
To improve the physicochemical stability of nanoparticles, freeze-drying in is usually performed 
to conserve the structure of particles, facilitate handling and transport, and help the further 
processing of particles into other dosage forms (e.g. tablets, capsules, and powder).  
 
1.7.1. Classification of Copolymers used for Nanoparticles Formation 
     Nanoparticles have been formulated using a wide range of polymers.  Copolymers are widely 
used than homopolymers in NPs preparation due to their tunable properties. Copolymers can be 
divided into 4 main types based on their architecture (how the building blocks are connected 
together) (Fig.1.3): 
1. Block copolymers: linear copolymers where the end group of one chain is covalently attached 
to the head of another chain giving diblock or triblock architectures [109]. 
2. Graft copolymers: branched copolymers with a comb-like architecture where different 
branches emanate from one main chain. 
3. Random copolymers: linear copolymers with the building blocks arranged randomly [110]. 
4. Alternating copolymers: linear copolymers with perfectly alternating arrangement of their 
building blocks. 
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1.7.2. Polyesters 
    Biodegradable polyesters (e.g. PLA, PGA, PLGA and PCL) are, so far, the most extensively 
used biomaterials for biomedical applications. They are the preferred synthetic polymers for 
nanoparticle preparation for the following reasons. They are mainly characterized by their 
biocompatibility and their controlled degradation to biocompatible monomers [111]. They are 
degraded by bulk hydrolysis of their ester bonds [112]. Their degradation products (e.g. lactic 
acid or glycolic acid) are eliminated from the body by citric acid cycle [113], hence, they do not 
require any kind of surgery to be removed from the body. They are easily synthesized through 
ring opening polymerization of cyclic lactones. They could efficiently protect the entrapped drug 
against degradation and control its site specific delivery. They are more efficient for 
encapsulation of many drugs particularly hydrophobic drugs. Encapsulated drugs are slowly 
released from polyester based matrices upon the controlled degradation of the polymeric 
materials. 
 
 
 
Diblock copolymer                                                                      Mutliblock copolymer 
 
 
  
 
 
                                                        Graft copolymer 
                                                 
 
Random copolymer                                                                                Alternating copolymer 
 
 
Fig.1.3. Architectures of different copolymers used in the preparation of polymeric 
nanoparticles. 
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Polymer 
class 
Examples Drug/application Preparation method Ref. 
Natural 
polymers 
 
Albumins 
 
Casein 
 
Alginate 
 
 
Gelatin  
 
Chitosan 
 
Ganciclovir 
 
Curcumin 
 
Antitubercular drugs (Isoniazide, 
Rifampicin, and Pyrazinamide) 
 
Paclitaxel 
 
Bovine serum albumin 
Coacervation 
 
Centrifugation redispersion 
 
Cation induced gelation 
 
 
Desolvation method 
 
Ionic gelation 
[93] 
 
[91] 
 
[94] 
 
 
[95] 
 
[97] 
Synthetic 
polymers 
Poly(alkyl cyanoacrylate)  
 
Poly(alkyl methacrylate) 
 
Polystyrene 
 
 
Poly(vinyl pyridine) 
 
 
Poly(ε-caprolactone) (PCL) 
 
 
 
Polylactic acid (PLA) 
 
 
 
Poly(lactic-co-glycolic acid) (PLGA) 
 
 
Tissue adhesives 
 
Tissue adhesives 
 
Progestrone 
 
 
Tebuconazole 
 
 
Many anti-cancer drugs and 
model proteins 
 
 
Bovine serum albumin 
 
 
 
Bovine serum albumin and 6-
coumarin 
Polymerization method 
 
Polymerization method 
 
Emulsification/solvent 
evapoartaion method 
 
Emulsification/solvent 
diffusion method 
 
Different Techniques are 
described in the cited 
review 
 
Emulsification/solvent 
evaporation method 
 
 
Emulsification/solvent 
evaporation method 
 
[46] 
 
[46] 
 
[99] 
 
 
[100] 
 
 
[112] 
 
 
 
[114] 
 
 
 
[74] 
Table 1.2. Polymers and methods widely used in nanoparticle preparation. 
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1.7.3. Poly(lactic acid) (PLA) 
    Poly(lactic acid) (PLA) belongs to the family of linear aliphatic polyesters commonly made 
from α-hydroxy acids. PLA mainly obtained from lactic acid monomers (Fig. 1.4.). Being 
biodegradable polyester, PLA is widely used nowadays for nanoparticle preparation. PLA is also 
used for the manufacture of resorbable sutures, bone implants, artificial organs, tissue screws, 
and contraceptive implants [115, 116].  
     PLA is the simplest hydroxy acid with an asymmetric carbon atom and exists in two optically 
active configurations. Polymers of L(+) lactic acid and D(-) lactic acid are partially crystalline, 
while the racemic poly(D,L-lactic acid) is amorphous. The self-condensation of lactic acid 
results in low molecular weight (Mwt) PLAs, whereas ring opening polymerization of lactide 
usually results into higher Mwt PLA polymers [117]. PLAs are insoluble in water and ethanol, 
but they are soluble in organic solvents such as dichloromethane and chloroform [117-119].   
     PLA  undergoes hydrolytic degradation of its ester bond in an aqueous medium [120]. The 
degradation products are biocompatible and metabolizable; they are removed from the body by 
the citric acid cycle. PLA degradation rate is mainly controlled by these factors; (i) Mwt (high 
Mwt PLAs degrade slower); (ii) crystallinity (amorphous PLA degrades faster); (iii) 
environmental conditions (pH, ionic strength, temperature); (iv) particle morphology (porous 
particles degrade faster); (v) size of the particles (small size particles degrade faster) [121]. 
Drugs encapsulated into PLA particles also could affect its degradation rate. Both acidic and 
basic drugs may catalyze the degradation of PLA polymeric carriers either microparticles or 
nanoparticles. 
 
 
 
 
 
 
 
Fig. 1.4. Chemical structure of poly(lactic acid). 
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1.7.4. Functionalized Polyesters for Nanoparticles Preparation 
             Extensive work has been recently devoted towards functionalizing polyesters in order to 
enhance the drug delivery behavior of the obtained nanoparticles, increase the number of drugs 
that can be encapsulated into the polymeric particles and finally to efficiently control the drug 
release pattern. Most polyesters do not have significant number of functional groups that could 
enhance their potential applications. Such applications are greatly widened when functional 
pendant groups are incorporated into the polymer backbone.  
            Introduction of functional groups that can be easily substituted or conjugated with the 
compound of interest is a challenge. Many synthetic protocols were tried in the past for the 
synthesis of functionalized polyesters with better characteristics [122-124]. Most of these trials 
were complex including various tedious steps and the process itself was not reproducible and out 
of control in many cases. For example, functionalized malolactonate copolymers were 
synthesized with low yields (12–45%) and polymerization reactions were very slow (over 4–30 
days) [122]. PLA grafted polysaccharide copolymers were also synthesized with a multistep 
method that required protection/deprotection step [125]. Moreover, most of the polyesters 
developed had molecular weights that are usually not high enough to be used for nanoparticles 
preparation [126]. Thus, there are very few methods that could be regarded as easy and efficient 
for the synthesis of functionalized polyesters. An efficient method for the synthesis of 
functionalized PCL and PLLA with controlled molecular weight and low polydispersity was 
previously reported [124].  
             In our study, nanoparticles were prepared from novel functionalized PLA copolymers. 
Those copolymers were developed by grafting different functional substituent as poly(ethylene 
glycol), PEG onto PLA backbone according to a previously reported method by our group [127]. 
This method simply depends on the development of versatile copolymers of PLA and allyl 
glycidyl ether. The grafted PLA with allyl group is undergoing subsequent steps to convert the 
allyl group into hydroxyl and then carboxyl groups to which various functional groups could be 
grafted easily to the polymer backbone. Various bioactive molecules like salens [128]  or ligands 
for E-selectin and for P glycoprotein were successfully grafted onto PLA Backbone. Also, 
methoxy PEG-g-PLA has been previously synthesized by our group using the same principle and 
successfully used to prepare colloidal nanoparticles for sustained drug release [129]. 
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1.7.5. Emulsification Solvent Evaporation 
             The emulsification solvent evaporation method was early described by Niwa et al and 
has been widely used to prepare NPs from a range of polymeric materials, particularly PLA and 
PLGA [130]. In this method, the polymer is first dissolved in a water immiscible, volatile 
organic solvent (e.g. chloroform, methylene chloride or ethyl acetate) then emulsified into an 
aqueous phase as shown in Fig.1.5.  Emulsification can be achieved with the help of mechanical 
stirring, sonication or a high-energy source such as ultrasound or homogenization [Fig. 1.5]. The 
aqueous phase usually containing a surfactant like poly(vinyl alcohol), PVA to stabilize the 
system and help the formation of relatively small sized particles with uniform size distribution 
[131]. Nanoparticles tend to precipitate into the aqueous phase in the form of solid particles after 
the organic solvent has been removed under reduced pressure. This technique has been widely 
used for encapsulating hydrophobic drugs. The procedure has been modified to help 
encapsulating hydrophilic compounds and large macromolecules as peptides and proteins. The 
modified protocol depends on the use of the double or multiple emulsion technique (w/o/w) 
instead of the single emulsion (o/w). Simply, a water soluble drug and a surfactant are dissolved 
in water. The primary emulsion is prepared by dispersing the aqueous phase into an organic 
solvent containing a dissolved polymer. This is then re-emulsified in an outer aqueous phase also 
containing surfactant [132-134]. From here, the procedure for obtaining the nanoparticles is 
similar to the single emulsion technique (o/w) for solvent removal.  
        Several factors can influence the physicochemical properties of the obtained particles, these 
include; type and molecular weight of the starting polymer, concentration of polymer in the 
organic phase, type of organic phase, volume ratio of organic: aqueous phase, nature and 
concentration of surfactant, and stirring speed. 
 
       The main advantages of using this technique is the use of water as the nonsolvent; this is 
reduces the cost of production, facilitates the washing step of the particles, facilitates the further 
processing of particles [102]. However, there are some major disadvantages associated with the 
use of this method to prepare NPs.  First of all, residual chlorinated solvents have serious toxicity 
potential. Second, the excess surfactant used is difficult to remove. Poly(vinyl alcohol), PVA is 
the most widely used stabilizer to prepare nanoparticles. However, PVA remains adsorbed at the 
surface of the nanoparticles and is difficult to be removed by multiple washing steps. It is 
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reported that PVA adsorbed at the surface of nanoparticles could change biodegradability, 
biodistribution, NPs cellular uptake, and drug-release pattern [135]. Third, this procedure is good 
for a laboratory-scale, but not for a large-scale pilot production.          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1.5. Schematic representation of the emulsification-evaporation technique (taken from ref. 
[102]). 
 
1.8. NPs Characterization 
            Nanoparticles as colloidal dispersions differ remarkably from other macroscopic 
dispersions.  Nanoparticles have some unique physicochemical properties related to their sub-
micron size as high surface area and surface free energy, and movement of particles by random 
motion (Brownian diffusion). Different physicochemical methods are being used specifically for 
NPs characterization to help understand their performance in vivo.  
 
1.8.1. Size and Morphology 
         Particle size affects release kinetics, biodistribution potential and cellular uptake properties 
of NPs [46, 136]. Therefore, it is crucial to measure the size of the particles before conducting 
any further characterization. A detailed knowledge of the NPs size could help identify the 
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success of the used preparation method and give an idea about the in vivo performance of the 
particles. Optical light microscopy is not suitable for nanoparticle characterization since its 
resolution limit is about 500 nm. The most commonly used techniques for the characterization of 
nanoparticle size and morphology are scanning electron microscopy (SEM) [137, 138], 
transmission electron microscopy (TEM) [105, 139], and atomic force microscopy (AFM) [15, 
129].   
         Atomic force microscopy (AFM) (scanning probe microscopy) enables the visualization of 
NPs at the atmospheric pressure without gold coating [140, 141]. Nevertheless, the resolution of 
AFM is still lower than that with SEM.  Visualization of NPs using AFM can be done by three 
modes; contact, non-contact, and tapping mode. Tapping mode AFM (TM-AFM) is more 
preferred than contact and no-contact modes because of the ability of that mode to probe soft 
samples like biological and polymeric materials under ambient conditions [142, 143]. In tapping 
mode, the cantilever oscillates close to its bending mode resonance frequency so that tip makes 
contact with the sample for only short period of time during each oscillation cycle. As the tip 
approaches the sample, the tip-sample interactions alter the amplitude, frequency, and the phase 
angle of the oscillating cantilever. During scanning, the amplitude at the operating frequency is 
maintained at the constant level, called the set-point amplitude by adjusting the relative position 
of the tip with respect to the sample. This operating method results in lower surface forces, 
particularly lateral forces causing less surface damage [142].  
        One recent approach in TM-AFM is the use of the changes in the phase angle of the 
cantilever probe to produce phase image. An interesting application of TM-AFM in nanoprticle 
field is to visually investigate the mode of chain organization of the used polymer during NPs 
formation. Phase imaging is based on the use of changes in the phase angle of cantilever probe. 
This image shows more contrast than the topographic one as well as more sensitivity to material 
surface properties such as stiffness, viscoelasticity, and chemical composition [142, 144, 145]. 
Depending on the viscoelastic differences between PLA and PEG chains, phase imaging could 
be done to directly examine PEG on the surface of pegylated NPs.  
       Photon correlation spectroscopy (PCS) is the most commonly used tool in size 
determinations of nanoparticles [15, 129, 139, 146]. PCS is mainly based on the principle of 
laser light scattering by particles in colloidal dispersion. It can be used for size measurement 
between 5 nm and 2 µm.  The size or diameter obtained by PCS is a value that refers to how a 
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particle diffuses within a fluid so it is referred to as a hydrodynamic diameter. The hydrodynamic 
diameter is the diameter of a sphere that has the same translational diffusion coefficient as the 
particle. Simply, PCS  detects the intensity variation of laser light scattered by the random 
motion of the particles (Brownian motion), and relates it to the particle size with the help of an 
autocorrelation function [147]. PCS allows the determination of the size distribution of mono and 
multidispersed particles. The advantage of this method is ease of sample preparation, fast 
technique, sensitive to nanoscale particles, and provides information about the whole colloidal 
dispersion. To be analyzed, the particles dispersion needs to be diluted, sometimes filtered to 
remove any dust particles that might interfere with the accuracy of results. Microscopic 
visualization and PCS should be used together in NPs size determinations. PCS is a 
computational technique that presumes that the particles are spherical and the size results are 
based on this assumption which might not be true in many cases. Instead, AFM/SEM provides 
visual and descriptive information, a real overview about the nanoparticles population.  
 
1.8.2. Surface Characteristics and Stability 
          Surface charge determines the stability of particles either in vitro or in vivo and also 
affects their cellular interaction in the body [58]. Colloidal dispersions are mainly stabilized 
either by electrostatic forces (surface charge) or by steric forces (polymers or surfactants at the 
particle surface), or by both forces [148, 149]. Information about the particle surface charge are 
usually obtained by zeta (ζ) potential measurement [150]. Stability for nanoparticle dispersion is 
usually achieved by high ζ-potential values. Particles with zeta potentials more positive than +30 
mV or more negative than -30 mV are normally considered stable, as the surface charge prevents 
aggregation of the particles [151]. Zeta (ζ) potential reflects the electric potential of the particles. 
It is the charge at the electrical double layer, created by ions of the liquid, which exists around 
each particle.  
      Zeta (ζ) potential measurement depends on determining the mobility of charged particles 
under the effect of electric potential (electrophoretic mobility). The electrophoretic mobility can 
be transferred to ζ-potential by applying Smoluchowski’s equation. Ζeta-potential is mainly 
affected by the conditions of the dispersing medium as pH and electrolyte concentration [152]. 
PLA NPs are mainly stabilized by ionization of carboxylic acid groups at basic pH which shifts 
the zeta potential towards the negative side (around -40 mV or more) [153, 154]. Zeta-potential 
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values can be altered by surface modification [155] or stabilizer concentration [156].  It can also 
be used to determine whether a charged drug is entrapped into NPs or adsorbed onto the surface 
[58]. 
      Another widely used surface characterization technique particularly used for PLA 
nanoparticles modified with PEG [157] is the X-ray photoelectron spectroscopy (XPS). This 
technique, also known as ESCA (electron spectroscopy for chemical analysis), is a surface 
sensitive technique that could give information about the chemical composition and structure of 
the particles surface qualitatively and quantitatively by measuring the binding energy of 
electrons associated with the atoms in a 5–10 nm depth of the NP surface. Other  widely used 
tools for investigating the chemical composition of NPs include Fourier-transform infrared 
spectroscopy (FTIR) [158] and nuclear magnetic resonance spectroscopy (NMR) [159]. 
 
1.8.3. Drug-Polymer Interactions 
         It is crucial during NPs preparation to identify any possible drug polymer-interactions. 
Drug loading can be done by two methods: (i) adding drug during NPs preparation 
(incorporation method); (ii) adsorbing drug onto the surface of preformed particles (adsorption 
technique). Drug loading efficiency depend greatly on the solid-state drug solubility in polymeric 
matrix (solid solution or dispersion), which is related to the polymer composition, the molecular 
weight, the drug polymer interaction and the presence of end functional groups (ester or 
carboxyl) [139, 160, 161]. Two types of drug polymer interactions exist either physical 
interaction (e.g. weak van der waals attraction) or chemical interaction (e.g. strong ionic 
interaction). As a result of drug-polymer interactions, drug can be adsorbed onto the particle 
surface [162] or bound chemically within the nanoparticles [163].  
       Physical state of the drug inside the particles also affects the drug diffusion and hence drug 
release from the particles. Amorphous materials have higher solubility and hence faster release 
rate compared to crystalline substances. Crystalline drugs need to be first dissolved before 
diffusing through the NPs matrix and hence, the release pattern would be slower. The preparation 
process of NPs can play a role in modifying the final state of drug in the particles.  
          Differential scanning calorimetry (DSC), (powder) x-ray diffractometry (PXRD) and FTIR 
are commonly used techniques to identify the final state of encapsulated drug, and to investigate 
any physicochemical interaction between the drug and the matrix polymer. DSC detects changes 
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Weight of drug entrapped in NPs 
Initial weight of drug added 
% EE = X 100  
(1) 
 
% DL = 
Weight of drug entrapped in NPs 
Weight of NPs 
X 100  (2) 
 
in heat flow between a sample and reference upon heating both substances at a constant heating 
rate. DSC is widely used to detect phase transitions such as glass transition, exothermic 
transitions (e.g. crystallization) and endothermic transitions (e.g. melting) [164]. PXRD analysis 
is based on determining the diffraction pattern of the x-rays from a sample as a function of 
scattering angle.  It is used to investigate the crystalline properties of drugs [165]. Absence of the 
drug melting peak and diffraction peaks of the crystal structure of the drug in DSC thermogram 
and PXRD pattern, respectively, are usually signs of amorphous or solid solution state of the 
drug within the polymer [166, 167]. FTIR can be used for identifying any chemical interaction 
between the drug and the polymer. An FTIR vibrational spectrum, characteristics for a given 
structure, is usually  obtained [168]. Any reduction or disappearance of the FRIR characteristics 
peaks of the encapsulated drug indicates an interaction between the drug and the polymer might 
have occurred.  
 
1.8.4. Drug Loading  
         After NPs preparation, it is of prime importance to determine whether the preparation 
procedure used for incorporating a drug into NPs was efficient or not. This point is also 
important when dealing with expensive drugs to be encapsulated into NPs. To this end, two main 
parameters are usually calculated to govern the process of drug loading; drug entrapment or 
encapsulation efficiency (% EE) and the loading efficiency (or drug loading, % DL). 
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      Because of the small size of nanoparticles, determinations of drug encapsulation, or drug 
loading are not always an easy task. Separation of free drug from bound or entrapped drug is 
firstly done by ultracentrifugation or ultrafiltration. Drug loading is then estimated either from 
the supernatant or after dissolution of the NPs sediment in an appropriate solvent [169-171]. In 
case of freeze-dried NPs, the particles are first dissolved then drug content can be easily analyzed 
[62, 85, 139, 172]. Depending on the loaded drug, various analytical methods can be used for 
drug detemination such as spectrophotometry, spectrofluorometry, and high performance liquid 
chromatography (HPLC). For example, UV spectroscopy was used to estimate drug loading 
efficiency of  PLGA NPs containing procaine hydrochloride after dissolving of NPs in 
acetonitrile [139]. In another case, high performance liquid chromatography (HPLC) was used to 
quantify acyclovir loaded into D,L-PLA NPs [85].  
 
1.8.5. Drug Release 
           In general, drug release from NPs is mainly governed by the following factors: (1) drug 
solubility; (2) desorption of the surface bound drug; (3) drug diffusion through the NPs matrix; 
(4) NPs matrix erosion; and (5) combination of erosion/diffusion process [58]. In case of 
uniformly distributed drug into the NPs matrix, the release occurs by diffusion or erosion of the 
matrix. In case of a crystalline drug being entrapped into the NPs matrix, drug dissolution occurs 
first followed by diffusion to initiate drug release. The rapid initial release or ‘burst’ is mainly 
attributed to desorption of the weakly bound or adsorbed drug close to the NPs surface.                                                              
          Unfortunately, the in vivo drug release environment is complex and may be difficult to 
simulate. However, in vitro release kinetics could be useful for quality control purposes and the 
prediction of in vivo release kinetic. Several techniques can be used to study the in vitro release 
pattern of the drug. Ultracentrifugation is widely used for studying the in vitro drug release [85, 
173-175]. Simply, it depends on stirring drug loaded NPs in a buffer solution mimicking blood 
components as phosphate buffer saline (PBS, pH 7.4) [175]. At predetermined intervals, a 
sample is withdrawn and ultracentrifuged. Then the drug content is analyzed from the 
supernatant by a suitable analytical method. Similarly, ultrafiltration can be used to separate the 
free drug from NPs [139, 176].   
        Dialysis bags are also used for studying the in vitro drug release. They are generally 
preferred over other methods because they save time and facilitate the separation of 
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nanoparticles from release media. NPs are immersed either in small dialysis bags in a stirred 
receptor (aqueous) medium [137, 146, 177] or in the medium containing drug-free dialysis bags 
(reverse dialysis) [171, 178]. The dialysis bag is impermeable to the NPs. The released drug 
could permeate the bag easily depending on the used molecular weight cutoff. Diffusion cells 
can also be used to monitor the drug diffusion from one compartment to another. Both 
compartments are separated from each other with a membrane that provides a possibility of drug 
not NPs permeation [179, 180]. 
 
1.9. Thesis Rationale and Research Objectives 
1.9.1. Rationale 
           Poly(lactic acid) (PLA) is a well-known biocompatible and biodegradable polyester 
polymer that is widely used in the medical field [46, 103, 181]. Different kinds of PLA-based 
drug carrier systems, such as nanoparticles, microparticles, nanocapsules, hydrogels and 
polymersomes have been prepared and investigated as a carrier for the delivery of numerous 
drugs.  Among these different carriers, nanoparticles are considered the most promising ones 
because of their superior performance either in vitro or in vivo. Nanoparticles made from 
biodegradable polymers or solid polymeric NPs including both nanospheres and nanocapsules 
offer some specific advantages over other nanoparticulate carriers. For instance, those polymeric 
NPs help to increase the stability of encapsulated drugs, and possess useful controlled release 
(CR) properties [58].    
          NPs made from PLA might suffer many drawbacks as their rapid uptake by the 
reticuloendothelial system after intravascular administration, low drug loading efficiency, 
inability to encapsulate a wide range of drugs particularly hydrophilic drugs, and in many cases 
inability to release their payload completely. Low drug incorporation of PLA usually leads to 
large drug loss during NP formulation, and hence, encapsulating insufficient drug amounts for 
therapeutic efficacy [137, 139]. The former situation necessitates the use of high polymer levels 
that might exceed their safety profile. Another drawback of PLA is that an initial burst release of 
drug can be observed in most loaded NPs, which may result in a loss of much of the therapeutic 
dose before the target site is reached by the NPs [58, 182].  Despite those drawbacks, little work 
was devoted to the development of functionalized PLA polymers in attempt to avoid the 
limitations of PLA homopolymer as drug carrier.  
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          Functionalized poly(D,L-lactide) (PLA) nanoparticles development mainly depend on  
introducing a flexible moiety onto PLA hydrophobic cores in attempt to improve the drug 
delivery properties of the obtained NPs. A variety of pendant substituents e.g. PEG, and palmitic 
acid could be grafted onto PLA to generate polymers of different physicochemical properties and 
hence different drug incorporation behavior than PLA itself. NPs formulated using those 
functionalized polymers is expected to have better delivery performance than PLA itself. 
Introduction of PEG into PLA cores could prolong the circulation time of PLA NPs in blood, 
enhance the encapsulation efficiency of PLA for many drugs particularly hydrophilic drugs, and 
enhance the drug release from PLA matrices.  
       Another interesting benefit from grafting PEG over PLA is to achieve small size particles 
benefiting from the surfactant properties of PEG-PLA polymers. This could be an advantage 
since the optimum size required to achieve an effective targeting is proposed to be 150-200 nm 
[52, 53]. Moreover, in order to achieve prolonged circulation of NPs in the blood, nanoparticles 
diameter should be ≤ 200 nm since the sub-200 nm size along with biocompatibility allows 
nanoparticles to avoid recognition by the MPS cells [183, 184]. Although the smallest capillaries 
in the body are 5-10 µm in diameter, the size of nanoparticles intended for parenteral 
administration and any possible aggregates should be far below this size to avoid blocking blood 
vessels and emboli formation [185]. Grafting PLA with palmitic acid moiety is expected to 
enhance the drug loading efficiency for hydrophobic drugs, change the release pattern of PLA 
particles since palmitate is expected to be embedded inside PLA domain lowering its chain 
rigidity. Fatty acid esters were found to have a remarkable plasticizing actions on PLA chains 
[186]. 
          It was the overall aim of this project to develop polymeric nanoparticles based on 
functionalized PLA polymers that could be used as an alternative to PLA homopolymer for the 
encapsulation of different drugs. Physicochemical properties of NPs, as well as their 
performance as drug delivery systems are affected; to a great extent by the properties of the 
copolymers used to formulate them [110, 187, 188]. Thus, chemical structure and surface 
properties of polymer biomaterials have been shown to affect NPs delivery performance either in 
vitro or in vivo [189, 190]. We believe that an understanding of the effects of polymer 
architecture on the properties of NPs in general and PLA in particular will result in the 
predictable improvement of existing biopolymers and the design of new biocompatible polymers. 
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To reveal the effect of these parameters on the properties of PLA NPs, we developed four 
functionalized PLA polymers: (i) two copolymers identical in terms of the grafting density (i.e. 
% of grafted moiety or pendant substituent inserted onto PLA backbone), but different in terms 
of the solubility of grafted moiety; and (ii) two copolymers identical in terms of the length of 
PEG blocks, but different in terms of the chain organization of the PEG block. The ability of 
these four copolymers to act as drug carrier was investigated using a model drug, ibuprofen. 
Moreover, the effect of polymer architecture on the physicochemical properties of PLA NPs was 
investigated in comparison to PLA itself. NPs were analyzed for the major physicochemical 
parameters such as encapsulation efficiency, size and size distribution, surface charge, thermal 
properties, surface chemistry, % poly(vinyl alcohol) (PVA) adsorbed at the surface of NPs, and 
drug release pattern. Surface chemistry analysis using x-ray photoelectron spectroscopy (XPS), 
and phase imaging AFM were used to study the chain organization behavior of each 
functionalized NPs during NPs formulation. Special emphasis was devoted to PEG-g-PLA 
polymers trying to optimize their drug delivery performance. The effect of different PEG 
grafting densities over PLA backbone on the properties of PEG-g-PLA NPs either 
physicochemical or biological properties was investigated to reveal the optimal PEG grafting 
density required to develop stealth particles. Finally, functionalized PEG/PLA polymer that 
showed the most satisfactory results in terms of various drug delivery aspects, such as small size, 
neutral surface charge, high drug loading, and controlled drug release was chosen for 
encapsulation of itraconazole in attempt to improve its aqueous solubility, bioavailbility and 
hence its fungal properties. 
 
1.9.2. Research Objectives 
1. Synthesis and characterization of functionalized PLA polymers according to a previously 
published protocol by our group [127]. 
      Summary: Various linear and branched poly(D,L-lactide) (PLA) based polymers, namely, 
PLA homopolymer, poly(ethylene glycol) (PEG) grafted on PLA backbone at 2.5% & 7% 
grafting density (PEG2.5%-g-PLA and PEG7%-g-PLA, respectively), palmitic acid grafted on 
PLA backbone at 2.5% grafting density (palmitic acid2.5%-g-PLA), and multiblock copolymer 
of PLA and PEG, (PLA-PEG-PLA)n were synthesized. 
 
  
27
2. Studying the effect of aqueous solubility of grafted moiety on the physicochemical properties 
of Poly (D,L-lactide) (PLA) based nanoparticles (research paper published in International 
Journal of Pharmaceutics). 
     Summary: In this part, the effect of grafting PLA backbone with two substituents of nearly 
similar grafting density but having different solubility profile, on the physicochemical properties 
of PLA NPs was investigated. The polymers used in this part are; PEG2.5%-g-PLA, and palmitic 
acid2.5%-g-PLA. 
 
3. Studying the effect of polyethylene glycol (PEG) chain organization on the physicochemical 
properties of Poly (D,L-lactide) (PLA) based nanoparticles (research paper published in 
European Journal of Pharmaceutics and Biopharmaceutics). 
      Summary: In this part, a comparative study of the physicochemical properties of NPs 
obtained from two PEG/PLA copolymers of different architecture and nearly similar PEG chain 
length, PEG7%-g-PLA and (PLA-PEG-PLA)n polymers was done. Mode of PEG chains 
organization on the surface of PLA NPs was also investigated using XPS and phase imaging 
AFM. 
 
4. Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): Effect of 
poly(ethylene glycol) grafting density (research paper published in International Journal of 
Pharmaceutics). 
      Summary: In this part, the effect of PEG grafting density (1, 7, or 20 % mol/mol of lactic 
acid monomer) on both physicochemical and biological properties (mainly plasma protein 
binding and in vitro macrophage uptake) of PEG-g-PLA NPs was studied. The optimal PEG 
grafting density required to develop stealth PEG-g-PLA NPs suitable for parenteral 
administration was also investigated. 
 
5. Improved antifungal activity of itraconazole loaded PEG/PLA nanoparticles (research paper 
to be submitted). 
      Summary: In this part, a nanocarrier drug delivery system based on PEG/PLA copolymers 
was developed for the encapsulation of the antifungal drug, itraconazole (ITZ). NPs were 
developed to provide a controlled release pattern of ITZ as well as to improve its aqueous 
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solubility and hence enhance its antifungal action. The antifungal capability of ITZ loaded NPs 
was investigated using both Candida and Aspergillus species. Two PEG modified PLA polymers 
(PEGylated polymers) were used in this part; PEG7%-g-PLA, and multiblock copolymer of PLA 
and PEG, (PLA-PEG-PLA)n with nearly similar PEG insertion ratio and the same PEG chain 
length. 
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2.1. Abstract 
          In order to evaluate the solubility effect of grafted moiety on the physicochemical 
properties of poly(D,L-lactide) (PLA) based nanoparticles (NPs), two materials of 
completely different aqueous solubility, polyethylene glycol (PEG) and palmitic acid 
were  grafted on PLA backbone at nearly the same grafting density, 2.5% (mol of grafted 
moiety/mol of lactic acid monomer). Blank and ibuprofen-loaded NPs were fabricated 
from both polymers and their properties were compared to PLA homopolymer NPs as a 
control. NPs were analyzed for major physicochemical parameters such as encapsulation 
efficiency, size and size distribution, surface charge, thermal properties, surface 
chemistry, % poly(vinyl alcohol) (PVA) adsorbed at the surface of NPs, and drug release 
pattern. Encapsulation efficiency of ibuprofen was found to be nearly the same for both 
polymers ~ 36 % and 39 % for PEG2.5%-g-PLA and palmitic acid2.5%-g-PLA NPs, 
respectively. Lyophilized NPs of palmitic acid2.5%-g-PLA either blank or loaded 
showed larger hydrodynamic diameter (~ 180 nm) than PEG2.5%-g-PLA NPs (~ 135 
nm). PEG2.5%-g-PLA NPs showed lower % of PVA adsorbed at their surface (~ 5% 
w/w) than palmitic acid2.5%-g-PLA NPs (~ 10 % w/w). Surface charge of palmitic 
acid2.5%-g-PLA NPs seems to be influenced by the large amount of PVA remains 
associated within their matrix. Thermal analysis using DSC revealed possible drug 
crystallization inside NPs. Both AFM phase imaging and XPS studies revealed the 
tendency of PEG chains to migrate towards the surface of PEG2.5%-g-PLA NPs. While, 
XPS analysis of palmitic acid2.5%-g-PLA NPs showed the tendency of palmitate chains 
to position themselves into the inner core of the forming particle avoiding facing the 
aqueous phase during NPs preparation using O/W emulsion method. The in vitro release 
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pattern showed that PEG2.5%-g-PLA NPs exhibited faster release rates than palmitic 
acid2.5%-g-PLA NPs. PEG and palmitate chains when grafted onto PLA backbone, 
different modes of chain organization during NPs formation were obtained, affecting the 
physicochemical properties of the obtained NPs. The obtained results suggest that the 
properties of PLA- based NPs can be tuned by judicious selection of both chemistry and 
solubility profile of grafted material over PLA backbone.  
 
2.2. Keywords 
         Poly(D,L-lactide), PEG-PLA NPs, palmitic acid-PLA NPs, chain organization, X-
ray photo-electron spectroscopy (XPS) , phase imaging atomic force microscopy (AFM). 
 
2.3. Introduction 
            Controlled release technology began in 1970s and since that time great interest 
has been paid to this technology. Recently, colloidal drug carriers are widely used for the 
development of controlled release systems for large number of drugs. Those carriers 
possess important applications in the pharmaceutical field. Moreover, they offer 
numerous advantages over conventional drug delivery systems such as controlled drug 
release rate, improved therapeutic efficiency, prolonged biological activity and decreased 
administration frequency [1]. They may also act as stabilizer protecting entrapped drugs 
against degradation. A way of modifying the original pharmacokinetics and 
biodistribution of drugs is to incorporate them in submicroscopic colloidal carriers. 
Numerous classes of colloidal carriers composed of different materials including lipids, 
polymers and inorganic materials have been developed, resulting in different delivery 
51 
 
systems that vary in their physicochemical properties and thus their pharmaceutical uses. 
Growing interest in formulating NPs from synthetic polymers with tunable properties is 
rapidly expanding. 
             Despite the identification of various factors that might influence the properties of 
polymeric NPs such as the physicochemical properties of polymer and the drug [2], their 
interaction with each other [3], drug load [4], drug distribution inside the carrier, and size 
and morphology of the carrier [5], chemical constitution effect and solubility profile of 
grafted moiety of the used polymer on various drug delivery aspects remains to be 
adequately addressed. Although different nanosystems have been developed, the effect of 
grafting the starting polymer with various grafted moieties needs to be realized and 
emphasized for each nanosystem. In fact, grafting the same polymer with different 
materials  will  not only affect the physicochemical properties of the polymer, but also 
various drug delivery facets including, drug release rate, pharmacokinetics and 
biodistribution of the carrier, and even cellular uptake of the nanocarrier in vivo. It was 
previously shown that the molecular architecture of the polymer affects the cellular 
interaction of NPs prepared from different polymers [6].  
        This work is the first in-depth study of the effect of chain organization of the grafted 
moiety of the starting polymer on the major physicochemical aspects of drug delivery 
from PLA-based NPs e.g. size of the carrier, surface charge, matrix erosion, and drug 
release profile. NPs formulated using PLA-b-PEG block copolymers were extensively 
investigated in the past [7-9]. Up to now, however, relatively fewer studies have focused 
on grafted pegylated copolymer of PLA and PEG, used in our study. 
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       Objective of the present work is to compare the effect of two grafted materials of 
different composition and aqueous solubility on the physicochemical properties of PLA-
based NPs.  Effect of grafted moiety on polymer chains organization during NPs 
formation was also investigated using relatively new techniques like XPS and phase 
imaging-AFM. PLA homopolymer was proposed as the control NPs and either 
hydrophilic (PEG) or hydrophobic (palmitic acid) substance was grafted onto PLA 
backbone at nearly the same grafting density 2.5 % (mol/mol of lactic acid monomer), 
according to a previously published method by our group [10]. Ibuprofen was used as a 
model lipophilic drug to be encapsulated by PLA and grafted PLA NPs.  NPs were 
prepared using (O/W) emulsion solvent evaporation method. PVA was used as an 
emulsifier during NPs preparation since it aids the formation of relatively small sized 
particles with uniform size distribution [11]. 
 
2.4. Material and methods:  
2.4.1. Materials: 
          D,L-dilactide, poly(ethylene glycol) methyl ether (MePEG; 2000 Da) , allyl 
glycidyl ether, tetraphenyltin, polyvinyl alcohol (PVA, average Mw 9000-10,000 Da, 80% 
hydrolyzed), pyridine, acetone, diethyl ether, thionyl chloride, borane-tetrahydrofuran 
complex (1 M), and palmitoyl chloride were purchased from Aldrich Chemical Company 
Inc., Milwaukee, USA. Ibuprofen was obtained from Medisca Pharmaceutical Inc., 
Montreal, Quebec, Canada. Sodium hydroxide pellets were purchased from Anachemia 
Canada Inc. and dichloromethane (DCM) was purchased from Laboratoire Mat Inc., 
Montreal, Quebec, Canada.   
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2.4.2. Synthesis of Polymers.  
          Poly(D,L)-lactide (PLA) was synthesized by ring-opening polymerization of 
dilactide in argon atmosphere, using tetraphenyltin as the catalyst. Briefly, dilactide was 
crystallized from toluene solution and dried under vacuum before use. A weighed amount 
of purified dilactide was then placed in a round-bottom flask and purged thoroughly with 
argon. Bulk polymerization was carried at 180 °C for 6 h. The polymer thus obtained was 
dissolved in acetone and was purified by precipitating in water.  
          Polymer with poly(ethylene glycol)-grafted randomly on poly(D,L)-lactide 
(PEG2.5%-g-PLA) (PEG; Mw 2000 Da) was synthesized in our laboratory as reported 
earlier [10]. Briefly, D,L-dilactide (21.5 g, 97.5 mol %) was polymerized in the presence 
of allyl glycidyl ether (0.872 g, 2.5 mol %) with tetraphenyltin as the catalyst (1:10 000 
mol with regards to D,L-dilactide) at 180 °C for 6 h under argon. Polylactic acid with 
allyl groups was purified by dissolving in acetone and precipitating in water. The allyl 
groups were converted to hydroxyl groups by hydroboration with an equimolar quantity 
of borane in tetrahydrofuran, followed by oxidation in the presence of hydrogen peroxide 
under alkaline conditions (1.5 mol of 3 N sodium hydroxide). The hydroxyl groups were 
oxidized to carboxylic acid groups using Jones reagent, which was further converted to 
an acid chloride using thionyl chloride (1:1000 M). Finally, methoxy-PEG was grafted 
onto the polymer backbone by the reaction between acid chloride and the hydroxyl 
groups of methoxy-PEG (2000 Da) in the presence of pyridine. The final polymer was 
purified by evaporating pyridine and washing with distilled water.  
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      Palmitic acid grafted on PLA backbone at 2.5% grafting density, palmitic acid2.5%-
g-PLA was synthesized as follows, to a solution of PLA grafted with 2.5 % hydroxyl 
pendant groups (1g, 0.136 mmol) in 50 mL pyridine, palmitoyl chloride (1.8 g, 6 mmol) 
was added. The solution was stirred for 3h and then, 10 mL water was added. The solvent 
was evaporated and the product was crystallized in diethyl ether to obtain a yellow 
product.1H NMR spectra were recorded on a Brucker ARX 400 spectrometer (Bruker 
Biospin, Billerica, MA). Chemical shifts () were measured in parts per million (ppm) 
using tetramethylsilane (TMS) as an internal reference. Gel permeation chromatography 
(GPC) was performed on a Water Associate chromatography system (Waters, Milford, 
MA) equipped with a refractive index detector and a Phenomenex Phenogel 5  column. 
Polystyrene standards were used for calibration with THF as the mobile phase at a flow 
rate of 0.6 mL/min.  
 
2.4.3. Preparation of nanoparticles (NPs) 
          NPs were prepared using an (O/W) emulsion-solvent evaporation method. For 
blank NPs, each polymer (1 g) was dissolved in 35 mL DCM and emulsified in 100 mL 
PVA solution (0.5% w/v) as an external aqueous phase using high-pressure homogenizer 
(Emulsiflex C30, Avestin, Ottawa, Canada) at a pressure of 10,000 psi for 5 min. The 
emulsion was collected by washing with another 100 mL 0.5% PVA. The DCM was 
evaporated under reduced pressure with constant stirring to obtain the NPs. Finally, NPs 
obtained as a suspension were then collected by centrifugation at 18500 rpm for 1 hr at 4 
ºC (Sorval® EvolutionRC, Kendro, USA), washed four times with distilled water, then 
lyophilized to obtain dry NPs (Freeze Dry System, Lyph.Lock 4.5, Labconco) and stored 
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at 4 ºC until further use. Ibuprofen loaded NPs were prepared in a similar manner to that 
of blank NPs using initial loading of 10% w/w of each polymer. Ibuprofen was first 
dissolved in the organic phase followed by dissolution of the polymer. The emulsification 
and purification steps procedure were repeated as before. 
 
2.4.4. Characterization of NPs 
2.4.4.1. Particle size and zeta ( ) potential measurements 
          The mean hydrodynamic diameters (dh) and the polydispersity indices (PDIs) of 
NPs were measured by DLS with a Malvern Autosizer 4800 instrument (Malvern 
Instruments, Worcestershire, UK) before and after lyophilization. For all samples, fresh 
NP suspensions (0.1 mL) or lyophilized NPs (1 mg) were diluted 10 times with Milli-Q 
Water. Measurements were taken at a fixed scattering angle of 90° and at 25° C. The 
CONTIN program was used to extract size distributions from the autocorrelation 
functions. Zeta-potential measurements of NPs suspended in 0.25% w/v saline solution 
(pH 7.4) were done on Malvern ZetaSizer Nanoseries ZS (Malvern Instruments, 
Worcestershire, UK). Both measurements were performed in triplicate 
2.4.4.2. Determination of residual PVA 
           A colorimetric analysis was used for determination of PVA amount remaining in 
the NPs. The method is simply based on the formation of a colored complex between two 
adjacent hydroxyl groups of PVA and an iodine molecule [11] . For surface associated 
PVA, certain weight of NPs was suspended in distilled water followed by vigorous 
vortexing for 10 min., then fixed volumes of all formulations were taken followed by 
addition of 5 mL of saturated solution of boric acid and 0.5 mL iodine (0.1 N), and the 
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volume was made up to 10 mL with distilled water. The absorbance of the formed 
complex was measured at 660 nm against similarly treated blank. Whereas for the total 
amount of PVA associated with the particles (amount entrapped inside the matrix as well 
as present on the surface), NPs were digested in 1 N NaOH then neutralized by 1 N HCl 
followed by stirring for 1 h and the volume was made up to 5 mL with distilled water. To 
this, 3 mL of saturated solution of boric acid and 0.5 mL iodine (0.1 N) were added, and 
the volume was made up to 10 mL with distilled water. The absorbance was measured as 
before. PVA actual amount was calculated by using a calibration curve of PVA prepared 
under the same conditions. 
 
2.4.4.3. NPs surface morphology and phase image analysis 
          Nanoscope IIIa Dimension 3100 atomic force microscope (Digital Instruments, 
Santa Barbara, CA, USA) was used to study both surface morphology and phase imaging 
of lyophilized NPs. Samples were prepared by deposition of particles suspension in Milli-
Q Water on freshly cleaved mica followed by air-drying for 10 min at room temperature. 
Topography and phase images of these samples were captured simultaneously using 
TappingModeTM etched silicon probes (TESP7) with tip radius of 5–10 nm, spring 
constant of 20–100 N/m and resonance frequency of 200–500 kHz. Cantilever length was 
125 m.  
 
2.4.4.4. Encapsulation efficiency (EE) 
           For ibuprofen loaded NPs of PLA homopolymer and PEG2.5%-g-PLA, weighed 
amount of NPs was digested in 1 N NaOH for 1 h. Ibuprofen concentration was measured 
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Amount of drug entrapped in NPs 
Initial amount of drug added 
% EE = 
X 100  (1) 
 
% LE = 
Total amount of NPs 
X 100  (2) 
 
Amount of drug entrapped in NPs 
by spectrophotometry at 264 nm (U-2001 UV/Visible spectrophotometer, Hitachi). 
While, for palmitic acid2.5%-g-PLA loaded NPs, weighed NPs were also suspended in 1 
N NaOH for 1 h to which chloroform was added followed by vigorous stirring for 
another 3 h to extract ibuprofen into the chloroform layer. Then, the chloroform layer was 
collected and ibuprofen concentration was measured by spectrophotometry at 263 nm. 
Percent encapsulation efficiency (% EE) and % actual loading efficiency (% LE) were 
calculated based on the following equations: 
 
 
 
 
 
 
 
 
 
 
2.4.4.5. Differential Scanning Calorimetry (DSC) 
          The thermal properties of polymers and drug in the physical mixture and NPs were 
characterized by DSC analysis (DSC 30, Mettler TA 4000, Schwerzenbach, Switzerland) 
with refrigerated cooling. Measurements were done (n =2) on all investigated samples. 
Physical mixtures were prepared by triturating polymer and ibuprofen in a ratio similar to 
drug loaded NPs. In brief, weighed samples were sealed in crimped aluminum pans with 
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lids and heated at a rate of 10 °C/min from -50 to 200 °C for polymers and physical 
mixtures, while for NPs the samples were heated from -50 to 90 °C  at the same heating 
rate. 
 
2.4.4.6. XPS analysis 
          X-ray photoelectron spectroscopy, XPS (VG Scientific ESCALAB MK II) with a 
monochromatized Mg Ka X-rays (hv 1253.6 eV) and an electron take off angle of 0º was 
used to study the surface chemistry of pure materials, polymers, blank, and drug-loaded 
NPs. A single survey scan spectrum (0–1000 eV) and narrow scans for C1s (210–305 eV) 
and O1s (525–550 eV) were recorded for each sample with a pass energy of 1 and 0.5 
eV, respectively. Acquisition and data analysis were performed by a VGS 5000 data 
system. Peak fitting of the C1s envelope was as described by Shakesheff et al [12].  
 
2.4.4.7. 1H NMR spectroscopy 
           50 mg of lyophilized NPs of each polymer was suspended in deuterium Oxide 
(D2O). 1H NMR spectra were recorded on a Brucker ARX 400 spectrometer (Bruker 
Biospin, Billerica, MA). Chemical shifts () were measured in parts per million (ppm) 
using tetramethylsilane (TMS) as an internal reference. 
 
2.4.4.8. Erosion study 
          Mass losses of  PLA (A), PEG2.5%-g-PLA (B), and Palmitic acid2.5%-g-PLA (C) 
NPs were done by  suspending 50 mg of NPs for each time interval in 10 mL PBS, pH 
7.4 at 37 ºC in shaking water bath. The study was terminated at 0, 5, 14, 25, 35 and 45 
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days. Samples were centrifuged (5000rpm, 10 min) at the end of each time interval. The 
residues were washed two times with water to remove phosphate buffer and lyophilized 
for 24 h. The final mass of NPs was determined at each time point. 
 
2.4.4.9. In vitro drug release study 
          NPs formulations prepared using different polymers were tested for in vitro release 
of ibuprofen in triplicates in phosphate buffered saline (PBS, 10 mM, pH 7.4.). 150 mg 
NPs were suspended in 3.5 mL PBS in a dialysis tubing (Spectra Por 1 membrane, 6–8 
kDa cut-off). This dialysis tubing was placed in a screw-capped tube containing 10 mL 
PBS. The tubes were shaken at 200 rpm on a horizontal water bath shaker (Orbit Shaker 
Bath, Labline) maintained at 37±0.5 ºC. At predetermined time intervals, the whole 
medium in the tube was withdrawn and replaced by fresh PBS to maintain sink 
conditions. The aliquots were assayed for the concentration of ibuprofen released by 
spectrophotometry at 262 nm. 
 
2.5. Results and discussion: 
2.5.1. Characterization of Polymers.  
          Gel permeation chromatography (GPC) was used to measure molecular weight and 
molecular weight distribution of the synthesized polymers. Results are shown in Table 
2.1. The polydispersity was calculated by the ratio of Mw to Mn from the GPC data. All 
the synthesized polymers exhibited uniform molecular weight distribution as revealed by 
the narrow polydispersity index values. Unimodal mass distribution ruled out the 
possibility of the presence of unreacted MePEG or palmitoyl chloride with Poly(D,L-
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lactide). Typical spectrum was obtained for PLA homopolymer with a characteristic peak 
at 5.2 ppm corresponding to the tertiary PLA proton (m, -CH), and another peak at 1.5 
ppm for the pendant methyl group of the PLA chain (m, -CH3) (spectrum not shown). 1H 
NMR spectra and chemical structures of PEG2.5%-g-PLA and palmitic acid2.5%-g-PLA 
polymers are shown in Figure 2.1. A characteristic peak at 5.2 ppm corresponding to the 
tertiary PLA proton (m, -CH) was observed. Another characteristic peak at 3.6 ppm for 
the protons of the repeating units in the PEG chain (m, OCH2-CH2O), a peak at 4.3 ppm 
for the PEG connecting unit to the PLA block (m, CH2-OCO), and a peak at 1.5 ppm for 
the pendant methyl group of the PLA chain (m, -CH3) were also observed. The grafting 
density of PEG over the PLA backbone was calculated by comparing the peak intensity 
ratios of PEG (3.6 ppm) to that of PLA (5.2 ppm). The actual PEG grafting density was 
found to be 2.3 % that is close to the initial feed ratio of PEG as shown in Table 2.1. For 
palmitic acid2.5%-g-PLA polymer, the signal observed at 1.2–1.3 ppm corresponds to the 
twelve hydrogens of the palmitate CH2. The signal at 0.8– 0.9 ppm is due to the 
palmitate CH3. Palmitate grafting density was calculated by comparing peak intensity 
ratio of palmitate CH3 (0.9 ppm) and PLA (5.2 ppm). The final palmitic acid grafting 
percentage was 1.02 % that is also close to the initial feed ratio as shown in Table 2.1.  
 
2.5.2. Particle size and size distribution 
          Dynamic light scattering (DLS) data showed unimodal distribution for freshly 
prepared and lyophilized NPs in all batches. Different blank formulations showed nearly 
similar particle size to that of loaded ones for all NPs types in the range of 120–200 nm 
(Table 2.2).  
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Table 2.1. Polymers characterization by 1H NMR, DSC, and Gel Permeation Chromatography (GPC). 
 
 
 
 
 
 
 
 
 
 This might indicate that drug loading had no observable effect on NPs size, suggesting 
that the size was mainly controlled by homogenization parameters during NPs 
preparation. Lyophilized palmitic acid2.5%-g-PLA NPs either blank or loaded seems to 
have larger hydrodynamic diameters than those obtained with PEG2.5%-g-PLA NPs as 
shown in Table 2.2. This could be explained by the fact that palmitic acid2.5%-g-PLA 
NPs is more hydrophobic compared to PEG2.5%-g-PLA NPs. The hydrophobic nature of 
the obtained particles might induce their aggregating tendency due to hydrophobic 
interactions. The aggregating tendency of palmitic acid2.5%-g-PLA NPs was confirmed 
later by AFM surface analysis (Fig. 2.2(c), left panel, T). While in PEG2.5%-g-PLA, the 
Polymer Mna Mwa Mw/Mna PEG/Palmitate   
(mol%)b 
Mn (1H NMR)b Tgc  
PLA 40,318 56,171 1.4 N/A N/A 46.4 ºC 
PEG2.5%-g-PLA 4706 5171 1.1 2.3 % 8209 50 ºC 
 
Palmitic acid2.5%-g-PLA 10,185 14,050 1.4 1.02 % 14,514 19 ºC  
N/A: not analyzed. 
a Determined by GPC analysis using narrow molecular weight polystyrene standards. 
a Mw/Mn =Polydispersity index of the polymers (PDI). 
b Calculated from peak intensity ratios of PEG (3.6 ppm) in PEG2.5%-g-PLA or palmitate  
CH3 (0.9 ppm) in palmitic acid2.5%-g-PLA and PLA (5.2 ppm) from 1H NMR data analysis. 
c Calculated from the second run of DSC as half of the extrapolated tangents in case of PLA  
and palmitic acid2.5%-g-PLA or as an endothermic peak in case of PEG2.5%-g-PLA. 
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 Figure 2.1. 1H NMR spectra and chemical structures of PEG2.5%-g-PLA (1), and palmitic acid2.5%-
g-PLA (2).  
 
polymer architecture will allow PEG chains to migrate freely towards the surface of NPs 
during NPs preparation by O/W emulsion method. This would create a steric barrier 
reducing NPs aggregating tendency.  
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2.5.3. Zeta ( ) potential measurements 
          PLA and palmitic acid2.5%-g-PLA blank NPs showed lower zeta potential (close 
to zero) values than expected, -3.5 mV and -0.4 mV, respectively. This low -potential 
for both NPs could be attributed to the effective adsorption of PVA on the surface of NPs 
as will be seen in the next section which could mask the surface charge of PLA and/ or 
palmitic acid in case of PLA and palmitic acid2.5%-g-PLA NPs, respectively. -Potential 
value of palmitic acid2.5%-g-PLA NPs were lower than PLA NPs and this might be due 
to higher amount of PVA adsorbed onto the surface (8.6 % w/w) compared to PLA NPs ( 
6.7 % w/w) (Table 2.2).  Loaded NPs of both polymers also showed low zeta potential 
values explained by the same reason. Zambaux et al. also obtained a low zeta potential 
value of -4 mV for PLA NPs prepared with PVA as an emulsifier [13]. PEG2.5%-g-PLA 
NPs had also low zeta potential and this could be attributed to shielding action of PEG on 
the surface charge. Similar results to ours were reported earlier by other authors [14-16]. 
Moreover, the greater reduction in zeta potential value of PEG2.5%-g-PLA NPs 
compared to other PEG-PLA NPs reported in the last cited references could be explained 
by the existence of PVA at the surface of NPs which played also a role in masking their 
actual surface charge. PEG2.5%-g-PLA NPs showed a remarkable adsorption of 5% w/w 
PVA onto their surface as shown in Table 2.2.  
 
2.5.4. Residual PVA 
          One of the drawbacks of NPs formulation using emulsion solvent evaporation 
method is the residual surfactant remaining in NPs suspension after particles precipitation 
in the aqueous phase. Residual surfactant becomes adsorbed onto the surface of freeze 
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dried nanoparticles irrespective of the number of washing steps performed to remove it. 
This might lead to alteration of NPs physicochemical properties such as particle size, 
hydrophilicity, release kinetics, cellular uptake, etc. [11]. PVA amount remained attached 
to the nanoparticles needed to be evaluated to detect whether they are affected by the 
composition and the architecture of the starting polymer or not. It could be seen that a 
different amount of PVA remained in all the formulations even after 4 washings (Table 
2.2). It was found that the highest amounts of PVA remained attached to NPs matrix were 
9.8 % and 6.8 % w/w for palmitic acid2.5%-g-PLA and PLA NPs, respectively (Table 
2.2). This might be attributed to the enhanced hydrophobic interaction between acetate 
group of PVA and the hydrophobic PLA matrix as reported before by other authors [11, 
17]. Similar findings were obtained before by other authors. When 1% w/v PVA was 
used as an external aqueous phase emulsifier, 5–6% w/w PVA remained attached within 
PLA NPs even after 3 washings [13]. PLGA NPs also exhibited a remarkable adsorption 
of 6.15% w/w PVA into their matrix when 5% w/v PVA solution was used as an 
emulsifier. Since palmitic acid2.5%-g-PLA is expected to be more hydrophobic than 
PLA so more interaction with acetate group of PVA might take place. PEG2.5%-g-PLA 
exhibited less PVA adsorption (5% w/w, Table 2.2) onto their surface and this might be 
due to their PEG content which offered a certain degree of hydrophilicity to the NPs 
matrix so a less favored interaction with PVA should be expected. PVA amount adsorbed 
at the surface of more hydrophilic PLGA microspheres was found to be less than PLGA 
microspheres [12]. Also, blank NPs showed similar amount of PVA adsorbed on their 
surfaces as loaded NPs indicating that drug loading had no apparent effect on the amount 
of PVA associated within the NPs matrix. An attempt was made to evaluate whether 
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PVA was present either inside the polymeric matrix or on the surface of the particles. 
Nearly the same amount of PVA was present in the given NPs formulations by both 
assays confirming that the amount of PVA was mainly associated with the surface of the 
particles (data not shown).  
 
2.5.5. Surface morphology and phase analysis 
          Tapping mode atomic force microscopy (TM-AFM) was used for analysis of 
surface morphology of NPs. TM-AFM revealed that both PLA and PEG2.5%-g-PLA NPs 
were spherical with smooth surfaces. While palmitic acid2.5%-g-PLA NPs seems to have 
some irregularities at their surface. This might indicated their aggregating tendency (Fig. 
2.2(c), left panel, T) confirming the size data obtained by DLS. Phase image analysis was 
done to investigate the surface chemistry of the obtained particles. It shows more 
sensitivity to material surface properties such as stiffness, viscoelasticity, and chemical 
composition [18-20]. Phase imaging is based on the use of changes in the phase angle of 
cantilever probe. Figure 2.2 shows TM-AFM topography (left panel, T) and their 
corresponding phase images (right panel, P) of PLA, PEG2.5%-g-PLA, and palmitic 
acid2.5%-g-PLA NPs, respectively. It is evident from Figure 2.2 that phase images 
displayed more contrast than the respective topographic images. Phase images of PLA 
NPs didn’t show any clear phase separation evidenced by no colour contrast was 
observed [Fig.2.2(a); right panel, P). On the other hand, PEG2.5%-g-PLA NPs showed 
the presence of an observable phase contrast at the surface of NPs revealed by some dark 
layers at the surface of bright cores [Fig.2.2(b); right panels, P]. PEG molecules of lower 
Mw 2000 (used in our study) have smaller Young’s modulus than PLA so they are 
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expected to be softer than PLA [21]. Those mechanical differences between PLA and 
PEG will result in such phase contrast. Thus, it was expected that PEG molecule will 
result into darker regions for PEG in the phase images. This was investigated before for 
poly(styrene-b-ethylene oxide) polymer films, where softer PEG segments appeared as 
darker regions embedded in lighter polystyrene domain [22]. The immiscibility of both 
PEG and PLA blocks would result in separation of both components during NPs 
formation. Thus, PEG2.5%-g-PLA NPs will be predominantly consisting of hydrophobic 
PLA cores surrounded by hydrophilic PEG chains on the surface (Figure 2.2(b), phase 
image, P). While, in case of palmitic acid2.5%-g-PLA (Fig.2.2(c), NPs appear as if they 
were collapsed together with some deformation. This might be due to energy dissipation 
during tip-sample interaction. The last finding could be explained on the basis of the soft 
nature of the polymer resulted from grafting palmitic acid over PLA backbone. Palmitate 
chains are expected to lower the chain rigidity of PLA domains evidenced by the lower 
Tg of the polymer (19 ºC) compared to PLA homopolymer (46.4 ºC ) as will be revealed 
from DSC data (Table 2.1). Another predisposing factor for palmitic acid-g-PLA NPs 
deformation by AFM tip is that they were dried at room temperature above their Tg (19 
ºC). This might favored the existence of the polymer chains in their mobile rubbery state. 
 
2.5.6. Encapsulation efficiency (EE) 
          As seen from Table 2.2, % EE of ibuprofen was found to be 36.6 % and 39.5 % for 
PEG2.5%-g-PLA, and palmitic acid2.5%-g-PLA NPs, respectively. No marked 
difference between both polymers ability to encapsulate the drug was detected. This 
might be due to small grafting density of each polymer since 2.5 % (mol of grafted subs. 
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/mol of lactic acid) might not be big enough to affect the loading level of PLA NPs. 
Another possible reason is  the larger surface area of the obtained NPs that resulted from 
the smaller particle size of either PEG2.5%-g-PLA (135 nm) or palmitic acid2.5%-g-PLA 
NPs (147 nm), readily result in higher drug diffusion to the aqueous phase and hence, 
limited drug loading (Table 2.2) [23]. Moreover, grafting palmitate over PLA backbone 
might decreased the density of the obtained NPs (evidenced by low Mw of palmitic 
acid2.5%-g-PLA compared to high Mw PLA, Table 2.1) leading to slower precipitation 
of NPs compared to the denser PLA and this might give a chance for the drug to diffuse 
freely into the aqueous phase.  
 
2.5.7. DSC 
           DSC was used to detect the effect of grafted substance of the used polymer on the 
thermal properties of NPs. DSC was also used for investigating any possible interaction 
between the drug and the polymeric matrix. PLA showed glass transition (Tg) at 46.4 °C 
(Table 2.1). Random grafting of PEG on the PLA backbone resulted in an increased Tg 
value (by about 4 °C) due to enhanced chain rigidity (Table 2.1 and Figure 2.3.a). For 
palmitic acid2.5%-g-PLA, the glass transition of the polymer was found to be 19 ºC with 
the existence of an endothermic peak at 58 ºC corresponding to the melting peak of the 
palmitic acid crystals (Table 2.2 and Fig.2.3.b). The melting endotherm of palmitic acid 
was shifted by 4 ºC lower compared to pure palmitic acid indicating the possibility of 
physical interaction (hydrophobic interaction) between the grafted palmitic acid group 
and PLA.  
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Table 2.2. Characteristics of different NPs formulation. 
 
 
 
 
 
 
 
 
 
 
 
Formulation Size (dh) before  
freeze drying  
(nm) a, d   
 PDI b Size (dh) after 
freeze drying  
(nm) a, d 
   PDI b        Actual 
loading 
(% w/w) d   
% EE c ,d Zeta  
potential  
(mV) a, d 
Surface  
adsorbed 
PVA 
(%w/w)  d 
PLA (*) 
 
184±20.8 0.13 161±18.4 0.01 N/A N/A -3.50 ±3.1 6.76±0.4 
 
PLA (**) 
 
194±30.0 0.08 162±22.3 0.09 4.50±0.2 45.0±2.2 -0.18 ± 3.2 6.80±0.2 
PEG2.5%-g-PLA (*) 
 
122±31.6 0.14 145±24.7 0.03 N/A N/A -1.30 ± 3.5 4.87±0.4 
PEG2.5%-g-PLA (**) 
 
135±22.9 0.11 135±32.7 0.01 3.56±0.1 36.6±1.5 -0.60 ± 3.9 5.00±0.7 
Palmitic acid2.5%-g-PLA (*) 
 
176±19.7 0.04 181 ±30.8 0.13 N/A N/A -0.40 ± 3.1 8.60±0.4 
Palmitic acid2.5%-g-PLA (**) 
 
147±22.4 0.06 183±22.2 0.12 3.86±0.2 39.5±0.7 -0.14 ± 3.7 9.80±0.5 
a median. 
b refers to polydispersity index. 
C refers to encapsulation efficiency. 
d All values indicate mean±S.D. for n=3 independent measurements. 
N/A: not analyzed. 
(*) refers to blank NPs (unloaded).              
(**) refers to Loaded NPs. 
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Figure 2.2. Tapping mode AFM images of NPs, left panel shows topography (T) and right 
panel shows corresponding phase images (P); all images are acquired in air. Scan size [400 
nm × 400 nm]; PLA (a), PEG2.5%-g-PLA (b), palmitic acid2.5%-g-PLA (c).  
(a) (b) (c) 
T PT T PP
PEG chains (dark layer) PLA chains (white core) 
 
 
 
 
 
 
 
 
 
 
 
  
 
Also, this might indicate that some of palmitate chains are embedded inside PLA domain 
lowering its chain rigidity evidenced by the lower Tg of the polymer (19 ºC) compared to 
PLA homopolymer (46.4 ºC). Fatty acid esters were found to have a remarkable 
plasticizing actions on PLA chains [24]. Ibuprofen showed an endothermic peak at 78 ºC 
corresponding to the melting of ibuprofen crystals (Fig.2.3.a). As shown in Fig. 2.3.a, 
DSC curve of PEG2.5%-g-PLA/ibuprofen physical mixture showed an endothermic peak 
corresponding to the glass transition (Tg) at ~ 50 ºC. The melting endotherm of ibuprofen 
crystals could also be detected at 74 ºC. The drug melting peak was shifted by 4 ºC lower 
with some broadening of the peak, indicating the possibility of an interaction between 
drug and polymer. After encapsulation of ibuprofen in the NPs, Tg was found to be 
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reduced by 15 ºC lower (~ 35 ºC) and this due to the effect of formulation parameters. 
Surprisingly, the melting endotherm of ibuprofen crystals could also be detected at 74 ºC 
with some broadening (Fig.2.3.a). For more verification, lyophilized loaded NPs were 
washed five times with water then centrifuged to remove the surface associated drug 
followed by their lyophilization. DSC scans were done again, surprisingly; the melting 
endotherrm of ibuprofen still exists. This might indicate the detected melting endotherrm 
is for encapsulated ibuprofen which was dispersed in a crystalline form (solid dispersion) 
not molecular dispersion into PLA matrix. Moreover, the shift and broadening of the 
melting peak also indicated that an interaction between the drug in its crystalline state and 
the polymer might take place. Similar observations were noticed with PLA (DSC figure 
not shown), and palmitic acid2.5%-g-PLA (Fig.2.3.b) in both physical mixtures and NPs 
with the consideration of different Tg for each investigated polymer. Similar finding to 
ours was obtained when lidocaine was embedded into PEG-PLGA nanospheres. 
Lidocaine exhibited an endothermic peak at lower temperature or broadened melting 
peak compared to lidocaine alone. The authors also suggested that there is an interaction 
between lidocaine and the polymeric carrier [25]. 
 
2.5.8. XPS analysis  
          Surface chemistry analysis of NPs prepared from both polymers was investigated 
by means of X-ray photoelectron spectroscopy (XPS) technique. It is possible to 
determine the surface chemical composition at a depth in the range of 1-10 nm. Any 
possible interaction between PLA and PVA at the surface of NPs could also be detected 
in that range. PVA polymer showed three main characteristic peaks corresponding to C-
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Figure 2.3.a. DSC curves of ibuprofen, physical mixture of PEG2.5%-g-PLA with ibuprofen, 
PEG2.5%-g-PLA polymer, and ibuprofen loaded NPs. Inset inside the figure shows clear 
thermograms for both physical mixtures and NPs, Ibuprofen melting peak is encircled. 
 
C/C-H (285 eV), C-OH (286.7 eV) and O-C=O (289 eV) components (Table 2.3). XPS 
spectrum of PEG showed one characteristic peak corresponding to ether carbons (286.5 
eV, Table 3). For PLA homopolymer, the best envelop fit was obtained using three main 
peaks corresponding to C-C/C-H (285 eV), C-OH (287 eV) and O-C=O (289 eV) (Table 
2.3) as previously reported [12]. Ibuprofen could not be experimentally analyzed because 
it sublimes under the high vacuum of the equipment. Theoretically, ibuprofen has two 
main characteristic peaks corresponding to C-C/C-H (285 eV), and O-C=O (289 eV) 
components (Table 2.3). 
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Figure 2.3.b. DSC curves of ibuprofen, physical mixture of palmitic acid2.5%-g-PLA with 
ibuprofen, palmitic acid2.5%-g-PLA polymer, and ibuprofen loaded NPs. Inset inside the figure 
shows clear thermograms for both pure polymer and NPs. Ibuprofen melting peak is encircled. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It should be mentioned that for ibuprofen to be detected at the surface of loaded NPs, an 
increase in atomic percentages of both its characteristic peaks mainly C-C/C-H (285 eV) 
is expected to be found. Both ibuprofen loaded and blank NPs of PEG2.5%-g-PLA 
grafted polymer as well as the polymer itself showed the existence of PEG chains on the 
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surface as seen by the presence of a characteristic peak corresponding to ether carbons 
(286.5 eV, Table 2.4). However, the atomic % of PEG decreased when the polymer (9.5 
%) was formulated into NPs either blank (5.4 %) or loaded NPs (5 %) as shown in Table 
2.4. This might be due to surface adsorption of PVA in case of blank NPs as shown 
before in PVA analysis section. While in loaded NPs, both PVA and ibuprofen might be 
adsorbed at the surface of NPs as evidenced from the increase in atomic % of C-C (285 
eV) in case of loaded NPs (10.8%) compared to blank NPs (7.3 %) [Table 2.4]. Such an 
adsorption might decreases the PEG content at the surface. Also, it could be seen from 
Table 2.4 that the atomic % of C-C (285 eV) decreases from the polymer (10%) to blank 
(7.3%) and then increased again in case of loaded NPs (10.8%). This might be due to 
presence of more PLA chains collapsed inside the NPs core (oil phase) during NPs chain 
organization by O/W emulsion method with less existence of PLA and hence, the C-C 
functional component at the NPs surface. This C-C content lowering was compensated by 
drug adsorption (rich in C-C component) at the surface in case of loaded NPs.  Moreover, 
to get the best envelop fit of both NPs, two additional peaks had to be added 
corresponding to C-O-*C=O (287.6 eV) and *C-O-C=O (286.2 eV) components (Table 
2.4). These new peaks obtained in both types of NPs could be the result of chemical 
interaction between PLA-COOH end and PVA-OH during NP formation. The last finding 
also supports the effective masking of negative charge of these NPs by both PEG and 
PVA chains at the surface of such NPs as shown in Table 2.2. It was shown before that 
despite of several washing steps of the separated NPs pellets, there is always a fraction of 
PVA remains associated with the NPs and this has been attributed to the hydrophobic 
interactions between vinyl acetate segment of PVA and PLA/ PLGA core [11]. O-C=O 
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functional component (289 eV) was detected also in the XPS spectrum of the PEG2.5%-
g-PLA polymer, both its blank and loaded NPs. This might be due to the presence of 
COOH functional group in the polymer structure (Fig.2.1) or due to adsorption of PVA 
(partially hydrolyzed) and ibuprofen (weak acid) at the surface of blank and loaded NPs, 
respectively. In case of palmitic acid2.5%-g-PLA polymer and its both NPs types, there 
was a marked decrease in C-C components (285 eV) atomic % from the polymer (63.8%) 
to blank (49.1%) and then to loaded NPs (42.8%). This might be due to chain 
organization during NPs formation by O/W emulsion method in such a way that showed 
the migration of palmitate (hydrophobic chain) towards NPs core (oil phase) to avoid 
facing the external aqueous phase. This process might force palmitate chains to be 
embedded into NPs core and hence decreasing the C-C content at the surface. Although 
we expected an increase in the atomic % of C-C (285 eV) from blank to loaded NPs as 
shown before with PEG2.5%-g-PLA loaded NPs, a decrease in the atomic % (from 
49.1% to 42.8%) of that component was surprisingly detected and this might be to due to 
the possibility of hydrophobic interaction between ibuprofen and palmitic acid which 
forces the drug to be embedded inside the core of NPs. The last hypothesis was supported 
by another finding that the atomic % of O-C=O (289 eV) [also characteristic for the drug] 
was very low (2.2%) in case of loaded NPs (Table 2.4).  This indicates that some 
interaction might occur between the drug and polymer shielding the drug functional 
groups from the surface. It also should be mentioned that the existence of that functional 
gp, O-C=O (289 eV) in the polymer and blank NPs spectra (4.6% and 5.7%, respectively) 
might be due to COOH of both PLA and PVA (partially hydrolyzed), respectively. Also, 
the existence of two new peaks at C-O-*C=O (287.6 eV) and *C-O-C=O (286.2 eV) 
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might confirmed PVA interaction with PLA in such kind of polymer.  This finding was 
also supported by the high % residual PVA detected at the NPs surface as shown in Table 
2.4. 
 
 
 
 
 
2.5.9. 1H-NMR of NPs in D2O 
              1H-NMR analysis of NPs in D2O was done to confirm the core-corona structure of 
PEG2.5%-g-PLA NPs and compare it with palmitate2.5%-g-PLA NPs structure. 1H-
NMR spectra of PEG2.5%-g-PLA NPs in D2O showed presence of methylene protons of 
PEG chains at 3.6 ppm (Fig.2.4).  Signals from PLA methyl or methylene protons were 
absent or diminished in intensity. Also both signals corresponding to the twelve 
hydrogens of the palmitate CH2 and the palmitate CH3 were completely absent in 1H-
NMR spectra of palmitic acid2.5%-g-PLA.  
 
 
      Binding Energy  
(functional component) 
                     Atomic Percentage (%) 
Ibuprofen PLA PVA PEG 
285   (C-C) 92.4 22.3 37.1 - 
   286.5 (C-O) - - - 100 
   286.7 (C-O) - - 23 - 
   287     (C-O) - 28.9 - - 
   289 (O-C=O) 7.6 13.9 4.3 
 
- 
Table 2.3. Relative atomic percentages calculated from XPS Surface Analysis of pure 
materials used in NPs preparation. 
N.B: Relative percentage of each functional component is calculated from the area under the 
curve from their respective peaks in XPS analysis. 
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This might indicate that both PLA and palmitate protons are in solid environment and 
can't be detected whereas PEG chains must be in mobile state. Core-corona structure of 
PLA-PEG diblock NPs was confirmed before from 1H-NMR analysis of NPs in  D2O 
[26]. 1H-NMR analysis was also used to confirm poly-(ethylene glycol)-b-(styrene-r-
benzocyclobutene) block copolymer (PEG-b-(S-r-BCB) NPs formation after 
intramolecular cross-linking of the S-r-BCB block to form a linear-nanoparticle structure. 
1H-NMR spectra of NPs showed complete disappearance of the aliphatic 
benzocylobutene protons at 3.05 ppm upon formation of the cross-linked nanoparticles 
[27] . Our results are in accordance with the above-cited references suggesting NPs made 
 
 
 
B.E.  
(functional 
component) 
     Atomic Percentage (%) 
PEG2.5%-
g-PLA  
BK NPs 
PEG2.5%-g-
PLA  
LD NPs 
PEG2.5%-g-
PLA 
polymer 
Palmitate 
2.5%-g-
PLA  
BK NPs 
Palmitate 
2.5%-g-
PLA  
LD NPs 
Palmitate 
2.5%-g-
PLA 
polymer 
285 (C-C) 7.3 10.8 10.0 49.1 42.8 63.8 
286.2 (*C-O-C=O) 2.1 2.5 - 8.6 13.9 - 
286.5 (C-O) 5.4 5.0 9.5 - - - 
287.6 (C-O-*C=O) 4.2 3.5 - 5.3 5.0 - 
289 (O-C=O) 5.5 4.1 5.0 5.7 2.2 4.6 
Table 2.4. Relative atomic percentages calculated from XPS Surface Analysis of synthesized 
polymers and formulated NPs using those polymers.  
(B.E.) refers to the binding energy 
(BK) refers to blank NPs 
(LD) refers to loaded NPs 
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of PLA and PEG corona in case of PEG2.5%-g-PLA NPs. Thus, 1H-NMR analysis 
together with XPS data of NPs might indicate that hydrophilic polymer parts (PEG) are 
oriented towards the outer phase (water) during precipitation and NP hardening whereas 
the more lipophilic polyester (either PLA or PLA and palmitate) residues form the inner 
core. A schematic representation of different chain organization of NPs depending on 
both their polymer composition and polymer architecture is shown in Figure 2.5.  For 
PEG2.5%-g-PLA NP, enhanced phase separation of both components during NPs 
formation was observed as confirmed from AFM phase imaging, XPS and 1H-NMR data. 
Thus, easy migration of PEG chains towards the surface of NPs will be favored while the 
cores will be predominantly hydrophobic. On the contrary, palmitic acid2.5%-g-PLA 
NPs showed the migration of palmitate chains into PLA core avoiding facing the aqueous 
phase during NPs preparation. 
 
 
 
 
 
 
 
 
 
 
 
(1) 
(2) 
(3) 
Figure 2.4. 1H-NMR of blank NPs of PLA (1), palmitic acid2.5%g-PLA (2), and PEG2.5%-g-
PLA (3) in D2O. PEG peaks at 3.6 ppm are encircled.  
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(a) 
(c) 
PLA  
PEG2.5%-g-PLA polymer 
PLA chains 
PLA 
chains 
PEG 
chains 
Palmitate 
chains 
PLA 
chains 
Palmitic acid2.5%-g-PLA 
(b) 
 
 
 
 
 
                                                                                                                                                                                                                                                                                        
 
 
 
 
 
 
 
 
 
 
 
 
2.5.10. Erosion study 
            This study was conducted to investigate the effect of polymer grafting on the in 
vitro degradation rate of PLA based NPs under conditions similar to physiological ones. 
Mass loss of copolymer in phosphate buffer started after 5 days for all the investigated 
NPs. A noticeable difference in mass loss is observed between PEG2.5%-g-PLA and 
Figure 2.5. Schematic representation of polymer chain organization inside the NPs: PLA (a),  
Palmitic acid2.5%-g-PLA (b), PEG2.5%-g-PLA (c).  
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palmitic acid2.5%-g-PLA NPs after 10 days of incubation. PEG2.5%-g-PLA exhibited 
faster erosion rate ~ 43 % compared to both PLA and palmitic acid2.5%-g-PLA NPs 
which showed slower rates around 17% and 32 %, respectively after 45 days. This pattern 
is shown in Figure 2.6. Mass loss of polyester copolymers is usually enhanced by ester 
hydrolysis and transesterification mechanisms [28]. NPs erosion was initiated by 
wateruptake followed by random hydrolytic chain scission of PLA block with release of 
lactide oligomers. The more hydrophilic PEG2.5%-g-PLA initially swells to a much 
greater degree than other polymers of lower hydrophilic content, allowing more water 
uptake into the matrix, further increasing the rate of hydrolysis and breakdown of NPs 
[29, 30]. Thus PEG grafting over PLA backbone was observed to increase the 
degradation rate of PLA. The possible reason that palmitic acid2.5%-g-PLA NPs showed 
faster degradation rates than PLA NPs is that palmitic acid2.5%-g-PLA polymer has 
lower Mw compared to PLA homopolymer (Table 2.1).  
 
2.5.11. In Vitro Drug Release. 
            One of the main purposes of this study is to compare and study the effect of the 
aqueous solubility of grafted substance over PLA backbone on drug release profiles from 
modified PLA NPs. Ibuprofen showed much more rapid release from solution than its 
release from the NPs indicating that drug diffusion through the dialysis bag was not the 
release rate-limiting step (Fig. 2.7). Different NPs formulations were compared for their 
in vitro release behavior as shown in Fig.2.7. It could be seen that all formulations 
exhibited biphasic release phenomenon.  
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A rapid initial burst release varied from 10 % to 20 % of their payload and this might be 
due to the immediate release of drug particles adsorbed at or near the surface of NPs [31]. 
This phase was followed by sustained release of the drug over 300 h. Drug release during 
that phase is mainly controlled by solubility of the drug in the matrix, diffusion of drug 
into the matrix, and matrix erosion [32, 33]. The physical state of the drug inside the NPs 
matrix might have an influence on the in vitro and in vivo release behaviour of the drug. 
DSC indicated that ibuprofen mostly exists in a crystalline state inside all NPs 
Figure 2.6. Erosion of different ibuprofen loaded NPs in phosphate buffer saline (PBS, 
pH 7.4) at 37 ºC. 
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irrespective of their polymer content. The last finding indicates that the main rate limiting 
step affecting drug release will be the dissolution of drug crystals into the polymeric 
matrix followed by their diffusion out of the matrix into the release media. This finding 
also confirmed the role of NPs core wetting in enhancing drug dissolution and hence drug 
release. PEG2.5%-g-PLA NPs showed faster drug release rates compared to other 
formulations and this could be attributed to their PEG content that might led to rapide 
core wetting  resulting in faster drug dissolution followed by its rapide diffusion and/or 
more enhancement of matrix erosion. On the other hand, palmitic acid2.5%-g-PLA NPs 
showed faster drug release compared to PLA NPs although the former is expected to be 
more hydrophobic and hence more interaction with drug will be favored. This is could be 
explained on the basis that PLA polymer had large molecular weight compared to 
palmitic acid2.5%-g-PLA polymer as shown before from GPC data (Table 2.1) and this 
might slow the process of matrix erosion [25]. Erosion study showed that PEG2.5%-g-
PLA NPs exhibited faster degradation rate (Fig. 2.6) than other NPs supporting the faster 
release behaviour exhibited by those NPs. These results showed that the hydrophilicity of 
the matrix is one of the major factors that markedly influence its hydration and, in turn, 
the drug release profile [34, 35]. It also should be mentioned that both erosion and release 
rates could be affected by the size of the particle tested. However, the small size 
differences between the three tested loaded batches (PLA, 162±22.3 nm), (PEG-g-PLA, 
135±32.7 nm), and (palmitic acid-g-PLA, 183±22.2 nm) might not be fully responsible 
for such big differences in both release and erosion.  
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2.6. Conclusion 
       NPs were fabricated using grafted copolymers of PLA with two grafted substances of 
different aqueous solubility. PEG2.5%-g-PLA NP and palmitic acid2.5%-g-PLA 
polymers were synthesized and fabricated into NPs. NPs were compared for the effect of 
Figure 2.7. Effect of PLA grafting on the in vitro release behavior of ibuprofen loaded NPs; 
 values are represented as mean ±S.D. of three independent experiments. 
. 
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the aqueous solubility of grafted substance of the polymer on their physicochemical 
properties. Mode of chain organization of each polymer was also investigated. Both AFM 
phase imaging and XPS studies showed the existence of PEG chains on the surface of 
PEG2.5%-g-PLA NPs. This resulted in rapide core wetting, faster degradation of the 
polymeric matrix and faster drug release from NPs. On the contrary, palmitic acid2.5%-
g-PLA NPs showed the existence of palmitate chains embedded inside NPs core. This 
organization affected some major physicochemical properties of NPs. Our future work 
will focus on studying the cellular uptake of rhodamine encapsulated NPs made from 
different architectures.  In brief, the aqueous solubility of grafted material over the 
polymer backbone is an important parameter controlling surface characteristics of NPs 
which in turn determine their physicochemical properties like % PVA adsorbed at the 
surface of NPs, zeta potential, thermal characteristic, NPs surface organization and drug 
release kinetics. 
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CHAPTER THREE 
__________________________________________________________________ 
RESEARCH PAPER 
 
Effect of Polyethylene Glycol (PEG) Chain Organization on the 
Physicochemical Properties of Poly(D,L-lactide) (PLA) based 
Nanoparticles1. 
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3.1. Abstract:  
       The aim of the present study is to evaluate the effect of polyethylene glycol (PEG) 
chain organization on various physicochemical aspects of drug delivery from poly(D,L-
lactide) (PLA) based nanoparticles (NPs). To reach that goal, two different pegylated 
polymers of poly(D,L-lactide) (PLA) were synthesized. Polymers used in this study are 
grafted one in which PEG was grafted on PLA backbone at 7% (mol/mol of lactic acid 
monomer), PEG7%-g-PLA, and multiblock copolymer of both PLA and PEG, (PLA-
PEG-PLA)n with nearly similar PEG insertion ratio and the same PEG chain length. 
Blank and ibuprofen-loaded NPs were prepared from both polymers and their properties 
were compared to PLA homopolymer NPs as a control. Encapsulation efficiency of 
ibuprofen was found to be ~ 25% for (PLA-PEG-PLA)n NPs and ~ 80% for PEG7%-g-
PLA NPs. (PLA-PEG-PLA)n NPs either blank or loaded showed larger hydrodynamic 
diameter (~ 200 nm) than PEG7%-g-PLA NPs (~ 135 nm). A significant difference was 
observed in the amount of PVA associated with the surface of both NPs where 3.6 and 
0.4 % (wt/wt) were found on the surface of PEG7%-g-PLA and (PLA-PEG-PLA)n NPs, 
respectively. No observed difference in zeta potential values for both NPs formulations 
was found. DSC showed the existence of the drug in a crystalline state inside NPs matrix 
irrespective of the type of polymer used with either shifting or/ and broadening of the 
drug melting endotherm. Both AFM phase imaging and XPS studies revealed the 
possibility of existence of more PEG chains at the surface of grafted polymer NPs than 
(PLA-PEG-PLA)n during NPs formation. The in vitro release behavior showed that 
(PLA-PEG-PLA)n NPs exhibited faster release rates than PEG7%-g-PLA NPs. The 
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physicochemical differences obtained between both polymers were probably due to 
different chain organization during NPs formulation. Such pegylated NPs made from 
these two different polymers might find many applications, being able to convert poorly 
soluble, poorly absorbed substances into promising drugs, improving their therapeutic 
performance, and helping them reach adequately their target area. Our results suggest that 
the properties of pegylated PLA-based NPs can be tuned by proper selection of both 
polymer composition and polymer architecture. 
 
3.2. Keywords 
        Poly(D,L-lactide), polymer architecture, graft polymers, multiblock, chain 
organization, X-ray photoelectron spectroscopy ( XPS), atomic force microscopy (AFM) 
phase imaging. 
 
3.3. Introduction: 
          Over the past few decades, there has been an intensive research on the development 
of biodegradable nanoparticles (NPs) as a suitable means for controlled drug release and 
targeting [1-3] Nanoparticles (NPs) are colloidal systems that vary in size from 10 to 
1000 nm. The drug is either dissolved, entrapped, encapsulated or attached to a 
nanoparticle matrix [4]. Poly(lactic acid) (PLA) or poly(lactide-co-glycolide) (PLGA) 
have been widely used to fabricate NPs owing to excellent biocompatibility, 
biodegradability and high encapsulation capability for hydrophobic drugs. However, 
uptake of such naked NPs by the reticuloendothelial system after intravascular 
administration presented a major problem for achieving effective targeting to specific 
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sites in the body other than liver and spleen [5]. Therefore, the design of long-circulating 
NPs or stealth NPs has emerged as an attempt to escape recognition by phagocytic cells 
of the blood. The most commonly used strategy for designing stealth NPs is reliant upon 
introducing flexible hydrophilic coat onto hydrophobic surfaces, shielding them against 
plasma protein adsorption, which is the first step of particle clearance mechanism by 
blood phagocytes. Covalently grafted PEG strategy was proven stable and more 
successful than physical adsorption of PEG containing surfactants onto NPs surface.  
Generally, covalent copolymers of PLA (A) and PEG (B) can be divided into single-sided 
grafted defined as grafted or diblock copolymer (A-B) and double-sided grafted denoted 
as triblock copolymer (A-B-A) or multiblock copolymer (A-B-A)n. Many attempts have 
been made in the past to fabricate NPs using diblock copolymers of either PLA-PEG or 
PLGA-PEG [3, 6]. Up to now, however, relatively fewer studies have focused on grafted 
pegylated and multiblock copolymers of PLA and PEG. In this study we are 
hypothesizing that it is difficult for hydrophilic PEG domains of multiblock copolymer 
NPs to move freely towards NPs surface as PEG-g-PLA NPs. The major objective of this 
study was first to optimize NPs formulation using two pegylated polymers of different 
PEG chain organization, one is grafted, PEG7%-g-PLA and the second is multiblock 
copolymer of PLA and PEG, (PLA-PEG-PLA)n. Second to study the effect of PEG chain 
organization on the physicochemical properties of the obtained NPs. Poly (lactic acid) 
(PLA) homopolymer was proposed as the hydrophobic control in our study. Ibuprofen 
was used as a model lipophilic drug to be encapsulated by PLA and PEG-modified PLA 
NPs. NPs were formulated using emulsion-solvent evaporation method and poly(vinyl 
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alcohol) (PVA) was  mainly used as an emulsifier to stabilize the emulsion droplets since 
it aids the formation of relatively small sized particles with uniform size distribution [7].  
 
3.4. Material and methods:  
 
3.4.1. Materials: 
          D,L-dilactide, poly(ethylene glycol) methyl ether (MePEG; 2000 Da), 
poly(ethylene glycol) (PEG, 1500 Da), allyl glycidyl ether, tetraphenyltin, polyvinyl 
alcohol (PVA, average Mw 9000-10,000 Da, 80% hydrolyzed), succinic acid, 1-ethyl-3-
[3-dimethylaminopropyl]-carbodiimide (EDC), 4-dimethylaminopyridine (4-DMAP), 
pyridine, acetone, chloroform, diethyl ether, and N,N-dimethylformamide were 
purchased from Aldrich Chemical Company Inc., Milwaukee, USA. Ibuprofen was 
obtained from Medisca Pharmaceutical Inc., Montreal, Quebec, Canada. Sodium 
hydroxide pellets were purchased from Anachemia Canada Inc. and dichloromethane 
(DCM) was purchased from Laboratoire Mat Inc., Montreal, Quebec, Canada.   
 
3.4.2. Synthesis of Polymers.  
          The homopolymer poly(D,L)-lactide (PLA) was synthesized by ring-opening 
polymerization of dilactide in argon atmosphere, using tetraphenyltin as the catalyst. 
Bulk polymerization was carried at 180 °C for 6 h in a round-bottom flask and purged 
thoroughly with argon. The obtained polymer was dissolved in acetone and then purified 
by precipitating in water.  
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    Polymer with poly(ethylene glycol)-grafted randomly on poly(D,L)-lactide at 7% 
grafting density , PEG7%-g-PLA (PEG; Mw 2000 Da) was synthesized in the laboratory 
as reported earlier by our group [8]. Multiblock copolymer, (PLA-PEG-PLA)n was also 
synthesized as previously reported [9] using PEG with Mn of 1500 and succinic acid was 
used as condensing agent to link triblock copolymers. (PLA-PEG-PLA)n was synthesized 
to yield a PEG (1500)/lactic acid monomer ratio of 7% (mol/mol).  1H NMR spectra were 
recorded on a Brucker ARX 400 spectrometer (Bruker Biospin, Billerica, MA). Chemical 
shifts () were measured in parts per million (ppm) using tetramethylsilane (TMS) as an 
internal reference. Gel permeation chromatography (GPC) was performed on a Water 
Associate chromatography system (Waters, Milford, MA) equipped with a refractive 
index detector and a Phenomenex Phenogel 5  column. Polystyrene standards were used 
for calibration with THF as the mobile phase at a flow rate of 0.6 mL/min.   
 
3.4.3. Preparation of nanoparticles (NPs) 
          NPs were prepared by an (O/W) emulsion-solvent evaporation method. It should be 
mentioned that NPs could not be prepared using the multiblock copolymer alone due to 
its low molecular weight as revealed by GPC data (Table 3.1); hence, a 1:1 mixture of 
PLA and multiblock copolymer was used for the preparation of NPs. For blank NPs, each 
polymer or polymer blend in case of multiblock (1 g) was dissolved in 35 mL DCM and 
emulsified in 100 mL PVA solution (0.5% w/v) as an external aqueous phase using high-
pressure homogenizer (Emulsiflex C30, Avestin, Ottawa, Canada) at a pressure of 10,000 
psi for 5 min. The emulsion was collected by washing with another 100 mL of 0.5% 
PVA. The DCM was evaporated under reduced pressure with constant stirring to obtain 
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the NPs. Finally, NPs obtained as a suspension were then collected by centrifugation at 
41.340 g for 1 hr at 4 ºC (Sorval® EvolutionRC, Kendro, USA), washed four times with 
distilled water, then lyophilized in the presence of 5 % w/v sucrose as a cryoprotectant to 
obtain dry NPs (Freeze Dry System, Lyph.Lock 4.5, Labconco) and stored at 4 ºC until 
further use. Ibuprofen loaded NPs were prepared in a similar manner to that of blank NPs 
using initial loading of 10% wt/wt of each polymer. Ibuprofen was first dissolved in the 
organic phase followed by dissolution of the polymer. The emulsification and purification 
steps procedure were repeated as before. 
 
3.4.4. Characterization of NPs 
 
3.4.4.1. Particle size and size distribution 
             Size and size distribution of NPs were measured by dynamic light scattering 
(DLS) with a Malvern Autosizer 4800 instrument (Malvern Instruments, Worcestershire, 
UK) before and after lyophilization. For all batches, fresh NP suspensions (0.1 mL) or 
lyophilized NPs (1 mg) were diluted 10 times with Milli-Q Water and size measurements 
were performed at 25 ºC and scattering angle of 90º. The CONTIN program was used to 
extract size distributions from the autocorrelation functions. Measurements were 
performed in triplicate. 
 
3.4.4.2. NPs surface morphology and phase image analysis 
              Surface morphology and phase imaging of NPs were studied using Nanoscope 
IIIa Dimension 3100 atomic force microscope (Digital Instruments, Santa Barbara, CA, 
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USA). Samples were prepared by deposition of particles suspension in Milli-Q Water on 
freshly cleaved mica followed by air-drying. Topography and phase images of these 
samples were captured simultaneously using TappingModeTM etched silicon probes 
(TESP7) with tip radius of 5–10 nm, spring constant of 20–100 N/m and resonance 
frequency of 200–500 kHz. Cantilever length was 125 µm. A set-point ratio (rsp, ratio of 
engaged oscillation amplitude to free air oscillation amplitude) between 0.5 and 0.7 
(moderate tapping mode) was used for all topographic and phase images unless otherwise 
stated. 
 
3.4.4.3. Zeta ( ) potential measurements 
             NPs were suspended in 0.22 µm filtered 0.25% (w/v) saline solution and -
potential was measured on Malvern ZetaSizer Nanoseries ZS (Malvern Instruments, 
Worcestershire, UK) in triplicate. 
3.4.4.4. Encapsulation efficiency (EE) 
            A weighed amount of NPs was digested in 1 N NaOH for 1 h. Ibuprofen 
concentration was measured by spectrophotometry at 264 nm (U-2001 UV/Visible 
spectrophotometer, Hitachi). Percent encapsulation efficiency (% EE) and % drug 
loading (% DL) were calculated based on the following equations: 
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Amount of drug entrapped in NPs 
Initial amount of drug added 
% EE = X 100  
(1) 
 
% DL = 
Total amount of NPs 
X 100  (2) 
 
Amount of drug entrapped in NPs 
 
 
 
 
 
 
 
 
 
 
3.4.4.5. Determination of residual PVA 
              The amount of PVA remaining in the NPs was determined by a colorimetric 
method based on the formation of a colored complex between two adjacent hydroxyl 
groups of PVA and an iodine molecule [7] . First to determine the surface associated 
PVA, certain weight of NPs was suspended in distilled water followed by vigorous 
vortexing for 10 min., then fixed volumes of all formulations were withdrawn followed 
by addition of 5 mL of saturated solution of boric acid and 0.5 mL iodine (0.1 N), and the 
volume was made up to 10 mL with distilled water. The absorbance of the formed 
complex was measured at 660 nm against similarly treated blank. Whereas for the total 
amount of PVA associated with the particles (amount entrapped inside the matrix as well 
as present on the surface), NPs were digested in 1 N NaOH then neutralized by 1 N HCl 
followed by stirring for 1 h and the volume was made up to 5 mL with distilled water. To 
this, 3 mL of saturated solution of boric acid and 0.5 mL iodine (0.1 N) were added, and 
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the volume was made up to 10 mL with distilled water. The absorbance was measured as 
above. The amount of PVA was calculated by using the calibration curve of PVA 
prepared under the same conditions. 
 
3.4.4.6. Differential Scanning Calorimetry (DSC) 
             The thermal properties of the pure polymers, physical mixtures of ibuprofen with 
each polymer, and NPs were characterized by DSC analysis (DSC 30, Mettler TA 4000, 
Schwerzenbach, Switzerland) with refrigerated cooling. The purge gas was purified 
nitrogen at a pressure of 20 psi. For pure polymers, weighed samples were sealed in 
crimped aluminum pans with lids using an empty pan as a reference and were heated at a 
rate of 10 °C/min from -50 to 200 °C (two runs), while for NPs the samples were heated 
from -50 to 90 °C (two runs) at the same heating rate.  
 
3.4.4.7. XPS analysis 
             Surface chemistry of pure materials, polymers, blank, and drug-loaded NPs was 
characterized by X-ray photoelectron spectroscopy (VG Scientific ESCALAB MK II) 
with a monochromatized Mg Ka X-rays (hv 1253.6 eV) and an electron take off angle of 
0º. A single survey scan spectrum (0–1000 eV) and narrow scans for C1s (210–305 eV) 
and O1s (525–550 eV) were recorded for each sample with a pass energy of 1 and 0.5 
eV, respectively. Acquisition and data analysis were performed by a VGS 5000 data 
system. Peak fitting of the C1s envelope was as described by Shakesheff et al [10].  
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3.4.4.8. 1H NMR spectroscopy 
               A weighed amount of nanoparticles lyophilized in presence of sucrose (50 mg) 
was suspended in 10 mL distilled water, centrifuged (5000rpm, 10 min). The residues 
were washed three times with water to remove sucrose (cryoprotectant) that might show 
any interference during 1H NMR analysis of NPs. Then, NPs were lyophilized for 24 h. 
Relyophilized NPs were suspended in deuterium Oxide (D2O). 1H NMR spectra were 
recorded on the same machine used before for analysis of synthesized polymers. 
 
3.4.4.9. Erosion study 
             Erosion (mass loss) studies of (A) PLA, (B) PEG7%-g-PLA, and (C) (PLA-PEG-
PLA)n NPs were done by  suspending 50 mg of NPs for each time interval in 10 mL 
PBS, pH 7.4 at 37 ºC in shaking water bath. The study was terminated at 0, 5, 14, 25, 35 
and 45 days. Samples were centrifuged (5000rpm, 10 min) at the end of each time 
interval. The residues were washed two times with water to remove phosphate buffer and 
lyophilized for 24 h. The final mass of NPs was determined at each time point. 
 
3.4.4.10. In vitro drug release study 
               Loaded formulations prepared using different polymers were tested for in vitro 
release of ibuprofen in triplicates in phosphate buffered saline (PBS, 10 mM, pH 7.4.). 
150 mg NPs were suspended in 3.5 mL PBS in a dialysis tubing (Spectra Por 1 
membrane, 6–8 kDa cut-off). This dialysis tubing was placed in a screw-capped tube 
containing 10 mL PBS. The tubes were shaken at 200 rpm on a horizontal water bath 
shaker (Orbit Shaker Bath, Labline) maintained at 37±0.5 ºC. At predetermined time 
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intervals, the whole medium in the tube was withdrawn and replaced by fresh PBS to 
maintain sink conditions. The aliquots were assayed for the concentration of ibuprofen 
released by spectrophotometry at 262 nm. 
 
3.5. Results and discussion: 
 
3.5.1. Characterization of Polymers.  
       1H NMR spectroscopy and gel permeation chromatography (GPC) were used to 
measure the number average (Mn) and weight average molecular weights (Mw) of the 
synthesized polymers. The polydispersity was calculated by the ratio of Mw to Mn from 
the GPC data. All the synthesized polymers exhibited uniform molecular weight 
distribution as revealed by the narrow polydispersity index values (Table 3.1). Unimodal 
mass distribution ruled out the possibility of the presence of unreacted MePEG or 
Poly(D,L-lactide) in case of PEG7%-g-PLA. The results are summarized in Table 3.1. 
Typical 1H NMR spectrum was obtained for PLA homopolymer with a characteristic 
peak at 5.2 ppm corresponding to the tertiary PLA proton (m, -CH), and another peak at 
1.5 ppm for the pendant methyl group of the PLA chain (m, -CH3). Moreover, the 
integration ratio of those two characteristic peaks was 3:1 that is also a characteristic 
feature for the protons of PLA homopolymer (data not shown).1H NMR spectra and 
chemical structures of PEG7%-g-PLA, and (PLA-PEG-PLA)n polymers are shown in 
Figure 3.1. Also typical spectrum for PEG7%-g-PLA was obtained with a peak at 5.2 
ppm corresponding to the tertiary PLA proton (m, -CH), a peak at 3.6 ppm for the 
protons of the repeating units in the PEG chain (m, OCH2-CH2O), a peak at 4.3 ppm for 
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the PEG connecting unit to the PLA block (m, CH2-OCO), and a peak at 1.5 ppm for the 
pendant methyl group of the PLA chain (m, -CH3). While, for the multiblock copolymer, 
an additional peak could be seen at around 2.7 ppm corresponding to the protons of the 
succinic acid group (m, CH2-COO) used to link the triblock chains during multiblock 
synthesis. The actual PEG insertion ratio of PEG7%-g-PLA, and (PLA-PEG-PLA)n was 
calculated by comparing the peak intensity ratios of PEG (3.6 ppm) to that of PLA (5.2 
ppm). The final PEG insertion ratio in both polymers was close to the initial feed ratio as 
shown in Table 3.1.  
 
3.5.2. Particle size and size distribution 
          Particle size distribution by dynamic light scattering (DLS) showed unimodal 
distribution for freshly prepared as well as lyophilized NPs. Freshly prepared (PLA-PEG-
PLA)n NPs either blank or loaded showed larger hydrodynamic diameter (~ 200 nm) 
than PEG7%-g-PLA NPs (~ 132 nm) as shown in Table 3.2. The last finding could be 
attributed to the difference in PEG chain organization during NPs formation between 
both formulations. In PEG7%-g-PLA, PEG chains are expected to be more mobile 
creating a steric barrier around PLA core preventing particle aggregation. While, for 
multiblock copolymer, the polymer architecture allows some PEG chains to be embedded 
inside PLA core leaving some uncovered areas at the surface that might showed some 
aggregating tendency due to hydrophobic interactions. Moreover, the higher PEG content 
of multiblock copolymer (8.9 %, Table 3.1) might favor the swelling of NPs in aqueous 
media to a much degree than PEG7%-g-PLA NPs which contains lower PEG ratio (4.1 
%, Table 3.1).  
101 
 
Table 3.1. Polymers characterization by 1H NMR, DSC, and Gel Permeation Chromatography (GPC).  
 
 
 
 
 
 
 
Blank formulations showed nearly similar particle size to that of loaded ones for all NPs 
types in the range of 135–200 nm (Table 3.2). Thus, drug loading level had no apparent 
effect on particle size, suggesting that the size was largely controlled by the 
emulsification process during NPs preparation. Also, it could be noticed that the size of 
most lyophilized NPs after resuspension into Milli-Q Water was smaller with narrow 
polydispersity compared to the freshly prepared NPs suspension. The possible reason 
behind that is the tendency of freshly prepared PLA particles particularly pegylated ones 
to uptake water, allowing more swelling of the NPs matrix [11, 12], further increasing the 
size of the particles. While, after lyophilization, the size of the particles was reduced due 
to shrinkage of the swollen cores after removal of entrapped water by sublimation.  The 
Polymer Mna Mwa Mw/Mna PEG insertion  
(mol%)b 
Mn (1H NMR)b Tgc 
PLA 40318 56171 1.4 N/A N/A 46.4 ºC 
PEG7%-g-PLA 3752 8392 2.2 4.1 % 8336 53 ºC 
(PLA-PEG-PLA)n 3508 3982 1.2 8.9 % 3780 39 ºC 
N/A: not analyzed. 
a Determined by GPC analysis using narrow molecular weight polystyrene standards. 
a Mw/Mn =Polydispersity index of the polymers (PDI). 
b Calculated from peak intensity ratios of PEG (3.6 ppm) and PLA (5.2 ppm) by 1H NMR. 
c Calculated from the second run of DSC as half of the extrapolated tangents in case of PLA  
and (PLA-PEG-PLA)n or as an endothermic peak in case of PEG7%-g-PLA . 
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Figure 3.1. 1H NMR spectra and chemical structures of PEG7%-g-PLA, and multiblock copolymer,  
(PLA-PEG-PLA)n. 
 
narrow polydispersity values indicate the ability of the used cryoprotectant used (sucrose) 
to prevent particle aggregation. It was previously reported that cryoprotectants could 
efficiently prevent NPs aggregation and protect them against the mechanical stress of ice 
crystals due to the immobilization of nanoparticles within their glassy matrices [13]. 
Particle size distribution data by DLS were also supplemented with a visual method like 
tapping mode AFM as will be revealed in the next section.  
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3.5.3. Surface morphology and phase analysis 
          Tapping mode atomic force microscopy (TM-AFM) is a versatile technique, which 
allows probing soft samples such as biological and polymeric materials [14, 15]. TM-
AFM surface analysis revealed that all lyophilized NPs were nearly spherical with 
smooth surface and displayed less aggregating tendency with a size range 100- 200 nm 
(Fig. 3.2, left panels, T) confirming the size data obtained by DLS. Phase image analysis 
using the same (TM-AFM) was done on NP samples to visually examine PEG chains at 
the surface of pegylated NPs. Phase imaging is based on the use of changes in the phase 
angle of cantilever probe. This image shows more contrast than the topographic one as 
well as more sensitivity to material surface properties such as stiffness, viscoelasticity, 
and chemical composition [14, 16, 17]. Figure 3.2 shows TM-AFM topography (left 
panel, T) and their corresponding phase images (right panel, P) of PLA, PEG7%-g-PLA, 
and multiblock copolymer, respectively acquired at moderate tapping force. It can be 
seen that PLA particles had nearly homogenous surface without any clear phase 
separation [Fig. 3.2(a); right panel, P). Therefore, no contrast was observed in phase 
images of PLA NPs. On the other hand, both pegylated NPs showed the presence of an 
observable phase contrast at the surface of NPs that varies in degree from grafted to 
multiblock [Fig. 3.2(b, and c); right panels, P]. This might be due mechanical differences 
between PLA and PEG that result in such phase contrast. PEG molecule is expected to be 
softer than PLA since PEG molecules of lower Mw 2000 or 1500 (used in our study) have 
smaller Young’s modulus than PLA [18]. Thus, it was expected that PEG molecule will 
appear as darker regions in the phase images due to negative phase shift. This has already 
been shown before for poly(styrene-b-ethylene oxide) polymer films, where softer PEG 
104 
 
segments appeared as darker regions embedded in lighter polystyrene domain [19]. In the 
case of PEG7%-g-PLA, highly intense dark coat surrounds the surface of brighter core 
could be seen indicating the existence of hydrophilic PEG chains around hydrophobic 
PLA chains that represents the core. The immiscibility of these two blocks should result 
in separation of both components during NPs formation. Thus, grafted copolymer NPs 
will be predominantly consisting of hydrophobic PLA cores surrounded by hydrophilic 
PEG chains on the surface (Figure 3.2 b, phase image, P). In the case of the (PLA-PEG-
PLA)n multiblock copolymer, few dark regions are found at the surface of NPs without 
complete coverage of the surface as seen with grafted polymer. This might be due to the 
peculiar architecture of the polymer itself that mainly consist of PEG chain covalently 
linked with two PLA chains. This might affect mobility of PEG chains towards the 
aqueous phase of the O/W emulsion during NPs formation. It was shown before in a 
previous study that multiblock copolymers of PLA and PEG exhibited enhanced 
miscibility of the two blocks compared to grafted copolymers [20].  
 
 
3.5.4. Encapsulation efficiency (EE) 
          As seen from Table 3.2, % EE of ibuprofen was found to be 25.3 % and 79.7 % for 
multiblock and PEG7%-g-PLA NPs, respectively. PEG7%-g-PLA showed better % EE 
than multiblock copolymers. The last finding could be attributed to the enhanced steric 
hindrance of the more mobile PEG chains at NPs surface in the case of the grafted 
copolymers, thus reducing premature diffusion of ibuprofen into the external aqueous 
phase during solidification of the NPs. This was confirmed before by AFM phase 
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imaging where PEG chains were found to completely cover the entire NPs surface. The 
higher encapsulation efficiency obtained with PEG7%-g-PLA may have significant 
implications on the feasibility of development of PLA–PEG nanoparticluate formulations 
optimized with regard to both the longer circulation behavior and the drug loading 
properties by judicious selection of both the composition and the suitable architecture of 
the nanoparticles. Thus, the obtained data suggest that it is possible to prepare 
nanoparticles with low PEG content, which would generate favorable conditions for the 
entrapment of a hydrophobic drug, without compromising the prolonged blood 
circulation properties of the nanoparticles.  
 
3.5.5. Zeta ( ) potential measurements 
          Although zeta potential measurements didn’t show big differences between 
different formulations but two findings worthy of note were observed in Table 3.2 : 1) 
PLA showed low zeta potential (close to zero) values than expected, -3.5 mV. This lower 
-potential for NPs could be attributed to the effective adsorption of PVA on the surface 
of NPs as will be seen in the next section which could mask the surface charge of PLA. 
Zambaux et al. also obtained a low zeta potential value of -4 mV for PLA NPs prepared 
with PVA as an emulsifier [21]. 2) Pegylated polymers either grafted or block had also 
low zeta potential values for both blank and loaded NPs as shown in Table 3.2. This 
could be attributed to the shielding action of PEG on the surface charge even if most of 
PEG chains were found embedded into the NPs matrix as in case of multiblock 
copolymer. Since some of the PEG chains would be present at the surface, the copolymer 
might also keep its stealth behavior. Similar results to ours were reported earlier by other 
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authors [9, 22, 23]. Moreover, the greater reduction in zeta potential values of pegylated 
NPs compared to other PEG-PLA NPs reported in the last cited references could be 
explained by the existence of a fraction of PVA at the surface of NPs which played also a 
role in masking their actual surface charge (Table 3.2). It also should be mentioned that 
zeta potential measurements were done again in 0.5 mM NaCl solution in order to clearly 
find significant differences between different NPs formulations. However, nearly similar 
zeta potential values to the ones observed with 0.25 % w/v NaCl were obtained (data not 
shown).   
 
3.5.6. Residual PVA 
           It is widely reported that although the several washing steps of nanoparticles, yet 
some residual surfactant remains in the suspension and becomes adsorbed onto surface of  
freeze dried nanoparticles and this might lead to alteration of their physicochemical 
properties such as particle size, hydrophilicity, release kinetics, cellular uptake, etc. [7]. 
So, one of our goals was to evaluate the amount of PVA remained attached to the 
nanoparticles and whether they are affected by different PEG chain organization of the 
polymer or not. It was observed that a variable amount of PVA remained in all the 
formulations even after 4 washings (Table 3.2). An attempt was made to evaluate 
whether PVA was present either inside the polymeric matrix or on the surface of the 
particles. Nearly the same amount of PVA was present in the given NPs formulations by 
both assays confirming that the amount of PVA was mainly associated with the surface of 
the particles (data not shown). It was found that the highest amount of PVA remained 
attached to NPs matrix was 6.7 % wt/wt for PLA NPs (Table 3.2). This might be 
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attributed to the enhanced hydrophobic interaction between acetate group of PVA and the 
hydrophobic PLA matrix as reported before by other authors [7, 24]. This result is in 
accordance with other previous studies by other authors. Sahoo et al.[7] have determined 
6.15% wt/wt PVA remaining associated within PLGA NPs matrix when they used 5% 
PVA solution as external aqueous phase. Another study done by Zambaux et al. showed 
also that 5–6% wt/wt PVA remained attached within  PLA NPs after 3 washings when 
1% PVA was used as an external aqueous phase [21]. For all the other pegylated 
polymers either graft or block, they exhibited less adsorption of PVA than PLA NPs as 
shown in Table 3.2. This might be due to the PEG content which offered a certain degree 
of hydrophilicity to the NPs matrix so a less favored interaction with PVA should be 
expected. Similar results were obtained before where the amount of adsorbed PVA 
decreased with increased PEG content within the NPs matrix [10]. Multiblock copolymer 
NPs showed less PVA adsorption ~ 0.5 % compared to PEG7%-g-PLA which showed ~ 
3.5 % wt/wt. The reason behind that is the possibility of a chemical interaction between 
PVA-OH and PLA-COOH and this interaction might be less favored in case of 
multiblock copolymer NPs as will be revealed by XPS data. Also, blank NPs showed 
similar amount of PVA adsorbed on their surfaces as loaded NPs indicating that drug 
loading had no apparent effect on the amount or the orientation of PVA within the NPs 
matrix.  
 
3.5.7. DSC 
          DSC was used to detect the effect of molecular structure of the used polymer on 
the thermal properties of NPs. Moreover, DSC was also used for detecting the state of the 
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Table 3.2. Characteristics of different NPs formulation. 
encapsulated drug inside the NPs matrix as well as investigating any possible interaction 
between the drug and the polymeric matrix. PLA showed glass transition (Tg) at 46.4 °C 
(Table 3.1). Grafting PEG on the PLA backbone resulted in an increased Tg value (by 
about 7 °C) due to enhanced chain rigidity (Table 3.1 and Fig. 3.3.a).  
 
 
 
 
 
 
 
 
 
Formulation Size before 
freeze 
drying (nm)
a, d   
     PI b Size after  
freeze drying 
(nm) a, d 
   PI b        Actual 
 loading 
(% wt/wt) d   
% EE c ,d Zeta  
potential  
(mV) a, d   
Surface 
associated  
PVA 
(%wt/wt) d   
PLA BK e 
 
184±20.8 0.13 161±18.4 0.01 N/A N/A -3.5 ±3.1 6.76±0.40 
PLA LD f 
 
194±30.0 0.08 162±22.3 0.09 4.5±0.22  45±2.24   -0.18 ± 3.2 6.80±0.20   
PEG7%-g-PLA BK e 
 
132±28.0 0.16 166±30.5 0.01 N/A N/A -2.2 ± 3.0 3.57±0.60 
PEG7%-g-PLA LD f 
 
145±34.0 0.07 137±82.1 0.04 7.9±0.04  79.7±0.56  -0.2 ± 3.1 3.79±0.50  
(PLA-PEG-PLA)n  BK e 
 
202±21.2 0.01 168±42.1 0.01 N/A N/A -1.0± 3.5 0.40±0.50   
(PLA-PEG-PLA)n  LD f 199±19.8 0.10 158±31.9 0.02 2.5±0.12  25.3±1.20  -0.24 ± 3.2 0.70±0.60  
N/A: not analyzed. 
a median                         
b refers to polydispersity index.                                C refers to encapsulation efficiency. 
d All values indicate mean±S.D. for n=3 independent measurements for the same particle preparation. 
e Blank NPS               f Loaded NPS 
N.B: (PLA-PEG-PLA)n consists of 1:1 mixture of PLA: (PLA-PEG-PLA)n. 
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Figure 3.2. Tapping mode AFM images of NPs, left panel shows topography (T) and right panel  
shows corresponding phase images (P); all images are acquired in air. PLA (a) [Scan size: 1 µm 
×1 µm], PEG7%-g-PLA (b) [Scan size: 2 µm×2 µm], and (PLA-PEG-PLA)n (c) [Scan size: 750 
nm×750 nm]. 
1 µm 
PEG chains (dark coat) 
PLA chains (white core) 
PEG chains (dark spots) 
T P T TP P 
(c) (b)(a) 
0 2 µm 0 4 µm 2 µm 1.5 µm 750 nm 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Similar findings were previously reported for hyperbranched polymers and dendrimers 
over their linear chain analogues [25]. However, multiblock copolymer showed lower Tg 
values at 39 °C, compared to grafted polymer (Table 3.1 and Figure 3.3.b). This might be 
attributed to their actual higher PEG content 8.9 mol % and/or low molecular weight as 
compared to the grafted polymers (Table 3.1). Also, this might indicate the presence of 
some PEG chains inside the core of PLA. The high PEG content embedded inside PLA 
chains might enhance the chain mobility of PLA due to its plasticization effect on PLA 
chains resulting in a lower Tg, as reported earlier [26, 27]. Thus, the effect of branching 
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was predominant for PEG grafting over PLA backbone, whereas the possibility of PEG 
chains entrapment inside PLA domains might lead to a predominant plasticizer effect. 
Ibuprofen showed an endothermic peak at 78 ºC corresponding to the melting of 
ibuprofen crystals (Fig. 3.3.a, and b). As shown in Fig. 3.3.a, DSC curve of PEG7%-g-
PLA/ibuprofen physical mixture showed an endothermic peak corresponding to the glass 
transition (Tg) at ~ 52 ºC. The melting endotherm of ibuprofen crystals could also be 
detected at 74 ºC. The drug melting peak was shifted by 4 ºC lower with some 
broadening of the peak, indicating the possibility of a weak interaction between the drug 
and the polymer. After encapsulation of ibuprofen into the NPs, Tg was found to be~ 20 
ºC, which might be due to process formulation parameters. Surprisingly, the melting 
endotherm of the drug was clearly observed with also some broadening of its melting 
peak (Fig. 3.3.a). This phenomenon has been related recently to the size of the 
nanocrystals obtained after the process of encapsulation [28]. For more verification of the 
final state of ibuprofen inside NPs, x-ray diffraction analysis (XRD) was carried out for 
ibuprofen loaded NPs and compared to both pure ibuprofen crystals and physical mixture 
of the polymer with the drug having the same ratio as in NPs. Ibuprofen loaded NPs 
showed the presence of crystalline ibuprofen but with slight reduction in the intensity of 
its diffraction peaks (Figure 3.S in the supporting information). XRD data confirmed 
DSC findings. Similar observations were also noticed with (PLA-PEG-PLA)n, in both 
physical mixtures and NPs with the consideration of different Tg for multiblock 
copolymer ~ 39 °C (Fig.3.3.b). Similar finding to ours was obtained when lidocaine 
embedded into PEG-PLGA nanospheres. Lidocaine exhibited an endothermic peak at 
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Figure 3.3.a. DSC curves of ibuprofen, physical mixture of PEG7%-g-PLA with ibuprofen, PEG7%-g-
PLA polymer, and ibuprofen loaded NPs. Inset inside the figure shows clear thermogram for NPs.  
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lower temperature or broadened melting peak compared to lidocaine alone. The authors 
also suggested that there is an interaction between lidocaine and the polymeric carrier [2]. 
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Figure 3.3.b. DSC curves of ibuprofen, physical mixture of (PLA-PEG-PLA)n with ibuprofen, (PLA-
PEG-PLA)n polymer, and ibuprofen loaded NPs. Inset inside the figure shows clear thermograms for 
both physical mixtures and NPs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5.8. XPS analysis  
          XPS analysis was done to investigate the surface chemistry of NPs prepared from 
different polymers and to detect any possible interaction between PLA and PVA on their 
surface. XPS spectrum of PEG showed one characteristic peak corresponding to ether 
carbons (286.5 eV, Table 3.3). PVA polymer showed three main characteristic peaks 
-4.5
-4
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
0.5
-20 0 20 40 60 80 100
Ibuprofen ( mwt/mgm)
Physical mixture of Ibuprofen/
(PLA-PEG-PLA)n (mwt/mg)
(PLA-PEG-PLA)n polymer
(mwt/mg)  
(PLA-PEG-PLA)n NPs (mwt/mg)
Heat 
Flow 
(W/g) 
  
E 
N 
D 
O 
T 
H 
E 
R 
m 
 
-0.8
-0.7
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
-20 0 20 40 60 80 100
Physical mixture 
NPs
Temperature (ºC) 
113 
 
corresponding to C-C/C-H (285 eV), C-OH (286.7 eV) and O-C=O (289 eV) components 
(Table 3.3). For synthesized PLA homopolymer, the best envelop fit was obtained using 
three main peaks corresponding to C-C/C-H (285 eV), C-OH (287 eV) and O-C=O (289 
eV) (Table 3.3). Similar results were obtained before with Shakesheff et al.[10]. 
Ibuprofen could not be experimentally analyzed since it was found to sublime under the 
high vacuum of the equipment. Based on theoretical estimation, ibuprofen has two main 
characteristic peaks corresponding to C-C/C-H (285 eV), and O-C=O (289 eV) 
components (Table 3.3). 
 
 
 
 
  
It should be mentioned that for ibuprofen to be detected at the surface of loaded NPs, an 
increase in atomic percentages of both its characteristic peaks mainly C-C/C-H (285 eV) 
is expected to be found. Both ibuprofen loaded and blank NPs of PEG7%-g-PLA grafted 
 
 
 
Binding Energy 
(functional component) 
Atomic Percentage (%) 
Ibuprofen PLA PVA PEG 
285   (C-C) 92.4 22.3 37.1 - 
286.5 (C-O) -  - - 100 
286.7 (C-O) - - 23 - 
287     (C-O) - 28.9 - - 
289 (O-C=O) 7.6 13.9 4.3 
 
- 
Table 3.3. Relative atomic percentages calculated from XPS Surface Analysis of pure 
materials used in NPs formulation. 
N.B: Relative percentage of each functional component is calculated from the area under the 
curve from their respective peaks in XPS analysis. 
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polymer as well as the polymer itself showed the existence of PEG chains on the surface 
as seen by the presence of a characteristic peak corresponding to ether carbons (286.5 eV, 
Table 3.4). However, the atomic % of PEG decreases from the polymer (16.9 %) to blank 
(11.8%) then to loaded NPs (8%) as shown in Table 3.4. This might be due to adsorption 
of PVA in case of blank NPs. While in loaded NPs, both PVA and ibuprofen might be 
adsorbed at the surface of NPs as evidenced from the increase in atomic % of C-C (285 
eV) in case of loaded NPs (18.6%) compared to blank NPs (13.1%) [Table 3.4]. Such an 
adsorption might decrease the PEG content at the surface. Also, it could be seen from 
Table 3.4 that the atomic % of C-C (285 eV) decreases from the polymer (18%) to blank 
(13.1%) and then increased again in case of loaded NPs (18.6%). This order might be due 
to chain organization during NPs formation by O/W emulsion method in such a way that 
PLA chains (rich in C-C) will be collapsed inside the oil droplets (internal phase) while 
PEG chains will be facing the external aqueous phase. Oil droplets tend to form the 
internal NPs core upon organic solvent removal and particle precipitation. This process 
will lower PLA chains and hence, C-C content at the NPs surface. This C-C content 
lowering was compensated by drug adsorption (also rich in C-C component as shown in 
Table 3.3) at the surface in case of loaded NPs as stated before.  Moreover, to get the best 
envelop fit of both NPs, two additional peaks had to be added corresponding to C-O-
*C=O (287.6 eV) and *C-O-C=O (286.2 eV) components (Table 3.4). These new peaks 
obtained in both types of NPs could be the result of chemical interaction between PLA-
COOH end and PVA-OH during NP formation. The last finding also supports the 
effective masking of negative charge of these NPs by both PEG and PVA chains at the 
surface of such NPs as shown in Table 3.2. The increase in atomic % of O-C=O (289 eV) 
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from the polymer (5%) to both blank and loaded NPs (7.1% and 6.9%, respectively) 
might be due to PVA (partially hydrolyzed) and ibuprofen (weak acid) adsorption at the 
surface of blank and loaded NPs types, respectively. This O-C=O (289 eV) component 
was also detected in the XPS spectrum of the polymer itself due to the presence of COOH 
functional group in the polymer structure (Fig.3.1). On the other hand, both drug loaded 
and blank NPs of (PLA-PEG-PLA)n polymer as well as the polymer itself showed also 
the existence of PEG chains on the surface as evidenced from the presence of the same 
characteristic peak corresponding to ether carbons of PEG (286.5 eV, Table 3.4). 
However, the atomic % of PEG was markedly decreased upon NPs formation compared 
to grafted polymer. PEG atomic % detected in the polymer was (31.2%) compared to 
blank (13%) and loaded NPs (11.6%). Taking into account that minimal amount of PVA 
was detected at the surface of multiblock NPs (~ 0.5% wt/wt, Table 3.2), so the last 
finding indicates that only a small fraction of the total PEG content of the multiblock 
copolymer exists at the surface of NPs while the remaining PEG chains might be 
entrapped inside NPs core. This could be also due to chain organization during NPs 
formation by O/W emulsion method in such a way that showed the difficulty of PEG 
chains migration towards the surface of NPs.  In fact the peculiar architecture of the 
multiblock copolymer (PLA-PEG-PLA)n shows that PEG chains are covalently linked 
between two neighboring PLA chains. That is why PEG chains are not easy to orientate 
towards the surface of NPs facing the aqueous phase and most of them is orientated or 
stretched more towards the core. AFM phase images of multiblock copolymer showed 
the existence of few PEG chains at the surface of NPs compared to grafted polymer 
confirming XPS findings (Fig.3.2). Moreover, no additional peaks were needed to 
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complete the fit indicating the absence of PLA interaction with PVA in multiblock 
copolymer NPs. This might be due to the lower number of free COOH end components 
available for reaction with PVA-OH components in multiblock copolymer NPs in 
contrast to grafted polymers. Since multiblock copolymer has been synthesized by the 
condensation of triblock copolymer, the number of available COOH components was 
expected to be low. The last hypothesis was supported by the lower atomic % of O-C=O 
(289 eV) component at the surface of the polymer (2.1 %), blank (2.3 %), and loaded NPs 
(3.2 %), respectively. The atomic % of C-C (285 eV) was detected in the XPS spectrum 
of blank NPs in a similar value to that of the polymer (19%) due to presence of some 
PLA chains (rich in C-C) at the NPs surface since PEG doesn’t cover the NPs surface 
completely. While, the increase in atomic % of C-C components (285 eV) in case of 
loaded NPs (21.8%) confirms the possibility of drug existence at the surface of NPs. 
 
3.5.9. 1H-NMR of NPs in D2O 
              1H-NMR analysis was done on NPs in attempt to investigate the core-corona 
structure of pegylated NPs. 1H-NMR spectra of all pegylated NPs in D2O showed 
presence of methylene protons of PEG chains at 3.6 ppm (Fig.3.4).  Signals from PLA 
methyl or methylene protons were absent or diminished in intensity. This might indicate 
that PLA protons are in solid environment and can't be detected whereas PEG chains 
must be in mobile state. 1H-NMR analysis for PLA-PEG diblock NPs confirmed their 
core-corona structure [29]. Similar finding was obtained for NPs made from comb 
polyesters of PVA-g-PLGA in water showing  reduced signal intensity of the more 
hydrophobic PLGA chains compared to hydroxyl terminated end groups of PVA [30].  
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Our results are in accordance with the above-cited reference suggesting NPs made of 
PLA core and PEG corona. Thus, 1H-NMR analysis of NPs might indicate that 
hydrophilic polymer parts (PEG) are oriented towards the outer phase (water) during 
precipitation and NP hardening whereas the more lipophilic polyester PLA residues form 
the inner core. However, these studies are not quantative to comment whereas all the 
PEG chains constitute the corona and to determine the amount of PEG exactly at the 
surface for both grafted and block pegylated NPs. 
                                                                                                                                                                                                                             
 
 
 
 
B.E.  
(functional 
component) 
Atomic percentage (%) 
PEG7%- 
g-PLA  
BK NPs 
PEG7%-
g-PLA LD 
NPs 
PEG7%-
g-PLA 
polymer 
(PLA-
PEG-
PLA)n BK 
NPs 
(PLA-
PEG-
PLA)n 
LD NPs 
(PLA-
PEG-
PLA)n 
polymer 
285 (C-C) 13.1 18.6 18 19 21.8 19.2 
286.2 (*C-O-C=O) 10.1 10.4 - - - - 
286.5 (C-O) 11.8 8 16.9 13 11.6 31.2 
287.6 (C-O-*C=O) 7.1 6.9 - - - - 
289 (O-C=O) 7.1 6.9 5 2.3 3.2 2.1 
(B.E.) refers to the binding energy 
(BK) refers to blank NPs 
(LD) refers to loaded NPs 
 
Table 3.4. Relative atomic percentages calculated from XPS Surface Analysis of 
synthesized polymers and formulated NPs using those polymers.  
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(1) 
(3) 
(2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5.10. Erosion study 
             This study was conducted to investigate the effect of PEG chain organization on 
the degradation rate of PLA based NPs under conditions similar to physiological ones. 
Mass loss of copolymer in phosphate buffer started after 5 days for all the investigated 
NPs. Pegylated NPs showed faster degradation rates (30 %,  and  44 % for PEG7%-g-
Figure 3.4. 1H-NMR of blank NPs of PLA (1), PEG7%-g-PLA (2), and (PLA-PEG-PLA)n 
(3) in D2O. PEG peaks at 3.6 ppm are encircled.   
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PLA, and (PLA-PEG-PLA)n, respectively) compared to PLA NPs which showed slower 
degradation rates around 12% after 25 days. This pattern is shown in Figure 3.5. Ester 
hydrolysis and transesterification mechanisms are both responsible for mass loss of 
polyester copolymers [31]. NPs erosion was initiated by water uptake followed by 
random hydrolytic chain scission of PLA block with release of lactide oligomers. So it 
might be expected that the more hydrophilic polymer initially swells to a much greater 
degree than other polymers of lower hydrophilic content, allowing more water uptake 
into the matrix, further increasing the rate of hydrolysis and breakdown of NPs [11, 32]. 
Cleavage of the ester bonds between the PLA-PEG backbone leads to free PEG units that 
will be formed and diffuse out of the matrix. With the loss of PEG from the backbone, 
degradation of the matrix is dominated by PLA with an increase of the internal matrix-
surface in contact with water leading to higher degradation rates than that of 
homopolymer [33]. The faster degradation rate of (PLA-PEG-PLA)n NPs (44%) 
compared to PEG7%-g-PLA (30%) after 25 days emphasizes the rapid core (PLA) 
wetting in the multiblock copolymer NPs. This might be due to entrapment of most of 
PEG chains into the NPs core while in case of grafted PEG7%-g-PLA polymer, most of 
PEG was found to be at the surface of NPs as shown before by AFM phase imaging and 
XPS studies.  
 
3.5.11. In Vitro Drug Release. 
             In order to study the effect of PEG chain organization on drug release profiles 
from different PLA NPs, ibuprofen loaded NPs were compared for their in vitro release 
behavior as shown in Fig. 3.6. It could be seen that all formulations exhibited biphasic  
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release phenomenon. After 8 h of NPs immersion into the release medium, a rapid initial 
burst of ibuprofen varied from 20 % to 53 % of the drug content was clearly observed in 
all batches. This finding might be due to the desorption of the drug particles adsorbed at 
or close to the surface of NPs [34] followed by sustained release of the drug over 300 h. 
This second sustained release phase would mainly depend on both drug diffusion and the 
Figure 3.5. Erosion of different ibuprofen loaded NPs in phosphate buffer saline (PBS,  
pH 7.4)  at 37 ºC. 
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matrix erosion that was a slower process [35, 36]. In such case, the effects of porosity of 
the nanoparticles on the release property should be verified. As mentioned above in 
experimental section, that we used 5% w/v sucrose as cryoprotectant to prevent NPs 
aggregation during lyophilization. Such higher concentration was found to have pore 
blocking action particularly surface pores, an effect caused by the precipitation of 
cryoprotectant on nanoparticle surface [37]. So, we expected that NPs porosity might 
have a minor effect on ibuprofen release from NPs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.6. Effect of PEG chain organization on the in vitro release behavior of ibuprofen  
loaded NPs; values are represented as mean ±S.D. of three independent experiments. 
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Thus, the last hypothesis might support that the slow release of drug might be mainly 
controlled by both solubility of the drug in the matrix and matrix erosion mechanism. The 
physical state of the drug inside the NPs matrix was investigated before using DSC since 
this would have an influence on the in vitro and in vivo release characteristics of the 
drug. DSC indicated that ibuprofen exists in a crystalline state inside all NPs irrespective 
of their polymer content. The last finding indicates that the main rate limiting step 
affecting drug release will be the dissolution of drug crystals into the polymeric matrix 
followed by their diffusion out of the matrix into the release media. This finding also 
confirmed the role of NPs core wetting in enhancing drug dissolution and hence drug 
release. Thus, the polymer that favors more water uptake and hence rapid core wetting 
would facilitate drug dissolution and hence faster drug release. The release pattern for all 
NPs formulations showed good correlation coefficient (R2 was close to 1) when fitted to 
Higushi square root equation of diffusion (data not shown) indicating that release will be 
mainly dominated by the diffusion of the solubilized drug crystals through the NPs 
matrix with some contribution from degradation decreasing in importance upon 
increasing the molecular weight of the polymer [36]. It could be seen that multiblock 
copolymers NPs showed faster drug release compared to PEG7%-g-PLA NPs. The 
possible reason behind that is the peculiar polymer architecture of the multiblock 
copolymer allows a major portion of PEG to be entrapped inside the core during NP 
formation as revealed from XPS and phase imaging data and hence, rapide wetting of the 
core will take place compared to grafted NPs. When PEG7%-g-PLA NPs are suspended 
into the release medium, a major fraction of PEG will be migrated easily towards the 
surface while the cores will be predominantly hydrophobic. In case of multiblock, a 
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considerable amount of PEG is expected to be embedded into the PLA core due to the 
covalent linkage of PEG with two PLA blocks as stated before which might hinder PEG 
chains to be migrated towards the surface. The hydrophilicity of the matrix is one of the 
major factors that markedly influence its hydration and, in turn, the drug release profile 
[38, 39].  Multiblock copolymer NPs were shown in the last section to erode faster than 
PEG7%-g-PLA NPs confirming the faster release rate obtained with such NPs. Another 
previous study showed that multiblock copolymers of PEG and PLA exhibited faster drug 
release compared to their PLA homopolymer and the authors attributed this also to the 
marked hydrophilic properties of multiblock copolymers [40, 41]. These results showed 
that core wetting is an important factor influencing the drug release kinetics. A schematic 
representation of different NPs chain organization depending on both their polymer 
composition and architecture is shown in Figure 3.7. This difference in chain 
organization was found to have an effect on the release kinetics of the encapsulated drug 
from NPs. Generally speaking, our results suggest the possibility of use of such pegylated 
NPs as drug carrier for poorly soluble drugs. Also, they could have the potential of 
targeting the encapsulated drugs into certain tissues depending on their ability to circulate 
for longer periods of time without being recognized by the immune system. It should also 
be mentioned that the use of multiblock copolymer would facilitate the encapsulation of 
hydrophilic drugs into their NPs matrix due to the formation of small pockets of PEG that 
might create an aqueous phase embedded inside a hydrophobic polymeric matrix. 
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3.6. Conclusion 
       NPs were fabricated using novel copolymers of PEG-modified PLA polymers with 
different PEG chain organization. Both AFM phase imaging and XPS studies showed the 
existence of PEG chains on the surface of grafted pegylated NPs. Both studies also 
showed that multiblock copolymer displayed less amount of PEG on the surface due to 
Figure 3.7. Schematic representation of polymer chain organization inside the NPs: PLA (a), 
PEG7%-g-PLA (b), and multiblock copolymers (PLA-PEG-PLA)n (c).  
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the possibility of PEG chains interpenetration inside the PLA core of NPs. This resulted 
in lower Tg, rapid degradation of the polymeric matrix, and faster drug release from NPs. 
On the contrary, grafted pegylated copolymer showed enhanced immiscibility of both 
PEG and PLA blocks resulting in enhanced phase separation of both components during 
NPs formation and hence, easy migration of PEG chains towards the surface of NPs 
while the cores will be predominantly hydrophobic. Our future work will focus on 
studying the cellular uptake of rhodamine encapsulated NPs made from different 
polymers with different PEG chain organization.  In brief, the way PEG chain organized 
onto PLA backbone is an important parameter controlling surface characteristics of NPs 
which in turn determine their physicochemical properties like encapsulation efficiency, % 
PVA adsorbed at the surface of NPs, zeta potential, thermal characteristic, and drug 
release kinetics. 
3.7. Appendix A. Supplementary material 
Supplementary data associated with this article can be found, in the online version, at 
doi:10.1016/j.ejpb.2010.03.002 
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Figure 3.S (supporting information): XRD spectra of ibuprofen, physical mixture of PEG7%-
g-PLA with ibuprofen, PEG7%-g-PLA polymer, and ibuprofen loaded NPs. 
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4.1. Abstract: 
       In our previous study, PEG-g-PLA nanoparticles were developed and characterized. 
The aim of the present work is to investigate the effect of PEG grafting density (% PEG 
inserted onto poly(D,L)-lactide, PLA backbone) on both physicochemical and biological 
properties (mainly plasma protein binding and in vitro macrophage uptake) of PEG-g-
PLA NPs. Rhodamine B (RHO) loaded NPs were prepared from a 1:1 (wt/wt) blend of 
PLA and PEG-g-PLA copolymer of varying PEG grafting density (1, 7, or 20 % mol/mol 
of lactic acid monomer) by an o/w emulsion solvent evaporation method. These NPs 
were characterized with regard to their morphology, size, surface charge, loading 
efficiency, and rhodamine release. The extent of protein adsorption to the surface of 
different NPs was qualitatively investigated by dynamic light scattering technique. 
Additionally, the in vitro macrophage uptake following incubation of RAW 264.7 cells 
with rhodamine loaded PEG-g-PLA and PLA particles was investigated by confocal laser 
scanning microscopy (CLSM). The amount of NPs phagocytosed following incubation of 
RAW 264.7 cells with different concentrations of rhodamine loaded PLA or pegylated 
NPs for 24 h at 37 °C was also determined by fluorescence spectroscopy. ALL 
lyophilized NPs showed larger diameter in the range of 300–400 nm compared to freshly 
prepared NPs suspension indicating particle aggregation upon lyophilization. % EE of 
rhodamine was found to be between 10% and 68% wt/wt depending on PEG grafting 
density. The higher the grafting density of PEG over PLA backbone, the more the 
entrapment efficiency. All pegylated NPs showed low zeta potential (close to zero) 
values. In vitro release analysis revealed that rhodamine leaked from all nanoparticles at a 
very slow rate at physiological pH, thus making it suitable for both imaging and uptake 
studies with RAW 264.7 cells. All PEG-g-PLA NPs of different PEG grafting density 
were well tolerated and exhibited no toxicity to RAW 264.7 cells as seen by cell 
proliferation assays. Cellular uptake of NPs was mainly dependent on polymer type as 
well as PEG grafting density. Grafted copolymer NPs resulted in lower degree of 
macrophage uptake compared to PLA NPs in macrophages cell lines. The higher the PEG 
grafting density, the lower the uptake of NPs by macrophage cells. Minimum NPs uptake 
for all the investigated concentrations was achieved when the PEG grafting density was 
7% mol/mol of lactic acid. When increasing the PEG grafting density in the nanoparticles 
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above 7 %, no significant reduction in NPs phagocytosis was achieved. Thus, this study 
shows that the optimal PEG density required for designing stealth PEG-g-PLA NPs 
suitable for drug delivery applications might vary from 4-7%. 
 
4.2. Keywords  
Nanoparticles, PEG-PLA, grafting density, rhodamine, macrophage, plasma proteins. 
 
4.3. Introduction 
 
        Biodegradable nanoparticles are promising carriers to improve the administration of 
certain drugs, vaccines, nucleic acid and therapeutic proteins [1-4]. Benefits offered by 
biodegradable nanoparticles include improved therapeutic efficiency, enhanced 
protection of the active moiety from degradation, maintenance of drug concentrations 
within acceptable therapeutic limits, the need for fewer doses thus reducing dose-limiting 
side effects, prolonged biological activity, and finally better patient compliance [5, 6]. 
       Poly(lactic acid) (PLA) or poly(lactide-co-glycolide) are the most widely used 
polymers in drug delivery systems. However, NPs formulated using either PLA or PLGA 
might suffer many drawbacks as their rapid uptake by the reticuloendothelial system after 
intravascular administration, low drug loading efficiency, inability to encapsulate a wide 
range of drugs particularly hydrophilic drugs, and in many cases inability to release their 
payload completely [7]. Low drug incorporation of PLGA and PLA usually leads to large 
drug loss during NP formulation, and hence, encapsulating insufficient drug amounts for 
therapeutic efficacy [8, 9]. The former situation necessitates the use of high polymer 
levels that might exceed their safety profile. Another drawback of PLGA and PLA is that 
an initial burst release of drug can be observed in most loaded NPs, which may result in a 
loss of much of the therapeutic dose before the target site is reached by the NPs [10, 11].  
With these drawbacks of PLGA/PLA, a novel biodegradable polymer, PEG-g-PLA was 
early developed by our group [12]. Our previous work focused mainly on the 
development and characterization of functionalized poly(D,L)-lactide (PLA) 
nanoparticles in order to improve the drug delivery behavior of PLA nanoparticles [13, 
14]. Functionalized poly(D,L)- lactide (PLA) nanoparticles development mainly depend 
on  introducing a flexible moiety onto PLA hydrophobic cores in attempt to improve the 
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drug delivery properties of the obtained NPs. A variety of pendant substituents could be 
grafted onto PLA to generate polymers of different physicochemical properties and hence 
different drug incorporation behavior than PLA itself.  In the same work, we have 
reported the development and characterization of PEG-g-PLA NPs with some optimal 
properties ideal for drug delivery applications. Those properties were uniform size with 
narrow size distribution (~150-200 nm), neutral surface charge, higher encapsulation 
efficiency, and finally their ability to control the release of the entrapped model drug, 
ibuprofen for a period of two weeks.         
     In this part, we are attempting to study the effect of PEG grafting density over PLA 
backbone on the properties of PEG-g-PLA NPs either physicochemical or biological 
properties mainly in vitro plasma protein adsorption and macrophage cellular uptake. 
Another aim is to investigate the optimal PEG grafting density required to develop stealth 
particles from such type of grafted copolymers. In order to reach these goals, we prepared 
NPs encapsulating rhodamine B (RHO) as a fluorescent marker using grafted pegylated 
polymer; PEG-g-PLA with different PEG grafting densities (1, 7, or 20% mol/mol of 
lactic acid monomer). RHO was loaded into NPs in order to have labeled formulations 
suitable for investigating the cellular uptake of NPs by macrophage cell lines, RAW 
264.7. It is important that the marker used is incorporated into the NPs at a sufficient 
level to give good detection by the used analytical methods. Thus, a 1:1 wt/wt blend of 
PLA: PEG-g-PLA of different PEG density was used to efficiently entrap RHO into NPs 
matrix. An o/w emulsion solvent evaporation method was used to prepare RHO loaded 
NPs.  RHO should remain associated with the NPs so that we follow the fate of the NPs 
rather than the marker itself. Accordingly the drug incorporation and release of the 
marker from NPs were determined.   
 
4.4. Material and methods 
 
4.4.1. Materials 
          D,L-Lactide, poly(ethylene glycol) methyl ether (MePEG; 2000 Da), allyl glycidyl 
ether, tetraphenyltin, polyvinyl alcohol (PVA, average Mw 9000-10,000 Da, 80% 
hydrolyzed), borane-tetrahydrofuran complex (1 M), acetone, toluene, pyridine, 
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chloroform, thionyl chloride, rhodamine B (RHO), and albumin bovine were purchased 
from Aldrich Chemical Company Inc., Milwaukee, USA. Sodium hydroxide pellets were 
purchased from Anachemia Canada Inc. and dichloromethane (DCM) was purchased 
from Laboratoire Mat Inc., Montreal, Quebec, Canada. Fetal bovine serum and all other 
materials for cell culture were purchased from Invitrogen (Burlington, ON, Canada) 
unless otherwise stated. 
 
4.4.2. Synthesis of Polymers.  
          Poly(D,L)-lactide (PLA) was synthesized by ring-opening polymerization of 
dilactide in argon atmosphere, using tetraphenyltin as the catalyst. Briefly, dilactide was 
crystallized from toluene solution and dried under vacuum before use. A weighed amount 
of purified dilactide was then placed in a round-bottom flask and purged thoroughly with 
argon. Bulk polymerization was carried at 180 °C for 6 h. The polymer thus obtained was 
dissolved in acetone and was purified by precipitating in water.  
       Polymer with poly(ethylene glycol)-grafted randomly on poly(D,L)-lactide (PEG7%-
g-PLA) (PEG; Mw 2000 Da) was synthesized as reported earlier [12]. Briefly, D,L-
dilactide (21.5 g, 93 mol %) was polymerized in the presence of allyl glycidyl ether (2.6 
g, 7 mol %) with tetraphenyltin as the catalyst (1:10 000 mol with regards to D,L-
dilactide) at 180 °C for 6 h under argon. Polylactic acid with allyl groups was purified by 
dissolving in acetone and precipitating in water. The allyl groups were converted to 
hydroxyl groups by hydroboration with an equimolar quantity of borane in 
tetrahydrofuran, followed by oxidation in the presence of hydrogen peroxide under 
alkaline conditions (1.5 mol of 3 N sodium hydroxide). The hydroxyl groups were 
oxidized to carboxylic acid groups using Jones reagent, which was further converted to 
an acid chloride using thionyl chloride (1:1000 M). Finally, methoxy-PEG was grafted 
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onto the polymer backbone by the reaction between acid chloride and the hydroxyl 
groups of methoxy-PEG (2000 Da) in the presence of pyridine. The final polymer was 
purified by evaporating pyridine and washing with distilled water. For the 1%, and 20% 
PEG-grafted polymers (PEG1%-g-PLA, and PEG20%-g-PLA, respectively) the 
concentrations of D,L-lactide and allyl glycidyl ether were adjusted to give the desired 
ratios with the remaining synthesis procedure being the same. 1H NMR spectra were 
recorded on a Brucker ARX 400 spectrometer (Bruker Biospin, Billerica, MA). Chemical 
shifts () were measured in parts per million (ppm) using tetramethylsilane (TMS) as an 
internal reference. Gel permeation chromatography (GPC) was performed on a Water 
Associate chromatography system (Waters, Milford, MA) equipped with a refractive 
index detector and a Phenomenex Phenogel 5  column. Polystyrene standards were used 
for calibration with THF as the mobile phase at a flow rate of 0.6 mL/min.  
 
4.4.3. Preparation of nanoparticles (NPs) 
          RHO loaded NPs were prepared by an O/W emulsion-solvent evaporation method.  
It should be mentioned that NPs were prepared using a 1:1 blend of high Mwt PLA (Mwt 
=56.000 Da, Table 4.1) with each pegylated polymer, PEG-g-PLA of different PEG 
grafting density (1, 7, or 20% mol/mol of lactic acid monomer) to ensure high retaining 
ability of NPs for rhodamine B (RHO). RHO loaded NPs were prepared using an initial 
loading of 0.24% wt/wt of each polymer blend. Rhodamine (RHO) was first dissolved in 
the organic phase, 10 mL DCM followed by dissolution of each polymer blend (1 g) in 
the same phase. The organic phase was then emulsified into 30 mL PVA solution (0.5% 
w/v) as an external aqueous phase using high-pressure homogenizer (Emulsiflex C30, 
Avestin, Ottawa, Canada) at a pressure of 10,000 psi for 5 min. The O/W emulsion was 
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collected by washing with another 30 mL 0.5% PVA. The DCM was evaporated under 
reduced pressure with constant stirring to obtain the NPs. Finally, NPs obtained as a 
suspension were then collected by centrifugation at 18500 rpm for 30 min. at 4 ºC 
(Sorval® EvolutionRC, Kendro, USA), washed four times with distilled water, then 
lyophilized to obtain dry NPs (Freeze Dry System, Lyph.Lock 4.5, Labconco) and stored 
at 4 ºC until further use. Small samples of the nanoparticle suspension were taken before 
lyophilization step in order to identify the original size of the particles obtained after 
homogenization and organic solvent evaporation.  
 
4.4.4. Characterization of NPs 
           Size and size distribution of NPs were measured by dynamic light scattering 
(DLS) with a Malvern Autosizer 4800 instrument (Malvern Instruments, Worcestershire, 
UK) before and after lyophilization. DLS uses photon correlation spectroscopy to 
determine particle size from the temporal variation of light scattering caused by 
Brownian motion of the suspended particles. For all batches, fresh NP suspensions (0.1 
mL) or lyophilized NPs (1 mg) were diluted 10 times with Milli-Q Water and size 
measurements were performed at 25 ºC and scattering angle of 90º. The CONTIN 
program was used to extract size distributions from the autocorrelation functions. 
Measurements were performed in triplicate. The zeta potential of the nanoparticles was 
measured with Malvern ZetaSizer Nanoseries ZS (Malvern Instruments, Worcestershire, 
UK). Freeze dried NPs were suspended in 0.22 m filtered 0.25% (w/v) saline solution 
(pH 7.4) and zeta potential was measured in triplicate. Nanoparticle morphology was 
studied using atomic force microscopy technique (AFM). AFM was performed with 
Nanoscope IIIa, DimensionTM 3100 (Digital Instruments, Santa Barbara, CA) in tapping 
mode. Samples were prepared by suspending the nanoparticles in water at a concentration 
of 10 mg/mL. These samples were deposited on freshly cleaved mica surface and were 
allowed to dry at room temperature. Subsequently, they were imaged in air at ambient 
conditions using etched silicon probes with tip radius of 5-10 nm and spring constant in 
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Drug entrapped in NPs 
Initial amount of drug added 
% EE = 
X 100  (1) 
 
% DL = 
Drug entrapped in NPs 
Weight of NPs 
X 100  (2) 
 
the range of 20-100 N/m, oscillated at its fundamental resonant frequency (200-400 
KHz). 
 
4.4.5. Encapsulation efficiency (EE) 
           A weighed amount of NPs was dissolved into dichloromethane (DCM) followed 
by 5 min. vortexing and then stirring for 1 h. Rhodamine (RHO) concentration was 
measured by spectrofluorimetry at excitation (λex) and emission (λem) wavelengths of 
552 and 585 nm, respectively, using a Tecan Safire plate reader (Durham, NC). Percent 
encapsulation efficiency (% EE) and percent drug loading (% DL) were calculated based 
on the following equations: 
 
 
 
 
 
 
 
 
 
 
4.4.6. In vitro drug release study 
          All formulations prepared using different polymers were tested for in vitro release 
in triplicates in phosphate buffered saline (PBS, 10 mM, pH 7.4.). 30 mg NPs were 
suspended in 10 mL PBS in a dialysis tubing (Spectra Por 1 membrane, 6–8 kDa cut-off). 
This dialysis tubing was placed in a screw-capped tube containing 40 mL PBS. The tubes 
were shaken at 200 rpm on a horizontal water bath shaker (Orbit Shaker Bath, Labline) 
maintained at 37±0.5 ºC. At predetermined time intervals, 15 mL of the external medium 
was withdrawn and replaced by fresh PBS to maintain sink conditions. The aliquots were 
assayed for the concentration of RHO released by spectrophotometry at 552 nm (U-2001 
UV/Visible spectrophotometer, Hitachi). 
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4.4.7. Evaluation of protein adsorption to NPs surface 
           Dynamic light scattering (DLS) was used for measurement of the size of different 
NPs incubated with either 5 % fetal bovine serum (FBS) or 2 % bovine serum albumin 
(BSA). A weighed amount of NPs in 5 mL of either 5% FBS or 2% BSA was incubated 
at 37 °C for 24 h. Controls included the incubation of serum alone and RHO-loaded NPs 
alone with only distilled water for the same period of time. Samples were analyzed by 
DLS (n=3) at the end of the incubation period to determine if there is any change in the 
size distribution pattern of different NPs. 
 
4.4.8. Cell culture 
          Macrophage cell line, RAW 264.7 was grown in Dulbecco’s modified Eagle cell 
culture medium (DMEM) containing 10% (v/v) heat-inactivated fetal bovine serum, 100 
U/mL penicillin-G, and 100 mg/mL streptomycin (Invitrogen, Burlington, ON, Canada) 
in an atmosphere of 5% CO2 and 95% relative humidity. The cells were routinely 
passaged at 90–95% confluence. 
 
4.4.8.1. Evaluation of cellular toxicity of PEG-g-PLA NPs 
             Inhibition of cell proliferation was assessed by tetrazolium salt 3-(4,5-
dimethylthiazol-2 yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Briefly, 1 x 105 
RAW 264.7 cells were seeded in 96-well flat bottom plates (Costar, Corning, NY) and 
allowed to grow for 24 h. The cells were then incubated with increasing concentrations of 
each PEG-g-PLA NPs of different PEG grafting density for 24 h. Cell layers were 
washed with cold PBS and further incubated with 10 µL of MTT solution (5 mg/mL in 
PBS) for 4 h at 37°C. Formazan crystals formed were then dissolved along with the cell 
layers and absorbance was measured on microplate reader at 570 nm. Cell viability was 
calculated with respect to PBS as control. 
 
4.4.8.2. Cellular interaction with RAW 264.7: CLSM study 
             RAW 264.7 cells (a murine macrophage-like cell line) were seeded in eight-well 
chamber plate that contained a pre-sterilized coverslip at a concentration of 1 × 105 cells 
per well and allowed to adhere overnight in DMEM with 10% serum at 37°C.  Next day, 
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the medium was removed; the cells were washed with a sterile Hanks balanced salt 
solution (HBSS). Then cells were incubated in RPMI 1640 medium with RHO-
encapsulated nanoparticles (ensuring that rhodamine content is the same for all NPs 
batches based on the actual RHO loading) for 24h at 37°C. Next, the cells were washed 
six times with HBSS and were fixed with 4% paraformaldehyde solution. Coverslips 
were then mounted onto microscopy slides using Gel-Tol mounting medium (Thermo 
Scientific, Pittsburgh, PA, USA) to protect the samples. Microscopy slides were observed 
with an inverted Olympus IX71 microscope (Olympus Canada Inc., Markham, ON) and 
an Evolution VF camera (MediaCybernetics, Bethesda, MD) with the same 60× objective 
lens and exposure time to allow comparison of measurements. Laser sources at 476, 488 
and 496 nm were used to excite RHO and the fluorescence signal were detected in the 
550–650 nm range. All microscopy gain and offset settings were maintained constant 
throughout the study. All images were processed with ImagePro software 
(MediaCybernetics, Bethesda, MD). 
 
4.4.8.3. Cellular interaction with RAW 264.7: Fluorimetry analysis 
              RAW 264.7 cells (1 x 105 cells/ well) were plated in 24- well flat bottom plates 
(Costar, Corning, NY) and allowed to adhere overnight in DMEM with 10% serum. Next 
day, the medium was removed and replaced by RPMI 1640 without serum. The cells 
were then incubated with different concentrations of RHO encapsulated NPs for 24 h at 
37 °C. The cell monolayers were washed four times with cold PBS (pH 7.4) and then 
lysed with 0.2% Triton-X 100 in 0.2N NaOH solution. The fluorescence was measured 
on microplate reader at excitation and emission wavelength of 552 and 585 nm, 
respectively. The amount of NPs phagocytosed was calculated from calibration curve of 
NPs under the same conditions.  
 
4.4.9. Statistical analysis 
Results were expressed as mean ± SD. All data were generated in three independent 
experiments with two or three repeat. The t-test and the one-way analysis of variance 
(ANOVA) were performed to compare two or multiple groups, respectively. The 
difference between treatments was considered to be significant at a level of P<0.05. 
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Statistical analysis was performed for sizing, zeta potential, release, cellular uptake 
results, and encapsulation efficiency and loading data. 
 
4.5. Results and discussion 
       Our previous development of PEG-g-PLA NPs with suitable drug delivery properties 
e.g. small size, higher encapsulation efficiency, and prolonged release features led us to 
investigate the effect of PEG coating density on the physicochemical and in vitro 
macrophage uptake properties of the obtained NPs. We hypothesized that a high PEG 
coating density on the particles and a small particle size would improve the potential of 
PEG-g-PLA as a stealth carrier in vivo. The optimal PEG coverage density that could 
impart stealth behavior for the PEG-g-PLA NPs without compromising NPs properties 
was investigated in that study. With this purpose in mind, we synthesized PEG-g-PLA 
copolymers which differ in the PEG grafting density but have the same PEG chain lengh 
(2 kDa). Then, PEG-g-PLA nanoparticles of different PEG coating densities loaded with 
the fluorescent molecule rhodamine (RHO) were prepared as a tool for investigating NPs 
interaction with Raw 264.7 macrophage cell lines. The extent of cellular uptake of 
different particles was evaluated by fluorescence microscopy and fluorimetry analysis. 
RHO was chosen as the fluorescent label because it is more stable than fluorescein to 
quenching by light [15], efficiently entrapped and molecularly dispersed into NPs 
matrices [16], easily loaded into NPs either by simple nanoprecipitation [17] or single 
o/w emulsion solvent/evaporation method [18]. Moreover, the conditions required for 
obtaining good images for NPs inside the cells by fluorescence microscopy were found to 
be easily optimized with RHO use [19, 20] . To develop RHO loaded PEG-g-PLA NPs 
suitable for investigating the cellular interaction, NPs must show high retaining ability for 
the fluorescent marker. In order to achieve this, a 1:1 wt/wt polymer blend consisting of 
high Mwt PLA with each pegylated polymer, PEG-g-PLA of different PEG density (1, 7, 
or 20 mol %) was used to prepare NPs.  
 
4.5.1. Characterization of Polymers  
          PLA homopolymer and PEG-g-PLA copolymers of different PEG grafting 
densities were synthesized by ring-opening polymerization method. 1H NMR 
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spectroscopy and gel permeation chromatography (GPC) were used to measure the 
number average (Mn) and weight average molecular weights (Mw) of the synthesized 
polymers. The polydispersity was calculated by the ratio of Mw to Mn from the GPC 
data. GPC results are summarized in Table 4.1. All the synthesized polymers exhibited 
uniform molecular weight distribution as revealed by the narrow polydispersity index 
values as shown in the same table. Unimodal mass distribution ruled out the possibility of 
the presence of unreacted MePEG or Poly(D,L-lactide) (data not shown). The molecular 
weight of PEG-g-PLA copolymer decreases with increasing grafting density of PEG. 
Similar finding was obtained before with PLA/PEG copolymer prepared by using 
different initial feed ratios for both PEG and PLA [21]. 1HNMR spectra and chemical 
structure of PEG-g-PLA of different PEG grafting densities are shown in Figure 4.1. A 
typical spectrum for all PEG-g-PLA polymers was obtained with a peak at 5.2 ppm 
corresponding to the tertiary PLA proton (m, -CH), a peak at 3.6 ppm for the protons of 
the repeating units in the PEG chain (m, OCH2-CH2O), and a peak at 1.5 ppm for the 
pendant methyl group of the PLA chain (m, -CH3). The grafting density of PEG over the 
PLA backbone was determined by comparing the integration ratio of resonances due to 
PEG blocks at 3.64 ppm (–O–CH2–CH2–) and to the PLA blocks at 5.17 ppm (Me–CH*     
) in the 1H NMR spectra. The actual grafting density of all synthesized polymers seems 
closer to the initial feed ratio as shown in Table 4.1. Also, it could be seen from Figure 
4.1 that the intensity of PLA peak at 5.2 ppm decreased remarkably upon increasing the 
grafting density and this might indicate the successful grafting of PEG over the PLA 
backbone.  
 
4.5.2. NPs characterization 
           RHO loaded PEG-g-PLA nanoparticles were successfully prepared using an O/W 
emulsion solvent evaporation method by co-dissolving RHO and polymer blend (1:1 
wt/wt PLA: PEG-g-PLA) in DCM and precipitating the polymer into nanoparticles in an 
aqueous phase having 0.5 % PVA as a stabilizer after organic solvent evaporation. Table 
4.2 summarizes the size distribution characteristics of RHO loaded PEG-g-PLA NPs of 
varying PEG densities (1, 7, and 20 mol %). For comparison, RHO loaded PLA was also 
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Figure 4.1. 1H NMR spectra and chemical structure of PEG-g-PLA copolymers of different  
PEG grafting densities over PLA backbone. 
 
included as the control. Particle size distribution by dynamic light scattering (DLS) 
showed unimodal distribution for freshly prepared NPs dispersion (before lyophilization)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X: molar ratio of poly(lactic acid) monomers. 
Y: molar ratio of PEG grafted over PLA 
backbone. 
PEG20%-g-PLA  
PEG7%-g-PLA  
PEG1%-g-PLA  
(a)  
(a)  
(c)  
(b)  
(a)  
(a)  
(b)  
(b)  
(c)  
(c)  
(c)  
(b)  
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Table 4.1. Polymer characterization by 1H NMR and Gel Permeation Chromatography (GPC). 
 
 
 
 
 
 
 
 
 
 
as well as lyophilized NPs. Freshly prepared NPs suspensions were found to be in the 
size range of 160–230 nm. Furthermore, a clear trend of decreasing the particle size was 
observed as their PEG content increased. Similar finding was obtained before with 
diblock copolymer PLA-PEG NPs [22]. The authors related that to the amphiphilic nature 
of PEG-PLA copolymers thus, reducing the interfacial tension between the aqueous and 
organic phases. Lyophilized NPs formulations showed larger particle size in the range of 
300–400 nm compared to freshly prepared particles (Table 4.2). Thus, lyophilization 
process might induce particle aggregation.  The size of the particles after freeze drying 
indicates that either a cryoprotectant or vigorous vortexing is needed to maintain the 
original size of the particles suspension. Vortexing for 5 min. of a suspension of 
lyophilized NPs in Milli.Q water was successfully able to break the aggregate and reduce 
Polymer     Mna  
   (Da) 
Mwa  
(Da) 
Mw/Mna  PEG (mol%)b  Mn (1H NMR)b 
         (Da) 
PLA  40.000 56.000 1.40 N/A N/A 
PEG1%- g-PLA  13.000 17.000 1.30 0.34 % 9.000 
PEG7%- g-PLA  4.000 8400 2.10 4.10 % 8.000 
PEG20%- g-PLA  2200 2300 1.05 17.00 % 4.000 
N/A not analyzed 
a Determined by GPC analysis using narrow molecular weight polystyrene standards. 
a Mw/Mn =PDI of the polymers. 
b Determined from the integration ratio of resonances due to PEG blocks at 3.64 ppm  
(–O–CH2–CH2–) and to the PLA blocks at 5.17 ppm (Me–CH*       ) in the 1H NMR spectra. 
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the size of the particles to almost its original size before lyophilization (Table 4.2). 
Particle size distribution data by DLS were also supplemented with a visual microscopic 
method like tapping mode atomic force microscopy (TM-AFM). Tapping mode atomic 
force microscopy (TM-AFM) is a versatile technique, which allows probing soft samples 
such as biological and polymeric materials [23, 24]. Figure 4.2 displays TM-AFM images 
of RHO-loaded PEG7%-g-PLA nanoparticles before and after lyophilization. The 
nanoparticles suspension before lyophilization has a roughly spherical morphology and 
sizes in the range of 100 and 250 nm, with most particles having a diameter of less than 
200 nm [Figure 4.2 (a)]. While after lyophilization, it could be seen that particles showed 
some aggregating tendency confirming the size data obtained by DLS [Figure 4.2 (b)]. 
AFM phase image analysis was also done to investigate the surface chemistry of the 
obtained particles as used before in our previous studies [13, 14]. PEG7%-g-PLA NPs 
either before or after lyophilization showed the presence of an observable phase contrast 
at the surface of NPs revealed by some dark layers at the surface of bright cores [Fig. 4.2 
(a, b); right panels, P]. These observations confirm the existence of PEG chains at the 
surface of PLA core. PEG-g-PLA NPs showed lower zeta potential values (close to zero) 
in comparison to the values reported before by other authors for PEG-b-PLA NPs [25-27] 
(Table 4.3). The greater reduction in zeta potential values of all PEG-g-PLA NPs of 
different PEG densities could be explained by the existence of a fraction of PVA at the 
surface of NPs (data not shown) which might have also played a role in masking the 
actual surface charge of PLA NPs. No significant difference in the zeta potential values 
of pegylated NPs of different PEG grafting densities was found (Table 4.3). This could 
also be explained by the same reason that the residual PVA chains at the NPs surface 
makes it difficult to estimate the real contribution of PEG coating density to surface 
charge reduction. What confirms this hypothesis that PLA NPs prepared by the same 
procedure also showed lower zeta potential values (-0.098 mV, Table 4.3) than expected 
(-40 mV) [25, 28, 29]. Zambaux et al. also reported a low zeta potential value of -4 mV 
for PLA NPs prepared with PVA as an emulsifier [30]. The zeta potential findings 
confirm that residual PVA remained onto NPs surfaces was able to reduce the actual zeta 
potential values of either PLA or PLA modified NPs (PEG-g-PLA). This could be 
explained by the ability of PVA to be adsorbed efficiently (not removed by successive 
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Table 4.2. Size distribution characteristics for different NPs after different stages of preparation. 
washing steps) onto the NPs surface masking the actual surface charge of PLA (resulted 
from COOH ionization). 
 
 
 
 
 
 
 
 
4.5.3. Encapsulation efficiency (EE) 
           As seen from Table 4.3, % EE of RHO was found to be between 10% and 68% 
wt/wt depending on the polymer type. Grafted pegylated polymers showed better % EE 
than PLA homopolymer. The higher the grafting density, the more the encapsulation 
efficiency.  The last finding could be attributed to the enhanced steric hindrance of the 
more mobile PEG chains existing at the surface of pegylated NPs, thus reducing 
premature diffusion of rhodamine into the external aqueous phase during solidification of 
the NPs. Although higher loading is readily possible since RHO favorably interacts with 
PLA, this was not necessary as the particles were already easily detected by fluorescence 
at the concentration levels tested. In a previous study by Sheng et al. [22], haemoglobin 
NPs formulation 
 
Size  before  
Freeze drying  
(nm) a, b   
  PDI  c  Size after  
Freeze drying 
 (nm)  a, b   
PDI c Size after  
Vortexing  
(nm) a, b   
 PDI c 
PLA  224.0±27 0.139 381.0±30 0.178 270.0 ±20 0.207 
PEG1%-g-PLA 200.6±28 0.002  318.0±20 0.220  250.0 ± 41 0.161 
PEG7%-g-PLA  185.6±21 0.161 388.0±14 0.078 230.0 ± 33 0.221 
PEG20%-g-PLA  169.5±23 0.092 380.9±21 0.320 211.0 ± 23 0.159 
a median. 
b All values indicate mean±S.D. for n=3 independent measurements for the same batch. 
C refers to polydispersity index. 
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Table 4.3. Other physicochemical characteristics for different NPs formulation. 
(HbP) was encapsulated into PLA-PEG block copolymer of different PEG contents. The 
% EE of HbP was found to increase by increasing the PEG content. But further increase 
of PEG content to 20 wt% caused an obvious decrease of % EE. In our case, increasing 
the grafting density to 20 mol% resulted in further increase in the % EE. This could be 
explained by the difference in the polymer architecture between PEG-g-PLA copolymer 
used in our study compared to PEG-b-PLA. PEG-g-PLA NPs exhibited different PEG 
chain organization pattern than their corresponding block copolymer NPs as confirmed 
before by us [13]. PEG chains are easily oriented towards the surface of PEG-g-PLA NPs 
compared to PEG-b-PLA NPs. This leads to effective surface coverage in case of PEG-g-
PLA NPs thus reducing the premature diffusion of drug towards the aqueous phase. 
While in PEG-b-PLA, some PEG chains might be interpenetrated inside the PLA core 
particularly at high PEG content (e.g. 20%), enhancing water uptake by the matrix, and 
hence, facilitating drug diffusion towards the external aqueous phase. 
 
 
 
 
 
 
 
 
 
NPs formulation 
 
     % EE a   % Lr (wt/wt) b  Zeta potential (mV)  
PLA  10.01±1.44 0.024±0.003 -0.098±3.78 
PEG1%-g-PLA  31.11±2.94 0.073±0.007 0.273±3.27 
PEG7%-g-PLA  37.85±0.97 0.090±0.002 0.012±3.72 
PEG20%-g-PLA  67.79±0.92 0.163±0.002 0.003±4.42 
Targeted loading for all batches=0.24% (wt/wt) 
All values indicate mean±S.D. for n=3 independent measurements. 
a  refers to encapsulation efficiency.  
b refers to actual or real loading.  
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Figure 4.2. AFM images of PEG7%-g-PLA NPs encapsulating rhodamine B (RHO), before 
(a) and after (b) lyophilization; surface morphology (left, S) and phase image (right, P). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5.4. In Vitro Drug Release. 
          An in vitro release study was conducted in PBS at 37 °C in order to evaluate if the 
fluorescent marker (RHO) remains associated to the particles for a prudential period of 
time suitable for tracking NPs inside the cells. This could help us decide if RHO loaded 
NPs formulation were an optimal formulation for cellular uptake studies with RAW264.7 
cell lines. RHO release profile over a 15 days period is shown for particles made from 
(a) 
(b) 
(S) (P) 
(P) (S) 
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Figure 4.3. In vitro release behavior of RHO from different PEG-g-PLA NPs in comparison 
to PLA NPs and RHO solution; values are represented as mean ±S.D. of three independent 
experiments. 
different pegylated polymers compared to PLA homopolymer. RHO was released slowly 
from different NPs compared to RHO release from solution (Fig. 4.3). Specifically, 
within 15 h less than 20% of the agent had been released when incubated at 37°C at pH 
7.4.  No significant difference in the release profile of NPs made from different PEG 
grating densities was seen. This might indicate the ability of the high Mwt PLA added 
into each NPs formulation to efficiently trap and control RHO release over a prolonged 
period of time. Importantly, and as will be described in the cellular uptake section, 
controlled release of RHO over a time period of 24 h is more than sufficient for studying 
the interaction and uptake of nanoparticles by cells in vitro.  
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4.5.5. Plasma protein adsorption 
           It is well established that phagocytosis is a cellular phenomenon mainly initiated 
by the attachment of the foreign particles to the surface receptors of the phagocytic cells 
[31]. This phenomenon is facilitated by the adsorption of plasma proteins (opsonins) to 
the particle surface [32, 33]. Therefore, DLS was used to investigate the possibility of 
plasma protein (PP) adsorption onto the NPs surface and whether there is any difference 
between different NPs batches in their ability to adsorb PP. This was simply done by 
monitoring the size distribution changes of NPs after incubation for a period of time with 
plasma proteins solution. DLS was used to determine the fate of RHO loaded PEG-g-
PLA NPs of different PEG grafting densities, first, in the presence of 5 % fetal bovine 
serum (5% FBS), and, second, in the presence of 2 % bovine serum albumin (2% BSA). 
RHO loaded PLA NPs was also included for comparison. DLS analysis was performed 
on solutions of 5% FBS, RHO loaded NPs in distilled water and RHO loaded NPs in the 
presence of 5 % FBS following incubation at 37 °C for 24 h. The same procedure was 
done with 2% BSA. DLS analysis of NPs in the presence of total serum is not possible as 
some blood proteins (i.e. immunoglobulins) form aggregates in aqueous solution. Size 
distribution analysis of 5% FBS solution revealed the presence of two size populations at 
~ 10, and 66 nm (data not shown). Prior to incubation with 5% FBS the average diameter 
of all the investigated NPs was ranging from 200-260 nm (Fig.4.4). After 24 h incubation 
with 5% FBS the average diameter of both PEG7%-g-PLA, and PEG20%-g-PLA NPs 
remained nearly unchanged. While PLA and PEG1%-g-PLA NPs showed clear 
aggregating tendency evidenced by the larger size and the broader polydispersity indices 
obtained after incubation with 5 % FBS for 24 h [Figures 4.4 (a), and 4.S1 (a)]. This 
might indicate that either PEG7%-g-PLA or PEG20%-g-PLA NPs didn’t adsorb 
significant quantities of plasma proteins compared to either PLA or PEG1%-g-PLA NPs.  
Bovine serum albumin (BSA) is the most abundant protein in serum. Many studies have 
shown before that the major protein adsorped onto NPs surface is albumin [25, 34]. DLS 
analysis of NPs incubated with 2% BSA was also done under the same conditions as 
before with 5% FBS. Size distribution analysis of 2% FBS solution revealed the presence 
of two size populations at ~ 2, and 18 nm (data not shown). And as found with 5 % FBS, 
PLA and PEG1%-g-PLA NPs showed remarkable aggregating tendency evidenced by 
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(a) 
Figure 4.4. a): DLS size distribution data (nm) of different NPs upon incubation at 37 °C for 24 
h with 5% FBS. b): DLS size data (nm) of NPs upon incubation at 37 °C for 24 h with 2% BSA. 
 
size distribution change after incubation with 2 % BSA for 24 h [ Figures 4.4 (b), and 
4.S1 (b)]. These observations confirm that either PEG7%-g-PLA or PEG20%-g-PLA NPs 
could withstand the serum environment and that protein adsorption onto their surface 
occurs to a limited extent, if at all [35]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
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4.5.6. Cellular toxicity and uptake studies 
           PLA is a well-known biodegradable and biocompatible polymer. NPs made from 
PEG-g-PLA polymers of different PEG densities were well tolerated and exhibited no 
adverse effects on the cell viability as shown by cell proliferation assays (Fig. 4.5).  
The interaction of RHO encapsulated nanoparticles with macrophage-like cells (RAW 
264.7 cells) was first observed by fluorescence microscopy (Fig. 4.6). Microscopy studies 
showed that a higher fluorescence intensity, corresponding to higher RHO concentration, 
was observed in cells exposed to both RHO loaded PLA, and PEG1%-g-PLA 
nanoparticles [Fig. 4.6 (b, and c, respectively)] compared to cells exposed to either RHO 
loaded PEG7%-g-PLA or PEG20%-g-PLA NPs [Fig. 4.6 (d, and e, respectively)]. This 
finding might indicate that nanoparticles made with PEG-g-PLA showed less 
internalization by macrophage cells than PLA nanoparticles. Moreover, to achieve 
sufficient masking by PEG on the surface of the nanoparticles, PEG grafting density 
higher than 1 % is usually required to obtain lower internalization by macrophage cells.  
To confirm the microscopy study results, estimation of the actual amount of NPs 
internalized after incubating RAW 264.7 cells for 24 h at 37 °C with different 
concentrations of RHO loaded NPs was investigated. Similar findings to microscopy 
results were obtained. Higher uptake was observed for PLA NPs as shown in Figure 4.7. 
This is the result of the higher hydrophobicity of PLA NPs. Increasing the incubated 
concentration resulted in an increase in the actual amount internalized. It is interesting to 
note that PEG-g-PLA NPs of different PEG densities resulted in lower degree of 
internalization compared to PLA NPs in macrophages cell lines. It also could be seen that 
the higher the PEG grafting density, the lower the uptake of NPs by macrophage cells. 
This may be ascribed to surface hydrophilicity and neutral charge of the grafted 
copolymer NPs. These results are in accordance with other authors [36-38] who have 
reported that the higher the hydrophilicity of the surface, the lower the adsorption of 
plasma proteins onto them and hence lower macrophage uptake. However, increasing the 
grafting density from 7% to 20 % didn’t show significant differences in their uptake 
ability indicating that the steric effect of PEG is concentration dependent [39].  
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Figure 4.5. Cytotoxicity of pegylated NPs of different PEG grafting densities over PLA backbone 
 (1, 7, and 20% mol/mol) in RAW 264.7 cells by MTT assay.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.6. Conclusions 
            In the present work, PEG-g-PLA copolymers of different PEG grafting density (1, 
7, or 20% mol/mol of lactic acid monomer) were used to prepare nanoparticles loaded 
with the fluorescent agent RHO. These nanoparticles were designed as models for the 
study of particles uptake by RAW macrophage cells using confocal microscopy and 
fluorimetry analysis. An O/W emusion solvent evapoartion technique was utilized for 
preparation of nanoparticles. Spherical particles with sizes in the range of 150–250 nm 
were prepared with sufficient RHO encapsulation efficiency. Release studies revealed 
that RHO nanoparticles were optimal for cellular interaction studies because the agent is 
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released at a very slow rate. DLS analysis for qualitatively studying the extent of plasma 
proteins adsorption to nanoparticle surface was also described and showed that PEG-g-
PLA NPs might adsorb less amount of PP onto their surface. In vitro cellular studies with 
RHO nanoparticles revealed that PEG7%-g-PLA NPs showed less internalization by 
RAW cells as determined by confocal microscopy and fluorimetry analysis. PEG20%-g-
PLA did not show significant difference in their phagocytosis tendency compared to 
PEG7%-g-PLA.  The obtained results suggest the possibility of use of grafted copolymer 
PEG-g-PLA NPs can be used as long-circulating drug carriers for intravenous 
administration. The optimal PEG grafting density required to achieve that might vary 
from 4-7 %. However, despite the promising ex vivo data, an actual in vivo data is 
needed to explore that indeed PEG-g-PLA NPs could exhibit stealth characteristics. A 
biodistribution study of Itraconazole loaded PEG-g-PLA NPs will be done in the future to 
support our preliminary data. 
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Figure 4.6. Fluorescence images (right panels) and their corresponding phase contrast images (left 
panels) of RAW 264.7 cells after incubation with a) RHO, b) RHO loaded PLA NPs, c) RHO 
loaded PEG1%-g-PLA NPs, d) RHO loaded PEG7%-g-PLA NPs, and d) RHO loaded PEG20%-g-
PLA NPs. red images show RHO. Scale bar=50 µm. 
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 Figure 4.7. RAW 264.7 cellular uptake of RHO encapsulated NPs made from PEG-g-PLA 
copolymer of different PEG grafting densities in comparison to PLA NPs. RAW 264.7 cells were 
incubated with NPs at 37°C for 24 h. 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.7. Appendix A. Supplementary material 
Supplementary data associated with this article can be found, in the online version, at 
doi:10.1016/j.ijpharm.2011.02.039. 
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Figure 4.S1. a): Polydispersity index values of different NPs upon incubation at 37 °C for 24 h 
with 5% FBS. b): Polydispersity index values of NPs upon incubation at 37 °C for 24 h with 2% 
BSA. 
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5.1. Abstract 
         PEG/PLA nanoparticles containing the hydrophobic antifungal itraconazole (ITZ) 
were developed to provide a controlled release pattern of ITZ as well as to improve its 
aqueous dispersability and hence enhance its antifungal action. Two PEG/PLA 
copolymers (PEGylated PLA polymers) were used in this study; branched PEGylated 
polymer in which PEG was grafted on PLA backbone at 7% (mol/mol of lactic acid 
monomer), PEG7%-g-PLA, and multiblock copolymer of PLA and PEG, (PLA-PEG-
PLA)n with nearly similar PEG insertion ratio and similar PEG chain length. ITZ loaded 
PLA NPs were also prepared and included in this study as a control. ITZ-NPs were 
prepared from a 1:1 w/w blend of PLA and each PEGylated polymer either PEG7%-g-
PLA or (PLA-PEG-PLA)n using an oil-in-water emulsion (O/W) evaporation method. 
The nanoparticles morphology, size and size distribution, zeta potential, loading 
efficiency, release profile, and antifungal activity were characterized. All ITZ-NPs were 
nearly spherical with smooth surface and showed less aggregating tendency with a size 
range 185- 285 nm. All ITZ-NPs measured nearly neutral zeta potential values close to 0 
mV. The % LE of ITZ was ~94% for PEG7%-g-PLA NPs and ~83% for (PLA-PEG-
PLA)n at 15.3% w/w theoretical loading. PEG/PLA NPs were stable over time regarding 
size and size distribution, and % ITZ loading efficiency (% LE). ITZ release showed an 
initial burst followed by a gradual release profile for ITZ-NPs over 5 days. (PLA-PEG-
PLA)n NPs exhibited faster release rates than PEG7%-g-PLA NPs particularly at the last 
two days. DSC and PXRD data confirmed that ITZ exists in an amorphous state or a solid 
solution state into the NPs matrix. FT-IR revealed the possibility of chemical interaction 
between ITZ and the NPs matrix polymer indicating the successful entrapment of ITZ 
inside the particles. In Hemolysis test, ITZ-NPs caused mild hemolysis over the 
concentration range (5-20 µg/mL) compared to free itraconazole (ITZ), indicating better 
safety profile of ITZ-NPs. ITZ loaded PEG/PLA NPs inhibited fungal growth more 
efficiently than either free ITZ or ITZ loaded PLA NPs. Our results suggest that 
PEG/PLA-ITZ could be used efficiently as a nanocarrier to improve the aqueous 
dispersability of ITZ, control its release over time and thereby enhance its antifungal 
efficacy. 
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5.2. Keywords 
       Nanoparticles, PEG-PLA, itraconazole, antifungal, poor solubility, hemolysis. 
 
5.3. Introduction 
 
           In recent years, fungal infections have become a serious health issue [1, 2], 
particularly in elderly patients, patients with neoplastic diseases, transplant surgeries, and 
the acquired immune deficiency syndrome (AIDS). Those patients have in common an 
immune system compromised by age, aggressive anticancer and antibacterial 
chemotherapy and long term use of immuno-suppressive agents after oral transplantation 
[3]. Moreover, spreading of clinical and microbiological resistance to current treatment 
and emergence of new pathogens have emerged the need for new effective management 
for those infections.  
           The widespread use of many available antifungal agents (amphoteriein B, 
flucytosine, miconazole, itraconazole, and ketoconazole) has achieved considerable 
success in treating fungal infections despite their potential limitations as poor solubility 
and higher toxicity.  Itraconazole (ITZ) is a triazole antifungal agent widely used 
clinically against a broad spectrum of fungal species such as those commonly caused by 
Candida albicans and Aspergillus species [4, 5]. Moreover, ITZ is highly effective for the 
treatment of both systemic fungal infections and superficial mycoses. Compared with 
other conventional antifungal agent, itraconazole has less nephrotoxicity than 
amphotericin B (AmB) [6, 7]. ITZ shows better activity and less resistance by many 
fungal species in comparison to other azole antifungals, such as fluconazole, 
voriconazole, and ketoconazole [8]. However, ITZ is poorly absorped when given orally 
since ITZ is a hydrophobic weak base with a low aqueous solubility of approximately 1 
ng/ml at pH 7 [9]. An acidic medium, such as the gastric environment of the stomach, 
enhances its solubilization (4 µg/ml at pH 1), which in turn increases its absorption [10]. 
An intravenous formulation for ITZ has been previously developed by complexing the 
drug with hydroxypropyl-β-cyclodextrin (HP-β-CD) in an attempt to enhance ITZ 
aqueous solubility. However, the accumulation of HP-β-CD can potentially lead to 
toxicity limiting the frequency of intravenous doses [11]. This is always a major concern 
for patients with renal complications, since the reduced clearance rate of HP-β-CD could 
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lead to extensive accumulation of HP-β-CD reaching toxic levels [10, 12].  Also, it has 
been reported that HP-β-CD caused pancreatic adenocarcinoma in rat carcinogenicity 
study [13]. There is an urgent need to develop ITZ formulations able to enhance its 
solubility, absorption and hence, improve its bioavailability. To address this concern, 
many formulations of ITZ such as emulsion [11], polymeric micelle [12], nanosuspension 
[14] and albumin bound nanoparticles [10] have been recently developed and studied.  
           Polymeric nanoparticles (NPs) prepared using either PLA (polylactic acid) or 
PLGA (polylactic-co-glycolic acid), have been widely used as a drug delivery tool due to 
their biodegradable and biocompatible nature, and controlled release characteristics [15, 
16]. Encapsulating bioactive moieties into these particles is expected to protect them 
from premature degradation, increase their solubility, and release the drug in a controlled 
fashion as shown before with other azole antifungal drugs [17]. The combined effect of 
these factors can lead to increased bioavailability and enhanced antifungal activity. 
Previous studies have shown improved bioavailability and reduced toxicity of AmB 
loaded PLGA nanoparticles compared to the commercially available form, Fungizone® 
[18]. Similarly, the antifungal activity of voriconazole loaded PLGA NPs was enhanced 
compared to free voriconazole [19]. PEG/PLA NPs has also been used  as a nanocarrier 
for various anticancer and antibacterial agents, achieving sustained and targeted drug 
concentrations at infected areas [20, 21]. PEG/PLA NPs offers an advantage over naked 
PLA particles in which the presence of PEG on the surface of PLA could confer a longer 
circulation of the particles in the blood [22, 23]. Studies have shown enhanced cellular 
uptake of PEG/PLA nanoparticles by various cancer cell lines, improving drug action and 
reducing its accumulation in healthy tissue [24-26].  
           To the best of our knowledge, neither PLA nor PEG/PLA NPs was investigated 
before as a vector for the delivery of an antifungal drug. The purpose of this study was 
first to develop a nanocarrier drug delivery system for the encapsulation of the 
hydrophobic drug, ITZ into either PLA or PEG-modified PLA polymers. Second to test 
the antifungal capability of ITZ loaded NPs in vitro using both Candida and Aspergillus 
species. Two PEG modified PLA polymers (PEGylated polymers) were used in this 
study; branched PEGylated polymer in which PEG was grafted on PLA backbone at 7% 
grafting density (mol/mol of lactic acid monomer), PEG7%-g-PLA, and multiblock 
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copolymer of PLA and PEG, (PLA-PEG-PLA)n with nearly similar PEG insertion ratio 
and similar PEG chain length. The capability of both polymers to act as drug carrier was 
previously investigated by us using ibuprofen as a model drug [27]. 
 
 
5.4. Material and methods:  
 
5.4.1. Materials: 
          D,L-Lactide, poly(ethylene glycol) methyl ether (MePEG; 2000 Da), poly(ethylene 
glycol) (PEG, 1500 Da), allyl glycidyl ether, tetraphenyltin, polyvinyl alcohol (PVA, 
average Mw 9000-10,000 Da, 80% hydrolyzed), borane-tetrahydrofuran complex (1 M), 
acetone, toluene, pyridine, acetonitrile (ACN), chloroform, succinic acid, 1-ethyl-3-[3-
dimethylaminopropyl]-carbodiimide (EDC), 4-dimethylaminopyridine (4-DMAP), 
diethyl ether, N,N-dimethylformamide, Tween® 80, dimethyl sulfoxide (DMSO), and  
thionyl chloride were purchased from Aldrich Chemical Company Inc., Milwaukee, 
USA. Itraconazole was purchased from PI chemicals Ltd., Shanghai, China. Sodium 
hydroxide pellets were purchased from Anachemia Canada Inc. and dichloromethane 
(DCM) was purchased from Laboratoire Mat Inc., Montreal, Quebec, Canada. C. 
albicans and A. fumigates clinical strains were obtained from the Laboratoire de Santé 
Publique du Québec, Canada.  
 
 
5.4.2. Synthesis of Polymers.  
          A detailed description of the synthetic protocols used for polymers synthesis was 
reported earlier by our group [27-29]. Briefly, Poly (D,L)-lactide (PLA) was synthesized 
by ring opening polymerization of D,L-lactide in argon atmosphere, using tetraphenyltin 
as the catalyst. The polymerization step was performed at 180 °C for 6 h in a round-
bottom flask and purged thoroughly with argon. The final polymer was purified by 
dissolving in acetone and precipitating in water.  
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      Polymer with poly(ethylene glycol)-grafted randomly on poly(D,L)-lactide at 7% 
grafting density , PEG7%-g-PLA (PEG; Mwt 2000 Da) was synthesized in the laboratory 
and the detailed procedure can be found in ref. [28]. Multiblock copolymer, (PLA-PEG-
PLA)n was also synthesized as previously reported [30] using PEG with Mn of 1500 and 
succinic acid was used as condensing agent to link triblock copolymers. (PLA-PEG-
PLA)n was synthesized to yield a PEG (1500)/lactic acid monomer ratio of 7% 
(mol/mol).  1H NMR spectra were recorded on a Brucker ARX 400 MHz spectrometer 
(Bruker Biospin, Billerica, MA). Chemical shifts () were measured in parts per million 
(ppm) using tetramethylsilane (TMS) as an internal reference. Gel permeation 
chromatography (GPC) was performed on a Water Associate chromatography system 
(Waters, Milford, MA) equipped with a refractive index detector and a Phenomenex 
Phenogel 5  column. Polystyrene standards were used for calibration with THF as the 
mobile phase at a flow rate of 0.6 mL/min.   
 
5.4.3. Preparation of nanoparticles (NPs) 
           ITZ loaded NPs were prepared by an O/W emulsion-solvent evaporation method. 
NPs were prepared using a 1:1 w/w blend of high Mwt PLA with each pegylated polymer 
either PEG7%-g-PLA or (PLA-PEG-PLA)n to ensure high retaining ability of NPs for 
ITZ. ITZ loaded NPs were prepared using an initial loading of 15.3 % w/w of each 
polymer blend. Briefly, 180 mg ITZ was first dissolved in the organic phase, 10 mL 
DCM followed by dissolution of each polymer blend (1 g) in the same phase. The organic 
phase was then emulsified into 30 mL PVA solution (0.5% w/v) as an external aqueous 
phase using high-pressure homogenizer (Emulsiflex C30, Avestin, Ottawa, Canada) at a 
pressure of 10,000 psi for 5 min. The O/W emulsion was collected by washing with 
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another 30 mL of 0.5% PVA. The DCM was evaporated under reduced pressure with 
constant stirring to obtain the NPs. Finally, NPs obtained as a suspension were then 
collected by centrifugation at 18500 rpm for 30 min. at 4 ºC (Sorval® EvolutionRC, 
Kendro, USA), washed four times with distilled water, then lyophilized without adding 
any cryoprotectant to obtain dry NPs (Freeze Dry System, Lyph.Lock 4.5, Labconco) and 
stored at 4 ºC until further use.  
 
5.4.4. Characterization of NPs 
          Dynamic light scattering (DLS) technique; Malvern Autosizer 4800 instrument 
(Malvern Instruments, Worcestershire, UK) was used for measuring both size and size 
distribution of NPs. Lyophilized NPs (1 mg) were dispersed into 10 mL Milli-Q Water 
and size measurements were recorded at a temperature of 25 ºC and a scattering angle of 
90º. Size distributions data were obtained from the autocorrelation functions using the 
CONTIN program. Measurements were done in triplicate. Malvern ZetaSizer Nanoseries 
ZS (Malvern Instruments, Worcestershire, UK) was used to measure the zeta potential of 
the nanoparticles as follows; Lyophilized NPs were suspended in 0.25% (w/v) saline 
solution (pH 7.4), sonicated for 1 min. and zeta potential was recorded in triplicate. 
Atomic force microscopy technique (AFM) was used to examine the nanoparticle 
morphology. AFM was performed with Nanoscope IIIa, DimensionTM 3100 (Digital 
Instruments, Santa Barbara, CA) in tapping mode. Samples were prepared by suspending 
the nanoparticles in water at a concentration of 10 mg/mL. These samples were deposited 
on freshly cleaved mica surface and were allowed to dry at room temperature. 
Subsequently, they were imaged in air at ambient conditions using etched silicon probes 
with tip radius of 5-10 nm and spring constant in the range of 20-100 N/m, oscillated at 
its fundamental resonant frequency (200-400 KHz). 
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Weight of drug entrapped in NPs 
Initial weight of drug added 
% LE = 
X 100  (1) 
 
% DL = 
Weight of drug entrapped in NPs 
Weight of NPs 
X 100  (2) 
 
5.4.5. Loading efficiency (% LE) 
          A weighed amount of lyophilized NPs was dissolved into acetonitrile (ACN) 
followed by 5 min. vortexing and then stirring for 1 h to ensure complete dissolution of 
the particles. Itraconazole (ITZ) absorbance was measured at a wavelength (λmax) of 265 
nm with a UV/ visible spectrophotometer (U-2001 spectrophotometer, Hitachi). ITZ 
concentration was determined using a standard curve of ITZ in acetonitrile solution 
(ACN). Percent loading efficiency (% LE) and percent drug loading (% DL) were 
calculated based on the following equations: 
 
 
 
 
 
 
 
 
 
 
 
 
5.4.6. Stability studies 
           Physical stability of the developed nanoparticles was monitored by following the 
particle size, polydispersity index, and loading efficiency (% LE) over time. A weighed 
amount of nanoparticles was reconstituted in PBS, pH 7.4 then stored for 30 days at room 
temperature. Size and size distribution was measured by DLS as described above in 
section 2.4. For loading efficiency, the amount of ITZ remaining in solution was 
measured using UV spectroscopy after extracting ITZ into ACN and then ITZ 
concentration was measured as described in section 2.5. 
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5.4.7. Differential scanning calorimetry (DSC) 
          The DSC measurements were performed on a Jade DSC instrument (PerkinElmer, 
USA). Simply, a weighed amount (5 mg) was sealed in crimped aluminum pans and 
heated at a rate of 10°C /min from -20° to 200°C. An empty aluminum pan was used as a 
reference and nitrogen gas was purged at a speed of 20 mL/min.  
 
5.4.8. Powder X-ray diffractometry (PXRD)  
          The powder X-ray diffraction patterns were acquired using a powder X-ray 
diffractometer (D8, Bruker, Germany). X-ray diffraction patterns were carried out for 
ITZ, ITZ-polymer physical mixtures and ITZ loaded nanoparticles (ITZ-NPs). All 
experiments were performed at room temperature. The conditions of the operation were 
as follows: a voltage of 40 kV and a current of 40 mA in the region of 5° ≤ 2θ ≤ 40° in 
step scan mode of 0.02° per second. 
 
5.4.9. Fourier transform infrared spectroscopy (FT-IR) study 
          FT-IR spectra were obtained using FT-IR spectrophotometer (Thermo Scientific 
Nicolet iS10 FT-IR Spectrometer) equipped with attenuated total reflection (ATR) cell. 
About 10 mg of sample was introduced onto the ATR crystal followed by acquisition of 
FT-IR spectra over the scanning range of 600–4000 cm−1. 
 
5.4.10. In vitro drug release study 
            In vitro release of itraconazole from ITZ-NPs was performed in triplicates as 
follows: 5mL of 3.3 mg/mL ITZ-NPs in PBS (10mM, pH 7.4) was sealed in a dialysis 
bag (Spectra Por 1 membrane, 6–8 kDa cut-off). The dialysis bag was immersed in a 
screw-capped tube of 45 mL PBS containing 10% (v/v) Tween® 80. The tubes were 
shaken at 100 rpm on a horizontal water bath shaker (orbit shake bath, Labline) and 
maintained at 37 ± 0.5 °C. At certain time intervals, sample (5 mL each) was withdrawn 
from the medium and same volume of fresh medium was added. ITZ solution at 1.5 
mg/mL in a solvent mixture of water: DMSO (1:3 v/v) was used as a control. The 
absorbance of the drug in the release samples was determined by UV spectrophotometry 
at 263 nm (U-2001 UV/Visible spectrophotometer, Hitachi). The concentration of ITZ 
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(Abs sample) - (Abs basal) 
 
(Abs 100%) - (Abs basal) 
 
%  Hemolysis = X 100  (3) 
 
was determined from a calibration curve of ITZ in PBS containing 10% (v/v) Tween® 
80. 
 
5.4.11. Hemolysis test 
            The lysis of erythrocytes by ITZ NPs was determined by incubating NPs with 
freshly isolated rat RBCs. Blood was collected from Wistar rats in heparinated collection 
vials as per Canadian guidelines for laboratory animals and animal ethical committee of 
University of Montreal. It was centrifuged at 5000 rpm for 10 min, washed with 0.1 M 
phosphate buffered saline (PBS, pH 7.4) three times to obtain RBCs. RBCs were diluted 
to 10 % with PBS [31]. 0.9 mL of NPs samples in PBS were incubated with 0.1 mL of 
RBC suspension at 37°C for 2 h.  After incubation, tubes were centrifuged at 5000 rpm to 
remove non-lysed RBCs. Control experiments to determine basal lysis of RBCs by PBS 
and 100 % lysis by 0.3% Triton X-100 were also carried out. The supernatant was 
collected and analyzed by UV spectrophotometer at 540 nm to estimate the amount of 
hemoglobin released.   Hemolysis was calculated by the following equation: 
 
 
 
 
Where, Abssample, Absbasal and Abs100 % are absorbance values of sample, basal lysis by 
PBS and 100 % lysis by 0.3% Triton X-100, respectively. 
 
5.4.12. Fungal Growth Inhibition Studies 
            The antifungal action of ITZ-NPs was tested on fungal growth as follows: growth 
inhibition on a lawn of conidia in a petri plate of either Candida albicans or Aspergillus 
fumigatus. ITZ-NPs were compared against two drug formulations consisting of ITZ in 
water (ITZ-Water) and an ITZ solution in DMSO (ITZ-DMSO). Stock solutions of ITZ-
Water, ITZ-DMSO, and ITZ-NPs in water were prepared at 1 mg/ml. Solvents and blank 
NPs were used as controls. Actual ITZ concentrations tested against fungal strains were 
20 µg/ml for C.albicans and 17 µg/ml for A. fumigatus. 
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5.4.13. Strains and growth media 
            Candida albicans SC5314 clinical strain was used in this study. Cells were grown 
at 30 ºC in YPD (1% yeast extract, 2% Bacto Peptone and 2% glucose), including 2% 
agar for solid medium. The Aspergillus fumigatus MY070968 clinical strain was grown 
on complete medium (CM) plates (0.1% yeast extract, 0.2% Bacto Peptone, 1% glucose, 
0.15% casamino acids, 0.6% NaNO3, 0.05% KCl, 0.05% MgSO4.7H20, 1% Vitamin 
stock solution, pH 6.8 and 2% agar). 
 
5.4.14. Petri Plate Culture 
5.4.14.1. C.  albicans 
                Cells grown overnight were resuspended in YPD to an optical density at 600 
nm (OD600) of 0.1 and 150 µl of cells were spread on YPD plates. A filter paper disc 
was placed in the center of each plate and 12.5 µl of each of the ITZ solutions was added 
to the disc. The plates were incubated for 2 days at 30 ºC before measuring the diameter 
of the zones of growth inhibition. Digital photos of the cultures were taken after 
treatments were initiated to assess the antifungal activity.  
 
5.4.14.2. A.  fumigatus 
              Cells were thawed from -80 ºC glycerol stock onto CM plates and grown for 3 
days at 30 ºC. Spores were transferred with a toothpick onto equal conc. of ITZ-
containing CM plates and incubated at 30 ºC for 3 days. Digital photos of the cultures 
were taken after treatments as before with C.  albicans.  
 
5.4.15. Statistical analysis 
              Results were expressed as mean ± SD. All data were generated in three 
independent experiments with two or three repeat. The t-test and the one-way analysis of 
variance (ANOVA) were performed to compare two or multiple groups, respectively. 
The difference between treatments was considered to be significant at a level of p<0.05. 
Statistical analysis was performed for sizing, zeta potential, release, and loading 
efficiency, hemolysis and antifungal activity. 
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5.5. Results and discussion: 
        Our previous development of PEG/PLA polymeric NPs either made from PEG-g-
PLA or (PLA-PEG-PLA)n with suitable drug delivery properties e.g. small size, higher 
loading efficiency, and prolonged release features led us to investigate the applicability of 
PEG/PLA as an efficient drug carrier [27]. We hypothesized that the presence of PEG on 
the surface of PLA particles and a small particle size would improve the potential of 
PEG/PLA as carrier for the hydrophobic drug, ITZ. To achieve this, we first synthesized 
PEG-g-PLA, and (PLA-PEG-PLA)n copolymers with nearly similar PEG insertion ratio 
and similar PEG chain length to facilitate the comparison between both PEGylated 
polymers. Then, PEG/PLA nanoparticles loaded with itraconazole (ITZ) were prepared in 
attempt to investigate the ability of such particles to enhance ITZ dispersability in water, 
control its release over time and potentially improve its bioavailability. The extent of 
PEG/PLA particles to enhance the antifungal action of ITZ was tested in vitro using both 
Candida and Aspergillus clinical strains.  
 
5.5.1. Characterization of Polymers.  
          The same polymers used in this study were previously described and characterized 
by us [27]. For a detailed discussion of the characterization results including 1H-NMR 
and GPC data, please refer to both Figure 1 and Table 1 in the last cited article.  
 
5.5.2. NPs characterization. 
          ITZ-NPs were successfully prepared using an O/W emulsion solvent evaporation 
method by co-dissolving ITZ and polymer blend [1:1 w/w of PLA: each PEGylated 
polymer either PEG7%-g-PLA or (PLA-PEG-PLA)n in DCM and precipitating the 
polymer into nanoparticles in an aqueous phase having 0.5 % PVA as a stabilizer after 
organic solvent evaporation. Major physicochemical characteristics of ITZ-NPs e.g. 
loading efficiency (% LE), particle size, PDI and zeta potential are shown in Table 5.1. 
Particle size distribution by dynamic light scattering (DLS) showed unimodal distribution  
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Table 5.1. Characteristics of different NPs formulations after lyophilization process. 
 
 
 
 
 
 
 
 
for lyophilized ITZ-NPs. All ITZ-NPs formulations showed particle size in the range of 
185–285 nm (Table 5.1). ITZ loaded PEG/PLA NPs either made from PEG7%-g-PLA, or 
(PLA-PEG-PLA)n NPs showed smaller size compared to ITZ-PLA NPs as shown in the 
same table.  This could be due to the amphiphilic nature (surfactant effect) of PEG/PLA 
copolymer thus, reducing the size of the emulsion droplet during the emulsification 
process [32, 33]. Particle size distribution data and NPs morphology were also 
investigated using a visual microscopic method like tapping mode atomic force 
microscopy (TM-AFM). Figure 5.1 displays TM-AFM images of ITZ-loaded PEG7%-g-
PLA nanoparticles after lyophilization. Lyophilized NPs were nearly spherical with 
smooth surface and displayed less aggregating tendency with a size range 150- 250 nm 
confirming the size data obtained by DLS. As seen from Table 5.1, % LE of ITZ at an 
initial loading of 15.3% w/w was found to be 82.7 % and 93.6 % for multiblock, (PLA-
PEG-PLA)n and PEG7%-g-PLA NPs, respectively. PEG7%-g-PLA showed better % LE 
than multiblock copolymers. The possible reason behind that is PEG chain organization 
Formulation Mean diameter 
     (nm) 
PDI a % DL 
(% w/w) c 
% LE b Zeta-potential                    
(mV) 
PLA 
 
284 ± 4 0.18 9.4 ± 0.3 61.7 ± 1.7     0.11 ± 4 
PEG7%-g-PLA 
 
197 ± 6 0.08 14.3 ± 0.3 93.6 ± 1.8     0.02 ± 3 
(PLA-PEG-PLA)n 185 ± 4 0.05 12.6 ± 0.4 82.7 ± 2.7     0.03 ± 4 
a  refers to polydispersity index. 
b refers to loading efficiency. 
c refers to drug loading. 
All values indicate mean±S.D. for n=3 independent measurements for the same particle  
preparation. 
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Figure 5.1.  AFM image of lyophilized ITZ loaded PEG7%-g-PLA NPs 
in case of branched polymer; PEG7%-g-PLA allows more mobile PEG chains at NPs 
surface. The PEG chains at the surface might exhibit enhanced steric hindrance, thus 
reducing premature diffusion of drug into the external aqueous phase during 
solidification of the NPs. Similar results were obtained before with us for ibuprofen 
loaded PEG/PLA NPs [27]. The zeta potential values of all ITZ-NPs were almost neutral 
(close to zero value) as shown in Table 5.1. The greater reduction in zeta potential values 
of all ITZ-NPs irrespective of the type of polymer used, could be explained by the 
existence of a fraction of PVA at the surface of NPs (data not shown) which might have a 
significant role in masking the actual surface charge of PLA NPs. Zambaux et al. also 
reported a low zeta potential value of -4 mV for PLA NPs prepared with PVA as an 
emulsifier [34]. PEG chains as well could shield the actual surface charge of PLA in case 
of PEG/PLA nanoparticles as previously shown [22, 35]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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5.5.3. Stability studies 
          One of the major goals of this study was to develop NPs formulations able to 
efficiently entrap ITZ for sufficient period of time and hence keep it dispersed in aqueous 
phase taking advantage of their nanosize. To check for NPs ability to perform that, 
physical stability of the prepared particles was monitored over time by following the 
changes of particle size, PDI, and % loading efficiency (% LE) during storage for one 
month after reconstituting ITZ-NPs in PBS. All ITZ-NPs seems stable to some extent in 
terms of particle size and PDI for 30 days. PLA NPs showed larger particle size and PDI 
after 30 days of storage (Fig. 5.2a, b); that is, particle size and PDI increased from 248 
nm, 0.181 up to 275 nm, and 0.345, respectively.  PEG/PLA NPs either made from 
PEG7%-g-PLA or (PLA-PEG-PLA)n looks more stable in terms of particles size and PDI 
for 30 days at room temperature than PLA particles (Fig.5.2a, b). % LE of all ITZ-NPs 
was decreased to some extent during storage (Fig. 5.2c). This might be due to ITZ 
diffusion from NPs over time followed by its precipitation in water. PEG/PLA NPs either 
made from PEG7%-g-PLA or (PLA-PEG-PLA)n showed an observable decrease in terms 
of % LE after 30 days of storage; that is, % LE decreased from 93 % to 82 %  and from 
82 % to 71 % for PEG7%-g-PLA, and (PLA-PEG-PLA)n, respectively (Fig. 5.2c). PLA 
NPs showed better stability profile after 30 days in terms of % LE; that is, % LE 
decreased from 61 % to 54 % compared to PEG/PLA NPs (Fig. 5.2c). The last finding 
could be attributed to the presence of PEG chains within PLA matrix which might 
enhance more water uptake into the particles, and hence more ITZ diffusion over time. 
However, irrespective of that decrease in % LE, the remaining ITZ in NPs seems enough 
to achieve a therapeutic effect considering dose adjustment. These results suggest that 
ITZ remains entrapped inside the PEG/PLA particles for a sufficient period of time 
without changing the particle size, PDI and slight change in % LE. 
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5.2a 
5.2b 
To be continued in the next 
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5.2c 
Figure 5.2. The stability index of ITZ-NPs in the particle size shown as diameter [D] (a), 
polydispersity index [PDI] (b), and loading efficiency [% LE] (c) during storage for 30 days [d] at 
room temperature. Data are expressed as the mean±S.D. (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5.4. Differential scanning calorimetry (DSC) 
          DSC was used to investigate the physical state of the encapsulated ITZ into ITZ-
NPs. As shown in Fig. 5.3a, a sharp endothermic peak characteristic of the melting of  
ITZ was seen at 167 °C. In the thermogram of lyophilized ITZ loaded (PLA-PEG-PLA)n 
NPs, the endothermic peak of ITZ completely disappeared. This indicates that ITZ exists 
in a non crystalline state inside NPs. The physical mixture of itraconazole and (PLA-
PEG-PLA)n copolymer showed both endothermic characters of both the bulk drug and 
the polymer. In case of ITZ loaded PEG7%-g-PLA NPs (Fig. 5.3b), the endothermic peak 
of ITZ was still observed but with significantly reduced intensity compared to the same 
weight of either pure ITZ or ITZ/PEG7%-g-PLA physical mixture. This indicated also 
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Figure 5.3a. DSC curves of ITZ, physical mixture of (PLA-PEG-PLA)n with ITZ, (PLA-PEG-PLA)n 
copolymer, and ITZ loaded (PLA-PEG-PLA)n NPs.  
 
   
 
     ITZ  
 
    
 
     (PLA-PEG-PLA)n + ITZ physical mix. 
 
    
 
    (PLA-PEG-PLA)n copolymer. 
 
                            ITZ loaded (PLA-PEG-PLA)n NPs. 
    
that PEG7%-g-PLA NPs were able to significantly reduce ITZ crystallinity compared to 
pure ITZ drug.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5.5. Powder X-ray diffractometry (PXRD) 
           For more verification of the final state of ITZ encapsulated into NPs, powder X-
ray diffractometry (PXRD) was used to investigate the crystalline structure of ITZ in 
ITZ-NPs compared to bulk ITZ as previously used by other authors [36-38]. It can be 
seen from (Figs. 5.4a, and 5.4b) that ITZ powder showed characteristic diffraction peaks 
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Figure 5.3b. DSC curves of ITZ, physical mixture of PEG7%-g-PLA with ITZ, PEG7%-g-PLA 
copolymer, and ITZ loaded PEG7%-g-PLA NPs.  
 
    
 
     ITZ  
 
    
 
     PEG7%-g-PLA + ITZ physical mix. 
 
                              PEG7%-g-PLA polymer. 
 
                              ITZ loaded PEG7%-g-PLA NPs. 
    
 
of crystalline ITZ  at 2θ scattered angles 14.5°, 17.6°, 20.4°, 23.5° and 25.4° as 
previously described [10]. The existence of sharp diffraction peaks indicates the 
crystalline nature of ITZ. While there were no diffraction peaks of ITZ in ITZ-NPs of 
either (PLA-PEG-PLA)n or PEG7%-g-PLA NPs (Figs. 5.4a and 5.4b, respectively), 
indicating that ITZ was at an amorphous state in the ITZ-NPs. Combined with DSC 
observations as shown in (Figs. 5.3a, and 5.3b), we can deduce that ITZ was dissolved 
into the NPs matrix in the form of solid solution. 
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Figure 5.4a. XRD spectra of ITZ, physical mixture of (PLA-PEG-PLA)n with ITZ, 
(PLA-PEG-PLA)n copolymer, and ITZ loaded (PLA-PEG-PLA)n NPs.  
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     (PLA-PEG-PLA)n + ITZ physical mix. 
 
    
 
     (PLA-PEG-PLA)n copolymer. 
 
                            ITZ loaded (PLA-PEG-PLA)n NPs. 
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Figure 5.4b. XRD spectra of ITZ, physical mixture of PEG7%-g-PLA with ITZ, PEG7%-g-PLA 
copolymer, and ITZ loaded PEG7%-g-PLA NPs. 
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     PEG7%-g-PLA+ ITZ physical mix. 
 
   
 
         ITZ loaded PEG7%-g-PLA NPs. 
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5.5.6. Fourier transform infrared spectroscopy (FT-IR) study  
           FT-IR analysis was done to investigate any possibility of chemical interactions 
between ITZ and each polymeric matrix. Specific FT-IR characteristic peaks of ITZ 
powder were seen at 800–3400 cm−1 as shown in (Figs. 5.5a and 5.5b). The characteristic 
peaks of itraconazole at 1700, 1520 and 1380cm−1 were still noticed in the physical 
mixture of each polymer and itraconazole. For ITZ-NPs of either (PLA-PEG-PLA)n or 
PEG7%-g-PLA NPs, ITZ characteristic FT-IR peaks were significantly reduced in 
intensity or could not be seen in the obtained spectra (Figs. 5.5a and 5.5b, respectively). 
Similar findings were observed before with ITZ loaded albumin NPs [10]. This suggested 
that there were some interactions between ITZ and either polymer in the ITZ-NPs giving 
another evidence supporting the successful encapsulation of ITZ inside PEG/PLA NPs. 
 
5.5.7. In Vitro Drug Release. 
          The in vitro drug release features of ITZ-NPs were evaluated by the dialysis bag 
method as shown in Fig. 5.6. Tween® 80 was added to the external release medium to 
maintain sink conditions for ITZ because it has limited solubility in PBS [39]. A biphasic 
release profile was observed for all investigated ITZ-NPs. A rapid initial ITZ release of 
about 20–45% of the drug content was observed after 10 h of the release experiment. This 
finding might be due to the desorption of the drug particles adsorbed at or close to the 
surface of NPs [40]. After the initial burst, sustained release of ITZ was seen in the 
following 100 h. Both processes of drug diffusion and NPs matrix erosion govern ITZ 
release from ITZ-NPs during the second sustained phase [41, 42]. In case of ITZ solution, 
ITZ was completely released after 18h (Fig. 5.6). This could be due to the rapid diffusion 
of ITZ out of the dialysis bag. While for ITZ-NPs, slow ITZ release was observed for all 
batches. Both PEG7%-g-PLA and (PLE-PEG-PLA)n NPs exhibited faster ITZ release 
compared to PLA NPs. This could be due to the role of PEG chains that favor more water 
uptake followed by rapid core wetting and hence faster ITZ diffusion or release from the 
NPs matrix. After 4.5 days, PEG7%-g-PLA, and (PLA-PEG-PLA)n released ~ 93% and 
100% of their ITZ contents, respectively. ITZ release pattern was nearly similar for both 
PEG/PLA systems for the first 50 h. During the next 50h of the release experiment, 
(PLA-PEG-PLA)n NPs showed faster release pattern compared to PEG7%-g-PLA NPs.  
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Figure 5.5a. FT-IR spectra of ITZ, physical mixture of (PLA-PEG-PLA)n with ITZ, (PLA-PEG-
PLA)n copolymer, and ITZ loaded (PLA-PEG-PLA)n NPs [ITZ main characteristic peaks are 
marked with arrows].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The possible reason behind that is the peculiar polymer architecture of the multiblock 
copolymer, (PLA-PEG-PLA)n  allows a major portion of PEG to be entrapped inside the 
core during NP formation as shown previously [27, 43]. This might lead to rapid wetting 
of the NPs core compared to PEG7%-g-PLA NPs, in which most PEG chains are located 
at NPs surface. Overall, the results show that ITZ is released from the ITZ-NPs at a 
Itraconazol
e  
(PLA-PEG-PLA)n 
copolymer 
ITZ+ (PLA-PEG-PLA)n  
Physical mix. 
ITZ/(PLA-PEG-PLA)n  loaded 
NPs. 
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Figure 5.5b. FT-IR spectra of ITZ, physical mixture of PEG7%-g-PLA with ITZ, PEG7%-g-PLA 
copolymer, and ITZ loaded PEG7%-g-PLA NPs [ITZ main characteristic peaks are marked with arrows]. 
 
 
slower rate than from its solution and that the release patterns could be controlled by 
modulating the polymer architecture.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Itraconazol
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Figure 5.6. In vitro release behavior of ITZ from PEG/PLA NPs either from PEG7%-g-PLA or 
 (PLA-PEG-PLA)n in comparison to PLA NPs and ITZ solution; values are represented as mean 
 ± S.D. of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5.8. Hemolysis analysis: 
          To ensure blood safety profile or hemocompatibility of the developed formulations, 
ITZ-NPs effect on RBCs hemolysis was investigated after incubating particles with rat 
blood. As shown in Fig. 5.7, all ITZ-NPs either PLA, PEG7%-g-PLA, or (PLA-PEG-
PLA)n NPs exhibited less hemolytic potential below 40% over the concentrations range 
of ITZ (5-20 µg/mL). For example, the hemolysis tendency values of ITZ-PLA, PEG7%-
g-PLA, (PLA-PEG-PLA)n NPs  at ITZ conc. of 20 µg/mL were 37.5, 33.7, and 33.5%, 
respectively. On the other hand, ITZ solution caused much more serious hemolysis. At 
the highest investigated concentration of ITZ, 20 µg/mL, the hemolysis tendency was 
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Figure 5.7. Erythrocyte lysis caused by ITZ loaded PEG/PLA NPs preparations compared 
to free ITZ and ITZ-PLA NPs. Values are expressed as mean of % lysis of three separate 
experiments ±S.D  
95%. The results indicated that ITZ-NPs did not exhibit any marked effect on RBCs 
hemolysis or in another way it could be concluded that ITZ-NPs were more 
hemocompatible than free ITZ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5.9. Fungal growth inhibition in Petri Plate Culture  
          Five treatments [ITZ-Water, ITZ-DMSO, ITZ/PLA NPs, ITZ/PEG7%-g-PLA NPs, 
and ITZ/(PLA-PEG-PLA)n NPs] were tested on two clinical strains of either Candida 
albicans or Aspergillus fumigatus (Figs. 5.8a and 5.8b, respectively). For Candida 
results, ITZ-DMSO solution showed the highest fungal inhibitory potency evidenced by 
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the largest diameter of the inhibitory zone surrounding ITZ-DMSO application (Figure 
5.8a and Table 5.2). This might be explained by the complete solubility of ITZ in DMSO 
giving a better chance for ITZ to penetrate into the fungal cell membranes. Control 
experiment with DMSO alone did not show any observable antifungal activity. ITZ-
Water did not exhibit any marked antifungal action over the incubation period of time (2 
days). This could be due to the limited solubility of ITZ in water and hence limited 
diffusion into the agar medium. The poor solubility of ITZ could also affect its 
penetration potential  into the fungal cell membrane.  It is reported that itraconazole is an 
ergosterol synthesis inhibitor that exert its action by inhibiting the fungal CYP450 
dependant enzyme, lanosterol 14-α-methylase in the fungal cell membrane [44, 45]. For 
ITZ, to exhibit its antifungal action, it must show a sufficient penetration level into the 
fungal cell membrane which could not be achieved by ITZ-Water formulation. All ITZ-
NPs showed greater inhibition compared to ITZ-Water. This could be explained by the 
ability of NPs to enhance the aqueous solubility of ITZ, improve its bioavailability and 
hence its penetration ability into the fungal cells membrane. Moreover, it is important to 
take into consideration that nanoparticles mobility in solid media as agar is expected to be 
limited or hindered; hence inhibition of the fungal growth will be an indirect estimate for 
the ability of the particles to release ITZ into the medium in a finally dissolved form that 
is able to penetrate the fungal membrane. PEG/PLA NPs of either PEG7%-g-PLA and 
(PLA-PEG-PLA)n showed enhanced antifungal capability in comparison to ITZ-PLA 
NPs. This might be due to the faster release of ITZ from PEG/PLA NPs as seen before in 
the release section (Fig. 5.6). Over two days, ITZ was released from PEG7%-g-PLA and 
(PLA-PEG-PLA)n NPs at 58.5 % and 60 %, respectively compared to PLA NPs  where 
only 45 % of ITZ was released. Similar results were obtained with the A. fumgiatus 
strains (Fig. 5.8b), where PEG/PLA NPs exhibited greater antifungal action compared to 
either ITZ-Water or ITZ-PLA NPs. This indicated an enhanced antifungal capability of 
ITZ loaded PEG/PLA NPs in comparison to other formulations. 
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Figure 5.8a. Plates inoculated with C. albicans fungal cells and incubated at 30 ºC, treated with 12.5 µl of 
(a) ITZ-Water, (b) ITZ-DMSO, (c) ITZ-PLA NPs, (d) ITZ-PEG7%-g-PLA NPs, and (e) ITZ-(PLA-PEG-
PLA)n NPs. Lower plates (a-e) represent control experiments corresponding to each upper plate either 
using only the solvent in case of ITZ-Water, and ITZ-DMSO or only blank NPs ( no ITZ) in case of NPs 
formulations. 
Table 5.2. Diameter of growth inhibition zone measured with c. albicans fungal strains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation            Test plate (cm) 
 
  Control plate (cm) 
 
ITZ-Water 0 0 
 
ITZ-DMSO 
 
1.9 
 
0 
 
PLA NPs 
 
 
0.7 
 
0 
PEG7%-g-PLA NPs 
 
1.1 0 
(PLA-PEG-PLA)n NPs 1 0 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
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Figure 5.8b. Plates inoculated with A. fumigatus fungal cells and incubated at 30 ºC, treated with (a) 
ITZ-Water, (b) ITZ-DMSO, (c) ITZ-PLA NPs, (d) ITZ-PEG7%-g-PLA NPs, and (e) ITZ-(PLA-PEG-
PLA)n NPs. Lower plates (a-e) represent control experiments corresponding to each upper plate either 
using only the solvent in case of ITZ-Water, and ITZ-DMSO or only blank NPs ( no ITZ) in case of NPs 
formulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.6. Conclusions 
            In the present work, ITZ loaded PEG/PLA NPs were prepared from two 
PEGylated polymers, PEG7%-g-PLA, and multiblock copolymer of PLA and PEG, 
(PLA-PEG-PLA)n with nearly similar PEG insertion ratio and similar PEG chain length. 
These nanoparticles were formulated in order to enhance the aqueous dispersability or 
solubility of ITZ, control its release and hence improve its antifungal effect. Spherical 
particles with sizes in the range of 185–285 nm were prepared with high loading 
efficiency. In vitro release studies showed that ITZ was released from NPs in a controlled 
fashion. Hemolysis analysis revealed that all ITZ-NPs were more biocompatible than the 
free ITZ itself.  ITZ loaded PEG/PLA NPs demonstrated an enhanced antifungal action in 
comparison to ITZ-Water. The obtained results suggest the possibility of use of 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
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PEG/PLA NPs as an efficient carrier for the delivery of ITZ. This may result in reduced 
frequency of ITZ administration, reduced accumulation inside the body and hence better 
clinical outcome. However, despite the promising ex vivo data, an actual in vivo data is 
needed to explore that indeed ITZ loaded PEG/PLA NPs could exhibit an improved 
antifungal effect than ITZ itself.  
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        Nanoparticles are a particular class of submicron colloidal carriers with special 
characteristics such as their unique combination of high drug loading and the possibility 
of high stability and controlled release. This study was constituted mainly with the 
following objectives in mind; firstly, to develop polymeric nanoparticles (NPs) based on 
functionalized PLA polymers. Secondly, to understand in depth the influence of 
copolymer chemical structure and copolymer architecture on the physicochemical 
properties of the obtained particles. Polymer architecture was early defined as the 
arrangement of a single polymer molecule, which has a role in determining the 
physicochemical parameters of the whole polymer [1]. Thirdly, to develop nanoparticle 
formulations with optimal drug delivery characteristics like small size, neutral surface 
charge, sufficient drug loading, and controlled release profile. The developed particles 
were investigated as a carrier for an antifungal drug, itraconazole (ITZ). In this study we 
are also trying to understand the effect of polymer architecture on drug loading and 
release pattern from NPs matrix.  
 
        Conventional polymers such as PLA, PGA and their copolymers (PLGA) have been 
widely investigated for nanoparticle preparation [2-5]. NPs made from those polymers 
might suffer many drawbacks as their rapid uptake by the reticuloendothelial system after 
intravascular administration, low drug loading efficiency particularly for hydrophilic 
drugs, and in many cases inability to release their payload completely [6-8]. Moreover, 
the physicochemical properties of the developed particles are not easy to be tuned as 
required for each application. Hence, functionalization of polymer blocks has been 
attempted to develop copolymers with enhanced drug delivery properties, mainly high 
drug loading and controlled release behavior. Functionalized poly(D,L-lactide) (PLA) 
nanoparticles development mainly depend on  introducing a flexible moiety onto PLA 
hydrophobic cores in attempt to improve the drug delivery properties of the obtained 
NPs. A variety of pendant substituents could be grafted onto PLA to generate polymers 
of different physicochemical properties and hence different drug incorporation behavior 
than PLA itself. PLA homopolymer structure was modified by attaching different 
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functional groups to the polymer backbone and the influence of such modification or 
functionalization on the nanoparticles properties was investigated. 
 
6.1.  Synthesis and characterization of functionalized poly(D,L)- lactide (PLA) 
polymers 
        Novel functionalized poly(D,L)- lactide (PLA) copolymers were successfully 
developed using a synthetic protocol, previously published by our group [9]. This 
protocol was developed to synthesize branched polyesters having reactive groups. Allyl 
glycidyl ether (AGE) was added to dilactide to obtain a PLA backbone with pendant allyl 
functions (PLA-allyl). The major advantage of using allyl molecule is its ability to be 
easily attached to the PLA backbone after ring opening polymerization of dilactide. PLA-
allyl itself is an intermediate used to obtain various chemical functions because the allyl 
function can be easily modified. For example, by hydroboration, a primary alcohol is 
obtained and by oxidation of alcohol with Jones mixture, the corresponding acid could be 
also obtained. 
 
        We have used this synthetic protocol to synthesize functionalized PLA copolymers 
that have some potential as drug delivery systems. Various functionalized PLA 
copolymers were successfully synthesized with different grafting moieties (palmitate 
versus PEG), different PEG grafting densities (2.5%, 7%, or 20% mol/mol of lactic acid), 
or different architectures (block versus grafted copolymer). Most of the developed 
polymers were solid enough at room temperature, showing their potential to self 
assemble into solid nanoparticles as confirmed later by DLS and AFM tools. The 
synthesized copolymers present the basic nucleus for designing a comparative physico-
chemical study of nanoparticles developed from those copolymers. A detailed 
investigation of the developed particles was done to get a deeper understanding of the 
effect of PLA functionalization on drug delivery behavior from PLA particles. 
Furthermore the chain organization behavior of nanoparticles developed from 
functionalized PLA copolymers was also investigated using phase imaging AFM, 
1HNMR and XPS.  
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       Following this protocol, palmitic acid was grafted onto PLA backbone at 2.5 mol % 
of lactic acid monomer, referred as palmitic acid 2.5%-g-PLA. Also, methoxy PEG was 
grafted onto PLA backbone at different densities; 2.5, 7, and 20 mole % of lactic acid 
monomer, referred as PEG2.5%-g-PLA, PEG7%-g-PLA, and PEG20%-g-PLA, 
respectively [9]. Multiblock copolymer, (PLA-PEG-PLA)n was also synthesized as 
previously reported by our group [10] using PEG with Mn of 1500 and succinic acid was 
used as condensing agent to link the already synthesized triblock copolymers.  
             
          Gel permeation chromatography (GPC) was used to characterize the synthesized 
polymers (Tables 2.1, 3.1, and 4.1). Synthesized polymers exhibited uniform molecular 
weight distribution as revealed by the narrow polydispersity index values from GPC data. 
1H NMR spectra and chemical structures of synthesized copolymers are shown in Figs. 
2.1, 3.1, and 4.1. Typical spectra were obtained for the synthesized copolymers with the 
characteristic peaks corresponding to the major protons constituting each polymer, were 
observed. A detailed description of the 1H NMR spectra with identification of the major 
characteristic peaks can be found in chapters 2, 3, and 4. 
 
          Thermal properties of functionalized PLA copolymers and, namely, their glass 
transition temperatures (Tg’s) were investigated using differential scanning calorimetry, 
DSC (Tables 2.1, 3.1). As seen from DSC data, the molecular structure of each polymer 
affects significantly the glass transition (Tg) of PLA. For example, grafting PEG chains 
onto the PLA backbone resulted in an increased Tg value compared to PLA homopolymer 
due to enhanced chain rigidity (Tables 2.1, 3.1). Another possible factor affecting Tg, is 
the nature of pendant functional group. Tg of palmitic acid2.5%-g-PLA was shifted to a 
lower value (19 ºC) compared to either PLA homopolymer (46.4 ºC) or PEG2.5%-g-PLA 
(50ºC) [Table 2.1]. The significant lowering of Tg indicates that the nature of the pendant 
group onto PLA backbone affects remarkably the PLA backbone rigidity. Fatty acid 
esters were found to have a remarkable plasticizing action on PLA chains [11]. 
 
         Another important factor affecting Tg of functionalized PEG/PLA copolymers, is 
the PEG chain organization behavior (i.e. the way PEG and PLA chains are connecting 
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together). The organization mode of PEG chains onto PLA chains results into either 
separation or mixing between both phases in the obtained copolymer. Thus, copolymer 
thermal properties, mainly the glass transition (Tg), could be affected. Phase mixing 
between PEG and PLA chains would augment the entrapment of PEG chains into PLA 
chains. This might enhance the mobility of PLA chains or what is called plasticization 
effect, resulting in a lower Tg, as reported earlier [12, 13]. During the phase separation, 
PEG chains branched over PLA backbone might enhance the chain rigidity of PLA 
resulting in higher Tg value. The physicochemical properties of the nanoparticles are 
affected by the phase organization behavior of the polymer chains. Multiblock 
copolymer, (PLA-PEG-PLA)n showed lower Tg value at 39 °C, compared to grafted 
PEG-g-PLA copolymers, 53 °C (Table 3.1). Thus, the effect of branching (phase 
separation) was predominant for PEG-g-PLA copolymer, whereas the effect of PEG 
chains entrapment (phase mixing) inside PLA domains might lead to a predominant 
plasticizing effect in case of (PLA-PEG-PLA)n coplymer.  
       
       It can be concluded from DSC data that molecular structure, polymer architecture, 
nature of the pendant functional group and, PEG/PLA chain organization behavior 
affected remarkably the thermal characteristics of functionalized PLA copolymers.  
 
 
6.2.  Preparation and physicochemical characterization of NPs 
        NPs were successfully prepared from functionalized PLA copolymers using an O/W 
emulsion solvent evaporation method by co-dissolving the polymer (with or without the 
drug) in DCM followed by precipitating the polymer droplets into nanoparticles in an 
aqueous phase having 0.5 % PVA as a stabilizer after organic solvent evaporation. High 
pressure homogenization technique was used efficiently to control the size of the 
emulsion droplet that will be solidified later into nanoparticles. The first task was the 
assessment of the major physicochemical properties of the obtained particles e.g. size, 
zeta-potential, drug-polymer interactions, and drug loading. Monodispersed and nearly 
spherical particles with smooth surfaces were obtained by this technique (Figs. 2.2, 3.2, 
4.2, and 5.1). NPs formulations showed particle size in the range of 150–300 nm (Tables 
2.2, 3.2, 4.2, and 5.1). Blank NPs formulations (no drug) showed nearly similar particle 
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size to that of loaded ones for all NPs types (Tables 2.2, 3.2). Thus, drug loading level 
had no apparent effect on particle size, suggesting that the size was largely controlled by 
controlling the homogenization parameters (mainly pressure and time of 
homogenization). The architecture of PEG/PLA copolymers (i.e. arrangement of building 
blocks) affected the size of the obtained particles (Table 3.2). In PEG-g-PLA NPs, PEG 
chains are expected to be more mobile creating a steric barrier around PLA core 
preventing particle aggregation. In case of (PLA-PEG-PLA)n NPs, the polymer 
architecture allows some PEG chains to be embedded inside PLA core leaving some 
uncovered areas at the surface that might showed some aggregating tendency due to PLA 
hydrophobic interactions.  
         The zeta potential was calculated to assess whether the presence of PEG in 
PEG/PLA NPs affects the particle surface charge or not. The zeta potential values of all 
NPs were almost neutral (close to zero value) as shown in Tables 2.2, 3.2, 4.3, and 5.1. 
The greater reduction in zeta potential values of all NPs irrespective of the type of 
polymer used, could be explained by the existence of a fraction of PVA at the surface of 
NPs (Table 2.2, 3.2) which might have a significant role in masking the actual surface 
charge of PLA NPs. This is a major drawback of using PVA as an emulsifier that it is 
easily adsorbed onto the NPs surface, hence affecting both physicochemical and 
biological behavior of NPs.  
        
         Phase image analysis using TM-AFM was done on NP samples to detect PEG 
chains at the surface of pegylated NPs. In case of PEG-g-PLA, highly intense dark coat 
surrounds the surface of brighter core could be seen indicating the existence of 
hydrophilic PEG chains around hydrophobic PLA chains that represent the core [Fig. 
3.2(b); right panel, P].  In the case of (PLA-PEG-PLA)n multiblock copolymer NPs, 
fewer dark regions are found at the surface of NPs compared to PEG-g-PLA NPs [Fig. 
3.2(c); right panel, P]. The main differences in the AFM phase imaging could be 
explained by the peculiar architecture of each polymer. In case of (PLA-PEG-PLA)n 
multiblock copolymer, PEG chains are covalently linked with two PLA chains. This 
might affect the mobility of PEG chains towards the aqueous phase of the O/W emulsion 
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during NPs formation. PEG chains could find difficulty migrating towards the surface of 
NPs in contrast to PEG-g-PLA NPs.  
       
       PEG-g-PLA NPs showed better encapsulation efficiency (% EE) than multiblock 
copolymers either for ibuprofen (Table 3.2) or itraconazole (Table 5.1). The last finding 
could be attributed to the enhanced steric hindrance of the more mobile PEG chains at 
NPs surface in case of grafted copolymers, thus reducing premature diffusion of drug into 
the external aqueous phase during solidification of the NPs. DSC was used for detecting 
the final state of the encapsulated drug inside the NPs matrix as well as investigating any 
possible interaction between the drug and the polymeric matrix.  
                                
      Thermal analysis of NPs showed that drug molecules might be molecularly dispersed 
(solid solution) into the polymer matrix as found with itraconazole, ITZ (Figs. 5.3, 5.4) or 
in other cases, drug crystals are dispersed in the polymer matrix (solid dispersion) as 
shown with ibuprofen (Figs 2.3, 3.3). The final state of the drug inside nanoparticles 
detected by the interaction between the drug and the polymer using DSC and PXRD 
analysis.  
          
           (PLA-PEG-PLA)n NPs showed faster degradation rate ~ 44% compared to 
PEG7%-g-PLA (30%) after 25 days emphasizing the rapid core (PLA) wetting in the 
multiblock copolymer NPs (Fig. 3.5). This might be due to entrapment of most of PEG 
chains into the NPs core while in case of grafted PEG-g-PLA polymer, most of PEG was 
found to be at the surface of NPs.  
 
        The last findings confirm the following assumptions. First, high pressure 
homogenization technique is an efficient one for obtaining small sized particles, suitable 
for drug delivery applications, irrespective of the type of polymer used initially to prepare 
the particles. Second, PVA remains attached to the NPs surface, whatever the number of 
washing steps done to remove it. This affects the real contribution of PEG chains in 
masking the surface charge of PLA particles. Third, PEG chain organization behavior had 
a major impact on the size of the particles, drug loading efficiency, and surface 
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characteristics of the obtained particles. Fourth, drug could be encapsulated onto NPs 
either in the form of crystalline or molecular dispersion depending mainly on the forces 
of interactions involved between drug and polymer. Those findings also suggest that the 
physicochemical properties of PLA- based NPs can be tuned by judicious selection of 
both polymer composition and polymer architecture. 
6.3. 1H-NMR and XPS analysis of NPs  
       XPS was used to gain information on the surface chemistry of nano-scaled carriers 
developed from functionalized PLA copolymers. Another benefit of XPS is to provide a 
method for differentiating the existence of PVA, PEG, and drug (ibuprofen) at the NPs 
surface. A comparison was made between PEG-g-PLA, and (PLA-PEG-PLA)n NPs of 
similar PEG insertion ratio. The results are listed in Table 3.4. An increase in C–C–O 
peak area at 286.5 eV representing the PEG chains and a decrease in C–C peak area at 
285 eV representing the PLA chains can be observed at PEG-g-PLA NPs surface, 
indicating an increase of PEG content on the particles surface. When PEG was covalently 
attached to the PLA backbone as in case of (PLA-PEG-PLA)n NPs, the concentration of 
the repeating glycol unit C–C–O at 286.5 eV (PEG chains) was decreased 
correspondingly to the increase in C–C at 285 eV (PLA chains). Simply, these results 
showed that (PLA-PEG-PLA)n NPs displayed less existence of PEG chains at the surface 
compared to PEG-g-PLA NPs of nearly similar PEG content (Table 3.4). PEG-g-PLA 
NPs exhibited an enhanced immiscibility of both PEG and PLA chains resulting in 
enhanced phase separation of both components during NPs formation and hence, easy 
migration of PEG chains towards the surface of NPs while the cores will be 
predominantly hydrophobic. The architecture of (PLA-PEG-PLA)n NPs allowed the 
interpenetration of a major portion of PEG chains into the NPs core that is consisting 
mainly of hydrophobic PLA chains. PVA was found adsorbed onto the surface of NPs 
irrespective of the multiple washing steps performed to remove it [14, 15]. XPS showed 
the possibility of chemical interaction between PLA-COOH and PVA-OH end groups in 
case of PLA and PEG-g-PLA NPs. This reaction was diminished in case of multiblock 
copolymer. To sum up, even with the same PEG chain length and grafted degree, the 
percentage of PEG migrated to the surfaces were greatly influenced by the polymer 
architecture either grafted or block copolymer of PEG/PLA. 
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      1H-NMR measurements resolved the NPs core-corona structure. 1H-NMR spectra of 
all pegylated NPs in D2O showed the presence of methylene protons of PEG chains at 3.6 
ppm (Figs. 2.4, 3.4).  Signals from PLA methyl or methylene protons were absent or 
diminished in intensity. The results from 1H NMR experiments suggest the formation of 
micelle like NPs with some ordered configuration, presumably a core-corona system, 
where PEG segments form a highly hydrated corona surrounding a core composed of 
solid PLA. 
 
          Based on all results (AFM, DSC, 1H-NMR, erosion, and XPS), a schematic 
representation of different chain organization of NPs (depending on the polymer 
composition and architecture), is shown in Figs. 2.5, and 3.7. The difference in chain 
organization behavior was found to have an effect on the physicochemical properties of 
the obtained NPs. 
6.4. In vitro release  
         One of the main purposes of this study was to investigate the effect of the starting 
polymer architecture and copolymer composition on drug release profiles from PLA NPs. 
In the first part of the study, different NPs formulations made from different 
functionalized PLA polymers were compared for their in vitro release of ibuprofen as a 
model drug (Figs. 2.7, 3.6).  Generally speaking, drug solubility, drug diffusion and 
biodegradation of the nanoparticle matrix control the release process. In the case of 
nanoparticles, where the drug is molecularly dispersed, the release occurs by diffusion or 
erosion of the matrix under sink conditions. In case of nanoparticles entrapping the drug 
in a crystalline form, the release process will be controlled mainly by the drug dissolution 
process which is the slowest step. DSC and PXRD indicated that ibuprofen exists in a 
crystalline state inside all NPs irrespective of their polymer structure. Thus, the main rate 
limiting step controlling drug release will be the dissolution of drug crystals into the 
polymeric matrix followed by their diffusion out of the matrix into the release media. The 
polymer that favors more water uptake and hence rapid core wetting would facilitate drug 
dissolution and hence faster drug release. PEG/PLA NPs either made from PEG-g-PLA 
NPs or (PLA-PEG-PLA)n showed faster drug release compared to PLA NPs and this 
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could be attributed to the role of PEG chains in enhancing nanoparticle core wetting  
resulting in faster drug dissolution followed by its rapid diffusion. The higher release 
rates exhibited by multiblock copolymers compared to PEG-g-PLA could be also related 
to the differences in polymer architecture that allows different chain organization 
behavior when the NPs are suspended into the release medium.  In case of PEG-g-PLA, a 
major fraction of PEG chains was located at the surface as confirmed by XPS and AFM 
while the cores will be predominantly hydrophobic. For (PLA-PEG-PLA)n, a major 
portion of PEG was entrapped inside the PLA chains, enhancing the process of core 
wetting and hence faster drug dissolution. This difference in chain organization was 
found to have a major effect on the release kinetics of the encapsulated drug from NPs. 
         PEG/PLA NPs either made from PEG-g-PLA or (PLE-PEG-PLA)n were 
investigated as a drug carrier for itraconzole, ITZ. The in vitro drug release features of 
ITZ-NPs are shown in Fig.5.6. The results show that ITZ is released from the ITZ-NPs at 
a slower rate than its diffusion from solution through the dialysis membrane. PEG/PLA 
NPs prepared either from PEG-g-PLA or (PLE-PEG-PLA)n copolymers exhibited faster 
ITZ release compared to PLA NPs. This could be explained by the same fact as before 
with ibuprofen except that PEG chains would favor more water uptake enhancing faster 
ITZ diffusion not dissolution as with ibuprofen. ITZ was found molecularly dispersed 
into NPs matrix as confirmed by DSC and PXRD (Figs. 5.3a, 5.3b, 5.4a, and 5.4b).  
 
6.5. Plasma protein adsorption 
       Differences in the protein adsorption behavior could help predict the in vivo fate of 
different NPs types, and hence, design optimal drug carriers suitable for intravenous drug 
targeting. DLS was used to reveal the possibility of plasma protein (PP) adsorption onto 
NPs surface and whether there is any difference between PEG-g-PLA NPs of different 
PEG grafting densities in their ability to adsorb PP (Figs. 4.4, 4.S1). This was simply 
done by monitoring the size distribution changes of NPs after incubation for a period of 
time with plasma proteins solution. PEG7%-g-PLA or PEG20%-g-PLA NPs did not 
adsorb significant quantities of plasma proteins compared to either PLA or PEG1%-g-
PLA NPs. In fact, PEGylated NPs tend to adsorp less proteins than PLA NPs [16, 17]. It 
was important for us to perform this test to confirm the ability of PEG chains on the 
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surface of PEG-g-PLA NPs to repel plasma proteins in vitro. These observations confirm 
that either PEG7%-g-PLA or PEG20%-g-PLA NPs could withstand the serum 
environment and that protein adsorption onto their surface occurs to a limited extent, if at 
all [18].  
       
      Based on the in vitro data, plasma protein adsorption on the surface of PEG-g-PLA 
nanospheres strongly depends on PEG chain density at the surface of the particles, which 
played a major role in repelling the plasma proteins in vitro. Moreover, the optimum PEG 
grafting density expected to induces stealthiness in vivo varies from 4-7%.  
 
6.6. Cellular toxicity and uptake studies 
       NPs made from PEG-g-PLA polymers of different PEG densities were well tolerated 
and   exhibited no adverse effects on the cell viability as shown by cell proliferation 
assays (Fig. 4.5).                                 
       The interaction of RHO encapsulated nanoparticles with macrophage-like cells 
(RAW 264.7 cells) was investigated by fluorescence microscopy (qualitative) and 
fluorimetry analysis (quantitative) [Figs. 4.6, 4.7]. It could be seen from microscopy 
results (Fig. 4.6) that nanoparticles made from PEG-g-PLA copolymers showed less 
internalization by macrophage cells than PLA nanoparticles. Moreover, to achieve 
sufficient masking of NPs hydrophobic core, PEG grafting density higher than 1% is 
usually required to obtain lower internalization by macrophage cells.  
      For estimation of the actual amount of NPs internalized after incubating RAW 264.7 
cells for 24 h at 37 °C with different concentrations of RHO loaded NPs, florescence 
analysis was used (Fig.4.7). Similar findings to microscopy results were obtained. PEG-
g-PLA NPs of different PEG densities resulted in lower degree of internalization 
compared to PLA NPs in macrophages cell lines. It also could be seen that the higher the 
PEG grafting density, the lower the uptake of NPs by macrophage cells. This may be 
ascribed to surface hydrophilicity and neutral surface charge of PEG-g-PLA NPs. 
However, increasing the grafting density from 7% to 20 % didn’t show significant 
differences in their uptake ability indicating that the steric effect of PEG is concentration 
dependent [19].  
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6.7. Hemolysis analysis of ITZ-NPs 
       To demonstrate the ability of PEG/PLA copolymers as an effective carrier for ITZ, 
we investigated drug loading efficiency, release pattern, and ITZ dispersion state into 
either PEG-g-PLA or (PLA-PEG-PLA)n NPs. Preliminary in vitro characterization data 
suggested that ITZ was entrapped into NPs with good loading efficiency, slow release 
pattern, and that ITZ was molecularly dispersed into NPs. However, the safety potential 
of ITZ loaded NPs should be tested to confirm the ability of NPs to efficiently entrap 
ITZ, slowly release it, and reduce its localized concentration in contact with tissues or 
cells. To achieve that, hemolysis test was investigated after incubating particles with rat 
blood. As shown in Fig. 5.7, all ITZ-NPs either PLA, PEG7%-g-PLA, or (PLA-PEG-
PLA)n NPs exhibited less hemolytic potential  than ITZ solution over the concentrations 
range of ITZ (5-20 µg/mL). On the other hand, ITZ solution caused much more serious 
hemolysis. The results indicated that ITZ-NPs did not exhibit any marked effect on RBCs 
hemolysis or in another way it could be concluded that ITZ-NPs were more 
hemocompatible than free ITZ.  
6.8. Fungal growth inhibition in Petri Plate Culture  
       It was crucial to confirm the pharmacological activity of ITZ loaded NPs to warrant 
the ability of NPs to improve the therapeutic potential of ITZ as hypothesized. This was 
done by investigating the antifungal ability of ITZ-NPs compared to ITZ itself. Two 
clinical strains of either Candida albicans or Aspergillus fumigates were used in this 
study (Figs. 5.8a and 5.8b, respectively). Those two strains were selected due to their 
high susceptibility to ITZ action. ITZ-NPs showed greater inhibition of both fungal 
strains compared to ITZ-Water. This could be explained by the ability of NPs to enhance 
the aqueous solubility of ITZ, improve its bioavailability and hence its penetration ability 
into the fungal cells membrane. PEG/PLA NPs of either PEG7%-g-PLA and (PLA-PEG-
PLA)n showed enhanced antifungal capability in comparison to ITZ-PLA NPs. This 
could be due to the faster release of ITZ from PEG/PLA NPs as seen before in the release 
section (Fig. 5.6). Similar results were obtained with A. fumgiatus strains (Fig. 5.8b), 
where PEG/PLA NPs exhibited greater antifungal action compared to either ITZ-Water 
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or ITZ-PLA NPs. This indicated an enhanced antifungal capability of ITZ loaded 
PEG/PLA NPs in comparison to other formulations. The enhanced activity of ITZ loaded 
PEG/PLA NPs could be explained by the smaller size of the particles and the existence of 
PEG chains onto PLA particles surface. Those two factors were responsible for not only 
enhancing the aqueous solubility of ITZ but also keeping it dispersed for a period of time 
sufficient to enhance its contact and penetration potential into the fungal cell membranes. 
      Two mechanisms can be hypothesized for the delivery of ITZ from NPs into the 
fungal cells: first by releasing ITZ near the cell surface resulting in a faster internalization 
of free ITZ, and second by cellular uptake of nanoparticles followed by release of ITZ in 
the cytosol. However the solid nature of agar hindering the mobility of NPs, suggests that 
the former mechanism is the more likely to occur. In combination to these mechanisms, 
the sustained release of ITZ explains the larger inhibition zones observed over time with 
the PEG/PLA NPs compared to ITZ-water and ITZ-DMSO (Figs 5.8 a, b). 
 
       PEG/PLA NPs ability to enhance the antifungal activity of ITZ is associated with 
two aspects. The first one is the ability of small sized, water soluble PEG/PLA 
nanoparticles to enhance the dispersability of ITZ in water. The second one is the ability 
of NPs to enhance ITZ contact with the fungal spores on the plate surface leading to 
faster drug internalization [20, 21], penetration into the spores and hence, improved 
antifungal action.  
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7.1. Conclusion 
       NPs were successfully fabricated using functionalized copolymers of PLA with 
different molecular architectures.  Applying different characterization tools, notably DLS, 
AFM, XPS, and DSC, changes could be detected in the physicochemical characteristics 
of the nanoparticles prepared from different functionalized copolymers of PLA. 
Molecular architecture of the polymer is an important parameter controlling surface 
characteristics of NPs which in turn determine their physicochemical properties like 
encapsulation efficiency, % PVA adsorbed at the surface of NPs, zeta potential, thermal 
characteristic, NPs surface organization and drug release kinetics. Both AFM phase 
imaging and XPS studies showed that (PLA-PEG-PLA)n NPs displayed less amount of 
PEG on the surface due to the possibility of PEG chains interpenetration inside the PLA 
core of NPs. This resulted in lower Tg, rapid degradation of the polymeric matrix, and 
faster drug release from NPs compared to PEG-g-PLA NPs. While for PEG-g-PLA NPs, 
most PEG chains were located at the NPs surface. The architecture of PEG-g-PLA 
copolymer allowed enhanced immiscibility of both PEG and PLA blocks resulting in 
enhanced phase separation of both components during NPs formation and hence, easy 
migration of PEG chains towards the surface of NPs while the cores will be 
predominantly hydrophobic. NPs prepared from PEG-g-PLA copolymers were found to 
have more suitable drug delivery characteristics e.g. small size, good drug loading, lower 
adsorption of plasma proteins, lower uptake by macrophage cell lines, enhanced 
antifungal activity of encapsulated ITZ, and sustained release profile. For those features, 
PEG-g-PLA could be explored further as a promising nanoparticles delivery system for 
many drugs trying to optimize their biopharmaceutical performance in the body. 
 
         These results suggest that the physicochemical properties of PLA- based NPs can 
be tuned by judicious control over the following factors; polymer composition, nature of 
pendant functional group, % grafting density over the polymer backbone, and finally 
polymer architecture. Our results also favor the urgent search for another biocompatible 
emulsifier other than PVA for the preparation of NPs to avoid the unwanted effect of 
PVA on NPs properties e.g. NPs surface charge and cellular uptake pattern. This study 
has also shed the light on the use of nanospheres as a dispersing agents for slightly 
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insoluble drugs taking advantage of NPs small size, and the surfactant property of the 
used polymer i.e. PEG/PLA, to keep the drug dispersed into aqueous solution over a 
prolonged period of time. This action could enhance the pharmacological activity of 
many water insoluble drugs. 
 
7.2. Future work 
        The in vitro encouraging results obtained in this thesis justify in vivo evaluation of a 
number of PEG-g-PLA NPs formulations. Thus, ITZ loaded PEG-g-PLA NPs will be 
evaluated in vivo to determine their pharmacokinetics and biodistribution. Furthermore, 
antifungal activity of ITZ NPs will be evaluated in albino guinea pigs infected with either 
systemic aspergillosis or candidosis. When it comes to the usefulness of PEG-g-PLA 
copolymers as delivery systems, other drugs e.g. anticancer drugs may be tried to be 
encapsulated into those types of particles. 
